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Summary 
Psoriasis is a chronic relapsing inflammatory skin disease affecting 2-3% of the 
population worldwide. It has a strong genetic component and is present in all racial 
groups. Psoriasis is the result of dysregulated interactions between the skin and the 
immune system mediated by T cells, dendritic cells and cytokines. The most 
important clinical and histological features are epidermal hyperplasia, increased 
dilatation and growth of blood vessels together with abnormal T cell proliferation and 
migration into the epidermis. While psoriasis aetiology remains unknown and no cure 
is currently available, considerable progress in the understanding of the genetics and 
immunopathology has been achieved in the last years. T cells together with their 
secreted cytokines and chemokines are currently believed to be the primary cause of 
the disease. It is likely that the cellular composition of the inflammatory infiltrate 
within the psoriatic plaques, as well as keratinocyte hyperproliferation, is directed by 
cytokines. There is a complex cytokine network in psoriatic lesions consisting of 
interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α) and other type I cytokines 
including interleukin (IL)-12 and the recently discovered IL-23 and IL-17.  
Accumulating evidences point to a potential role of the two new identified 
cytokines, IL-23 and IL-17, in the development of inflammatory and autoimmune 
diseases such as rheumatoid arthritis, multiple sclerosis and potentially psoriasis. 
The possible role of IL-23 in the pathogenesis of psoriasis is supported by the 
evidence that monoclonal antibodies targeting the p40 subunit of IL-23 have shown 
marked clinical efficacy in psoriasis patients. Moreover a single nucleotide 
polymorphism in the IL-23 receptor (IL-23R) gene has been associated with 
psoriasis. IL-17 is produced by a specific subset of T helper (Th) cells, called Th-17, 
and it has been shown to be involved in different animal models of autoimmunity. The 
first part of this study gives insights into the role of IL-23 and IL-17 during psoriasis 
pathogenesis and investigates their potential as targets for therapy. By analysing the 
blood of psoriatic patients, an increased expression of IL-23R on helper T cells and 
dendritic cells when compared to healthy controls was found. Furthermore high 
expression of IL-23R was seen on both epidermal and dermal T cells as well as 
epidermal and dermal dendritic cells of psoriatic patients. Significantly increased 
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levels of IL-17 were secreted by T cells present in the blood as well as skin of 
psoriatic patients compared to T cells isolated from healthy donors. Interestingly, in 
lesional psoriatic skin, in addition to IFN-γ producing Th1 cells and Th-17 cells, a 
consistent subpopulation secreting both cytokines was identified. By using a 
xenotransplantation mouse model with spontaneous development of psoriasis, the in 
vivo relevance of IL-23 and IL-17 in psoriasis was then analysed. Uninvolved human 
skin from patients with psoriasis was engrafted onto AGR mice, which are deficient in 
type I and type II interferon as well in the recombinase activating gene 2 (Rag2). 
While blocking antibodies for IL-23 inhibited psoriasis development, injection of anti-
IL17 monoclonal antibodies did not have significant effects. Remarkably, the 
inhibition mediated by anti-IL-23 was as potent as using anti-TNF-α antibody, a “gold 
standard” in anti-psoriatic treatment. Taken together these results demonstrated a 
functional and potentially therapeutic role of IL-23 in psoriasis as well as 
dysregulated production of the effector cytokine IL-17. 
As integrin signalling plays a critical role in many aspects of normal growth, 
differentiation, and injury response the second part of this work focused on the 
functional expression of two major collagen-binding receptors, integrin α1β1 and α2β1. 
Firstly, the relevance of α1β1, the major collagen IV-binding receptor, for expansion of 
epidermal T cells and psoriasis manifestation was investigated. In active psoriasis 
lesions, α1β1 integrin was exclusively expressed by infiltrating epidermal but not 
dermal CD8+ and CD4+ T cells. Interaction of freshly isolated T cells with collagen IV 
was shown to up-regulate the expression of α1β1, demonstrating the positive-
feedback induced by this collagen on α1β1 expression. α1β1 positive T cells were 
shown to be effector memory Th1 cells highly expressing the E-cadherin receptor 
αEβ7 important for T cell retention into the epidermis. Blockade of α1β1 inhibited 
migration of T cells into the epidermis in the AGR mouse model and completely 
prevented psoriasis onset. Secondly, the important role of collagen I receptor, 
integrin α2β1, during psoriasis development was analysed. Attachment of 
keratinocytes to the basement membrane is mediated by integrin receptors, the most 
abundant of which is α2β1. Gaps or areas with reduced staining for collagen IV and 
laminin can be noted at the epidermo-dermal interface in psoriasis, exposing dermal 
collagen I to psoriatic keratinocytes expressing integrin α2β1. The hypothesis of this 
project was that collagen I engagement through α2β1 induced keratinocyte 
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hyperproliferation in psoriasis. In vitro studies showed that keratinocyte 
hyperproliferation on collagen I coated plates was significantly reduced by blocking 
α2β1, indicating that the possible loss of basement membrane integrity in psoriasis 
exposed epidermal cells to collagen I and induced keratinocyte hyperproliferation in 
an α2β1 dependent manner. α2β1-collagen I interactions were shown to be also the 
cause of dermal endothelial cells (DMECs) hyperproliferation, as anti-α2 monoclonal 
antibodies markedly reduced the proliferation rate of DMECs cultivated on collagen I-
coated wells. Additionally, α2-blockade efficiently inhibited DMECs migration and 
tube formation, thereby demonstrating the functional role of this integrin during 
angiogenesis. Finally, in vivo experiments using the AGR mouse model showed that 
blockade of α2β1 significantly inhibited the development of psoriasis. These results 
demonstrated the beneficial role of blocking α2β1 function in psoriasis and presented 
a T-cell independent mechanism for inhibiting the development of the disease.  
In conclusion, this study gives new insights into the pathogenesis of psoriasis 
trying to elucidate the complex relationship between the skin and the immune 
system. In particular, this work demonstrated the importance of cytokines, T cells and 
integrin interactions during psoriasis onset and might provide the basis for new 
strategies in psoriasis treatment.  
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Zusammenfassung 
 
Psoriasis, zu Deutsch Schuppenflechte, ist eine chronisch wiederkehrende, 
entzündliche Hauterkrankung, von welcher 2-3% der westlichen Bevölkerung 
betroffen sind. Genetische Faktoren haben einen starken Einfluß auf die 
Krankheitsbildung, unabhängig von der ethnischen Zugehörigkeit der Betroffenen. 
Psoriasis ist das Resultat einer Fehlregulation bei der Interaktion zwischen der Haut 
und dem Immunsystem. T-Lymphozyten, Keratinozyten, dendritische Zellen und 
verschiedene Zytokine sind an der Pathogenese der Psoriasis beteiligt. Die 
wichtigsten klinischen und histologischen Eigenschaften der Psoriasis sind eine 
epidermale Hyperproloferation, Dilatation und Wachstum von Blutgefässen im 
Zusammenspiel mit erhöhtem T-Zell-Wachstum und T-Zell-Migration in die 
Epidermis. In den letzten Jahren haben beachtliche Forschungsergebnisse neue und 
umfassendere Einblicke in die Genetik und in die immunologischen Vorgänge der 
Psoriasis möglich gemacht. Dennoch bleibt die Ätiologie der Psoriasis immer noch 
unbekannt, und eine Therapie im Sinne einer Heilung ist zur Zeit nicht verfügbar.  
Die heutige Datenlage weist darauf hin, dass T-Lymphozyten und die von diesen 
produzierten Zytokinen und Chemokine die Krankheit auslösen. Es ist 
wahrscheinlich, dass sowohl das entzündliche Infiltrat innerhalb der psoriatischen 
Läsion als auch die Hyperproliferation der Keratinocyten durch Zytokine stimmuliert 
werden. In einer psoriatischen Läsion besteht ein komplexes Zytokinnetzwerk, 
welches sich unter anderen aus Interferon (IFN-γ), tumor necrosis factor-α, anderen 
Typ I Zytokinen wie Interleukin (IL)-12.  
In den letzten Jahren deutet eine immer größer werdende Zahl an 
ForschungsePunktmutationen innerhalb des IL-23-Rezeptor (IL-23R)-Gens mit der 
Entwicklung der Psoriasis in Zusammenhang stehen. Ausserdem fördert IL-23 die 
Expansion einer Subpopulation von T-Zellen, die IL-17 produziert, den so genannten 
Th17 Zellen. Eine erhöhte Expression von IL-17 konnte in den letzten Jahren auf 
Grund von Tierversuchen mit verschiedenen Autoimmunerkrankungen assoziiert 
werden. 
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Der erste Teil dieser Arbeit gibt Einblicke in die Rolle von IL-23 und IL-17 bei der 
Pathogenese der Psoriasis und beschreibt des weiteren, das Potential dieser 
Zytokine als mögliche Zielproteine bei therapeutischen Ansätzen. Bei Analysen des 
Bluts von psoriatischen Patienten wurde, im Vergleich zu gesunden Probanden, eine 
erhörte Expression von IL-23R auf T-Zellen und dendritischen Zellen nachgewiesen. 
In der psoriatischen Haut zeigen sowohl epidermale und dermale T-Zellen, als auch 
epidermale und dermale dendritische Zellen eine erhöhte Expression von IL-23R. Im 
Blut und in der Haut von psoriatischen Patienten wurde des weiteren auch eine 
Überexpression von IL-17 durch T-Zellen beschrieben. Interessanterweise wurde in 
der psoriatischen Haut neben den IFN-γ produzierenden T-Zellen und den Th17 
Zellen auch eine beträchtlich grosse Subpopulation von T-Zellen nachgewiesen, die 
beide Zytokinen ausschütteten. Die in vivo Rolle von IL-23 und IL-17 während der 
Entstehung der Psoriasis wurde in einem Mausmodell für Psoriasis (AGR Maus) 
analysiert. Die AGR Mäuse besitzen zusätzlich zu den fehlenden T- und B-
Lymphozyten keine Typ-I- und Typ-II-Interferon-Rezeptoren und somit keine 
funktionellen NK(Natural Killer)-Zellen. Diese AGR Mäuse sind optimale Empfänger 
für die Transplantationsexperimente, bei denen nicht-involvierte Haut eines 
Psoriasis-Patienten auf den Rücken der Mäuse transplantiert wird. Innerhalb von 5 
Wochen nach der Transplantation entwickelt sich die nicht involvierte Haut zu einem 
psoriatischen Phänotyp, der alle charakteristischen histologischen Merkmale der 
Psoriasis zeigt. Die Blockierung von IL-23 durch neutralisierende Antikörper 
verhindert die Entstehung des psoriatischen Phänotyps in den Transplantaten, 
wogegen die Entwicklung einer Psoriasis durch die Hemmung von IL-17 mit 
monoklonalen anti-IL-17 Antikörpern nicht inhibiert werden konnte. Diese Ergebnisse 
zeigen klar das Potential, welches eine Blockierung von IL-23 als mögliche Therapie 
für Psoriasis Patienten hat und beweist die dyrgebnissen darauf hin, dass die 
kürzlich beschriebenen Zytokinen, IL-23 und IL-17, eine wichtige Rolle in der 
Entwicklung von Autoimmunerkrankungen, wie Rheumatoide, Arthritis, multiple 
Sklerose und Psoriasis spielen. Ein neuer Therapieansatz, welcher die Funktion der 
p40 Untereinheit der Zytokine IL-12/IL-23 blockiert, hat beeindruckende klinische 
Resultate in der Behandlung der Psoriasis gezeigt und weist gleichzeitig auf eine 
Schlüsselrolle dieser Zytokine bei dem Krankheitsverlauf hin. Es konnte gezeigt werden, 
dass zwei verschiedene sregulierte Produktion des Effektor-Zytokins IL-17. 
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Da Integrine bei normaler Proliferation, Differenzierung und in der Wundheilung 
eine zentrale Rolle spielen, wurde in dem zweiten Teil dieser Arbeit die Expression 
der Kollagensrezeptoren α1β1 und α2β1 untersucht. Zuerst wurde die Bedeutung von 
α1β1, dem wichtigsten Kollagen IV Rezeptor, während der Expansion von 
epidermaler T-Zellen und der Entstehung der Psoriasis analysiert. In der betroffenen 
psoriatischen Haut wurde α1β1 Integrin nur auf eingewanderten, epidermalen und 
nicht auf dermalen CD8+ und CD4+ T-Zellen nachgewiesen. Die Interaktion von 
frisch isolierten T Zellen mit Kollagen IV führte zu einer gesteigerten Regulation von 
α1β1. Dieses Experiment demonstriert die positive Rückkopplung, induziert durch 
Kollagen IV, auf die Expression von α1β1. Es wurde gezeigt, dass α1β1 T-Zellen zu 
der Klasse der Effektor-Gedächnisszellen gehören und Th1 Zellen sind. Diese α1β1 
T-Zellen exprimieren den E-Cadherin Rezeptor αEβ7, welcher für die Anhaftung von 
T-Zellen an die Epidermis wichtig ist. Die Hemmung von α1β1 in dem AGR Maus 
Modell blockierte die Einwanderung von T-Zellen in die Epidermis und inhibierte die 
Entstehung einer Psoriasis. Im zweiten Teil dieses Projektes wurde die Rolle des 
Kollagen I Rezeptor (Integrin α2β1), während der Entwicklung einer psoriatischen 
Läsion analysiert. Keratinozyten binden an die Basalmembran durch Integrin-
Rezeptoren. Unter diesen ist der Integrin α2β1 der am stärksten exprimierte Rezeptor. 
Immunfärbungen zeigen Lücken oder sogar ganze Areale mit verminderter Färbung 
für Kollagen I und Laminin, besonders an der epidermo-dermalen Grenze in 
psoriatischer Haut. Dadurch wird dermales Kollagen I an die Keratinocyten 
präsentiert, welche Integrin α2β1 exprimieren. Die Hypothese welche diesem Projekt 
zu Grunde liegt, ist das die Interaktion von Integrin α2β1 mit Kollagen I zu einer 
Hyperproliferation der Keratinozyten führt. In vitro Experimente zeigten, dass die 
Blockierung dieses Integrins die Hyperproliferation der Keratinocyten und die 
Angiogenese systemisch reduziert. Um die in vivo Relevanz zu untersuchen, wurden 
die Experimente in dem AGR Mausmodell durchgeführt. Mäuse, die mit anti-α2-
Antikörper injiziert wurden, zeigten keine Hyperproliferation der Keratinocyten und 
die Entstehung ein psoriatischen Phänotyp wurde vollständig inhibiert. Da während 
der Entwicklung der Psoriasis keine Expression von α2β1 auf T-Zellen nachgewiesen 
werden konnte, scheint die Blockierung der Psoriasis durch anti-α2-Antikörper ein T-
Zellen unabhängiger Mechanismus zugrunde zu liegen.  
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Zusammenfassend gibt diese Arbeit einen Einblick in die Pathogenese der 
Psoriasis und versucht den komplexen Zusammenhang zwischen der Haut und dem 
Immunsystem zu erläutern.  
Insbesondere zeigt diese Arbeit wie wichtig die Interaktion zwischen Zytokinen, T-
Zellen und Integrinen für die Pathogenese der Krankheit sind und liefert somit die 
Basis für neue, therapeutische Strategien zur Bekämpfung der Psoriasis. 
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Abbreviations 
 
Ab   Antiobody 
AGR  mice deficient in type I (A) and type II (G) IFN receptors, in  
   addition to be RAG-2–/– 
APC  Antigen Presenting Cells 
APC (Staining) Allophycocyanin 
BFA  Brefeldin A 
BSA  Bovine Serum Albumin 
CIA  Collagen Induced Arthritis 
CNS  Central Nervous System 
DC  Dendritic cell 
DMECs  Dermal Microvascular Endothelial Cells 
EAE  Experimental Autoimmune Encephalomyelitis 
ECs  Endotjelial Cells 
ECM  Extracellular Matrix 
FACS  Fluorescent Associated Cell Sorter  
FCS  Foetal Calf Serum 
FITC  Fluorescein Isothiocyanate 
GM-CSF  Growth Factor 
IBD  Inflammatory Bowel Disease  
IFN  Interferon 
IL   Interleukin 
IL-23R  IL-23 receptor 
LC   Langerhans cells 
KC   Keratinocytes 
mAb  Monoclonal antibody 
MACS  Magnetic Activated Cell Sorting 
MHC  Major Histocompatibility Complex 
NK   Natural Killer 
NN  Skin of healthy volunteers 
PBMCs  Peripheral Blood Mononuclear Cells 
PBS  Phodphate Buffered Saline 
PE   Phycoerythrin 
PHA  Phytohemagglutinin 
  Abbreviations 
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PI   Propidium Iodide 
PMA  Phorbol-12-Myristate-13-Acetate 
PN   Non involved Psoriatic skin 
PP   Invovlved Psoriatik skin 
RAG-2  Recombinase Activating Gene 2 
RT-PCR   Real Time Polymerase Chain Reaction  
SDF-1α   Stromal cell-Derived Factor 1α 
VEGF  Vascular Endothelial Growth Factor 
VLA  Very Late Antigen 
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1. General introduction 
1.1. Introduction to skin biology 
The skin is a complex barrier organ, which separates internal structures from the 
outside environment. Its essential functions include protection against external 
environmental insult, maintenance of fluid homeostasis and thermoregulation. The 
skin is composed of three structurally and functionally distinct layers, the epidermis, 
the dermis and the subcutis (Fritsch 2004) (Figure 1.1). 
The epidermis forms the outer most layer and it can be further subdivided into five 
recognisable strata or layers. From the inner to the outer they are respectively the 
stratum basale, spinosum, luicidum, granulosum, and corneum. Each of these layers 
is primarily composed of keratinocytes at various differentiation stages that are 
derived from the basal layer. Following cell division some keratinocytes remain in the 
basal layer as stem cells while others move up towards the surface. During this 
migration the keratinocytes gradually flatten, lose their nuclei and most other 
structures to finally leave only the keratin cytoskeleton to make up the stratum 
corneum. This keratinisation process takes approximately four weeks after cell 
division at the basal layer (Eckert and Rorke 1989). Keratinocytes not only compose 
the scaffold and structure of the epidermis, but they also take active part in its 
inflammatory and immunological reactions. During normal homeostasis keratinocytes 
secrete few factors, but in response to wounding or infection they release a broad 
spectrum of proinflammatory cytokines such as IL-1, IL-6, TNFα, GM-CSF, IL-8, 
MCP-1 and TGF-β thereby initiating or propagating inflammatory and immune 
reactions (Fritsch 2004). In addition to keratinocytes, the epidermis is also populated 
by smaller numbers of other cells, such as melanocytes and Langerhans cells. 
Melanocytes sit in the basal layer and produce melanin primarily in response to 
ultraviolet radiation. Using large numbers of dendrite-like processes melanocytes 
distribute melanin to the surrounding keratinocytes, protecting their nuclei from 
further UV-damage. Melanin is principally responsible for pigmentation of the skin. 
Langerhans cells are antigen presenting cells which contribute to protect the skin 
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from infection, by capturing and delivering various antigens to lymphoid tissues 
where they can activate naïve T lymphocytes (Janeway 2001). While the epidermis 
contains no blood vessels, its cells are supported by the diffusion of nutrients from 
dermal capillaries. 
A basement membrane separates the epidermis from the dermis and provides a 
structural support for melanocytes and proliferating keratinocytes. This layer is 
composed of the lamina lucida and lamina densa. The lamina lucida is adjacent to 
the epidermis and consists of laminin and collagen type IV; while collagen type VII is 
the main constituent of the lamina densa. 
 
Figure 1.1  Structure of the skin Skin is composed of the epidermis and dermis, which 
are separated by the basement membrane. As indicated, keratinocytes, collagen 
fibres and blood vessels are present in these two layers. 
 
Beneath the basement membrane lies the dermis which principally consists of a 
dense layer of fibrous connective tissue that gives the skin its flexibility and strength. 
The dermis can be subdivided into the stratum papillare and the deeper stratum 
reticulare, which show a continuous transition to subcutis. The dermis is rich in a 
network of nerves and vasculature. Embedded within the dermis are several different 
cells types, including fibroblasts, mast cells, various antigen presenting cells and 
lymphocytes. Fibroblasts are responsible for secretion of the collagen and elastin 
fibers that constitute the extracellular matrix of connective tissue. Mast cells are 
found concentrated around blood and lymphatic vessels and together with antigen 
presenting cells they represent one of the first lines of defense against pathogens. 
The subcutis, also called hypodermis, is the deepest layer of the skin. Attached to 
the dermis by collagen and elastin fibres it divides the dermis from muscle, bone and 
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other tissues. This layer is mainly composed of adipocytes, a type of cell specialised 
for the accumulation and storage of fat.  
1.2. The skin immune system 
As a protective interface between the body and the external world, the skin 
functions not only as a physical barrier, but it is also an active immune organ. 
Cutaneous immune responses involve the coordinate action of immune cells 
distributed through all the layers of the skin. In 1978, Streilein was among the first to 
propose a branch of the immune system specialized to provide skin immunity, that he 
named skin associated-lymphoid tissues (SALT) (Streilein 1983). Skin associated-
lymphoid tissues include epidermal and dermal cells that work together to provide 
immune protection against microbial, chemical and physical insults.  
 
1.2.1. General concepts in immunology 
1.2.1.1. Human immune system 
The immune system consists of two functional arms classified as innate and 
adaptive immunity. Innate immunity is a first line body defence and is characterised 
by a rapid but unspecific response and by the lack of immunological memory. The 
components of the innate immune response are constitutively present and always 
ready to be mobilised upon infection. To protect the host upon infection the innate 
immune system uses both physical barriers, such as the skin and the mucosal 
epithelium, and rapid cellular responses enhanced by monocytes, natural killer cells, 
antigen presenting cells and granulocytes. These cells express pattern-recognition 
receptors that recognise specific pathogens components. An important subset of this 
receptors belong to the Toll-like receptor (TLR) family, which bind pathogen 
associated molecular pattern (PAMP) molecules such as peptide molecular 
structures from bacteria, single- and double-stranded RNA from viruses, and yeast 
mannans (Gay, Gangloff et al. 2006). TLRs are transmembrane glycoproteins 
expressed on the cell surface and endosomally and are capable of initiating innate 
immune responses and influencing subsequent adaptive immune responses. 
Because adaptive immunity is tailored to the antigen (antigen- specific) it takes more 
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time to be activated, but is highly specific and has a memory, so that subsequent 
exposure to the same antigen leads to a more effective and rapid response. Key 
players during this response are antigen-presenting cells and T lymphocytes 
(Schwarz 2003). 
 
1.2.1.2.  Antigen presentation  
The function of the major histocompatibility complex (MHC) is to bind peptides in 
an intracellular location and display them on the cell surface for the recognition by the 
appropriate T cell. The MHC genes are the most polymorphic genes known, as there 
are multiple variants of each gene within the population. Moreover, every individual 
has a set of MHC molecules with different ranges of peptide-binding specificities. 
There are two types of peptide-MHC complexes: class Ι molecules bind peptides 
from proteins degraded in the cytosol, such as viral or tumour proteins, and are only 
recognised by CD8+ T cells. While class ΙΙ molecules process exogenous antigens 
taken up by endocytosis and are recognised by CD4+ T cells. 
Class Ι molecules are found on almost all nucleated cell of the body, while class ΙΙ 
proteins are mainly expressed by  antigen presenting cells. 
 
Antigen presenting cells (APC) are highly specialised cells that serve two major 
functions during adaptive immunity. First they capture and process antigens on their 
cell surface together with MHC molecules required for lymphocytes activation and 
second they express receptors (CD80, CD86 and CD40) required for the proliferation 
and differentiation of lymphocytes. APC include dendritic cells, macrophages and B 
cells. 
 
Dendritic cells (DCs) are the most important professional APC for the induction of 
primary immune responses and are the key link between the innate and adaptive 
immune system.  
Dendritic cells start out as immature dendritic cells (iDCs) which are characterized 
by high endocytic activity and low T-cell activation potential. DCs utilize several 
pathways to capture antigen including pinocytosis, receptor mediated endocytosis 
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and phagocytosis. Captured antigens are then processed in distinct intracellular 
compartments and loaded onto MHC molecules. By the time iDCs process the 
antigen they leave the skin, enter lymphatic vessels and migrate to the nearest lymph 
node where they arrive as mature DCs. This maturation process enhances antigen 
processing and up-regulates the expression of MHC and surface molecules, known 
as co-stimulatory molecules (CD80, CD86 and CD40) which are fundamental for T 
cell activation. 
There are two major subsets of dendritic cells in humans: plasmacytoid DCs 
(pDCs) and myeloid (mDCs), including dermal DCs and Langerhans cells (LCs) 
(Banchereau, Pascual et al. 2004). In accordance to their different TLR expression 
pattern these two subsets of DCs respond to different pathogen-associated 
molecular patterns. 
The only TLR members expressed on pDCs are TLR-7 and-9, which are 
intracellular receptors specialized in the recognition of viral nucleic acids. In contrast, 
mDCs express a broader profile of TLR molecules, including the surface expressed 
TLRs (TLR-1, TLR-2, TLR-4 and TLR-6) that are mainly involved in the recognition of 
bacterial components and the intracellular TLR-3 and TLR-8, which bind double-
stranded RNA from viruses (Seya, Akazawa et al. 2006).  
PDC have low capacity to activate naïve T cells and represent key effectors in the 
innate antiviral immunity. They are characterized by their capacity to secrete large 
amounts of IFN-α in response to viruses and have also be found to play a role during 
autoimmune disease development (Nestle, Conrad et al. 2005). During homeostasis 
pDCs are found at low frequencies in the blood and secondary lymphoid organs but 
upon viral infection they are recruited to the site of inflammation. Finally, virally 
triggered pDCs differentiate into mature DCs able to induce the differentiation of 
CD4+T cells able to eliminate infected cells. By contrast, mDCs have a high capacity 
to activate naïve T cells and are mainly activated by microbial signals such as 
lipopolysaccharides or CpG bacterial DNA motives. They are usually located at the 
interface between outer world and the body such as the skin, the respiratory tract and 
the gastrointestinal tract. After activation mDCs produce IL-12 which is a dominant 
cytokine involved in the development of cytotoxic T cells.  
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Macrophages provide a first line of defence against infection. They can also be 
activated to express co-stimulatory and MHC class-ΙΙ molecules. This enables them 
to work as APC, even if they are less potent in activating T cells. In some situation, B 
cells can also function as APC. They contribute to adaptive immunity by presenting 
peptides from antigens that they have ingested and by secreting antibodies. 
 
1.2.1.3.  T cells and self-tolerance 
T cells are the main effectors of the adaptive immune response and they only 
recognise antigen-peptides presented in the groove of host MHC molecules. This 
recognition occurs through the T cell receptor (TCR), a heterodimeric protein 
composed of an α and β chain, or less frequently of a γ and δ chain. Stably 
associated with the TCR on cell surface is the CD3 complex, which signals to the 
interior of the cell upon antigen binding. Among the α/β T cells are two important 
subpopulations: CD4+ T- helper cells (Th) and CD8+ T cytotoxic (Tc) cells. These 
two subpopulations differ fundamentally in how they recognise antigen and for the 
different types of regulatory and effector functions. The differentiation of T cells in 
CD4 versus CD8 occurs during their development in the thymus (Janeway 2001). 
During this stage T cells are also “educated” to tolerate the host molecular structures 
(self) and therefore react only when foreign peptides are bound to MHC molecules.  
T cells originate from the bone marrow and then migrate to the thymus where they 
are called thymocytes. Thymocytes do not express specific T cell surface markers 
(TCR, CD3 and CD4/CD8) and are called double negative cells (because they are 
CD4-CD8-). During T cell development a first critical step is the selection for a 
functional T cell receptor, which occurs when T cell precursors pass through the 
thymic cortical region. Cells that successfully pass this stage become double positive 
cells (CD4+CD8+). Double positive thymocytes are then subjected to the other two 
selection processes, called positive and negative selection. During positive selection 
only progenitors that have low affinity for self MHC are selected for proliferation, the 
others undergo programmed cell death (apoptosis). This stage assures also that 
thymocytes which are MHC-Ι restricted are positively selected towards CD8 ligands 
whereas the MHC-ΙΙ restricted cells are positively selected to the CD4 lineage 
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(Sebzda, Mariathasan et al. 1999). Finally, negative selection leads to the deletion of 
thymocytes, whose T cell receptors have too high affinity for self antigens.  
 
1.2.1.4. T cell activation   
After their export from the thymus, T cells, called naïve T cells, enter the 
bloodstream and start a constant recirculation through secondary lymphoid organs 
and the blood, until they encounter a foreign antigen. 
 
Figure 1.2  Signals for T cell activation. (A) First interaction: molecular association of CD4+ T cells 
with MHC-II and CD8+ with MHC-I. (B) Costimulatory signals necessary to continue the immune 
response 
 
In order to be activated naïve T cells require two signals (Figure 1.2). The first 
signal arises from the interaction of their TCR with the specific MHC/antigen complex 
expressed on APCs. During this event CD3 molecules signal to the interior of the 
cells that recognition has occurred. However this interaction alone fails to induce 
complete T cell activation. An additional second signal, derived by co-stimulatory 
molecules expressed on APC, is needed. The main co-receptors for T cell activation 
are CD80, CD86 and CD40 that respectively bind CD28, CTLA-4 and CD40 ligand 
on T cells. Antigen binding to the TCR in the absence of co-stimulation does not 
activate the cell but rather leads to cell death or to a state called anergy, by which T 
cells become functionally inert (Parkin and Cohen 2001). If both stimulatory signals 
are present, T cells start to proliferate and secrete interleukin-2 (IL-2), a cytokine that 
promotes T-cell growth in an autocrine fashion by binding to its receptor IL-2R 
(Janeway 2001). During this proliferation some of the T cells will differentiate into 
A B
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effector T cells while another fraction will form memory T cells that will survive in an 
inactive state until they re-encounter the same antigen that will reactivate them. 
 
1.2.1.5. Effector T cells 
There are two major types of effector T cells, T helper cells (Th) or T cytotoxic 
cells (Tc). Th cells bear CD4 molecules and are the main cells of the adaptive 
immune response. Tc cells are CD8+ cells able to destroy virally infected cells, 
tumour cells and are also implicated in tumour rejection. 
Th cells can further be divided in Th1 or Th2 cells, according to the type of 
cytokines they secrete. Whether a CD4 T cell will differentiate into a Th1 or Th2 is 
determined by the nature of the antigen recognised, the co-stimulators used to drive 
the response and the cytokine environment (Janeway 2001). Th1 cells typically 
secret IFN-γ, TNF-α and IL-2. They are mostly generated upon infection with 
intracellular pathogens such as viruses or mycobacteria. These pathogens are 
recognised by TLR on the surface of macrophages and DC, which consequently 
produce IL-12. Binding of IL-12 to its receptor on CD4+ T cells activates the 
transcription factor T-bet and STAT-4, and these promote the differentiation in Th1 
cells. 
Th2 cells, instead, secrete IL-4, -5 and -13 and their development depends on the 
IL-4 cytokine. Binding of IL-4 to its receptor on CD4+ cells induces the transcription of 
STAT-6 and GATA-3 which are essential for Th2 differentiation. Th2 cells mainly 
mediate anti-parasitic and allergic responses. It is important to note that cytokines 
produced by one subtype function as negative regulator of the other subtype’s 
development and function (Paul 1999). 
Tc cells recognise the antigen in association with MHC-Ι molecules and are 
directly cytotoxic to cells infected with viruses (or other pathogens), or are otherwise 
dysfunctional. There are two mechanisms by which activated Tc cells kill target cells. 
One method involves release of secretory granules containing perforin and 
granzyme, two proteins capable of inducing the lysis of target cells. The second 
mechanism is Fas-mediated apoptosis. Tc cells express on their surfaces a death 
activated protein, called Fas Ligand, which bind to its receptor, called Fas, present on 
almost all target cells. When Tc cells recognise a target cell, they overexpress Fas 
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ligands, which bind with the Fas receptor present on the target cell leading to its 
death. 
In the last years increasing interest has been focused on regulatory T cells 
(Tregs), previously called “suppressor T cells”. Tregs participate in suppressing 
autoimmune reactivity against self structures, in controlling microbial infection, allergy 
and facilitating transplantation tolerance (Sakaguchi 2006). 
Several distinct subsets of Treg cells have been described based on distinct 
expression patterns of surface markers and cytokines. The best characterized Tregs 
in humans and mice are the so called naturally occurring Tregs (nTregs) a subset of 
CD4+ T cells constitutively expressing CD25, the IL-2 receptor α chain. nTregs can 
also be identified by their expression of FoxP3 that encodes the forkhead box P3 
transcripiton factor, a key gene in their development and function. Typically high 
levels of CTLA-4 (cytotoxic T lymphocyte antigen 4), known as a negative regulator 
of T cell activation, and GITR (glucocorticoid-induced TNF receptor) are also 
expressed on this cell population (Tai, Cowan et al. 2005).  
One well accepted function of CD4+CD25+ natural Tregs is the maintenance of 
self-tolerance suppressing the activation and function of autoreactive T cells, thereby 
preventing autoimmune diseases. After TCR-mediated stimulation, nTregs cells 
suppress the activation and proliferation of other CD4+ and CD8+ cells in an antigen-
non specific manner, via mechanisms that require cell-to-cell contact. In mice, 
depletion of CD4+CD25+ T cells by neonatal thymectomy leads to spontaneous 
development of organ-specific autoimmune disease, condition that can be reversed 
by adoptive transfer of Treg (Asano, Toda et al. 1996).  
Treg were originally considered to derive only from thymic precursors, to be 
exported to the periphery, and to represent less than 10% of CD4+T. Further studies 
(Wahl, Swisher et al. 2004) showed that Treg can be also expanded and induced in 
the periphery from CD4+CD25- naive T cells. This conversion is driven by TGF-β 
which is a physiologic inducer of Foxp3. When co-activated with TCR and TGF-β, 
CD4+CD25- cells begin to express the transcription factor Foxp3, which is the master 
regulator for their transition into CD4+CD25+ Treg cells. This conversion may be 
happen in a site of autoimmune reactivity in order to increase locally the number of 
Tregs cells.  
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Recently it has become evident that TGF-β is also involved in the generation of a 
recently discovered cell population called Th-17 (Bettelli, Carrier et al. 2006; 
Veldhoen, Hocking et al. 2006). Th-17 cells are well accepted to be involved in the 
pathogenesis of certain mice autoimmune diseases such as rheumatoid arthritis, 
experimental autoimmune enchemalomyelitis (EAE) and allergen-specific responses 
(Nakae, Komiyama et al. 2002; Cua, Sherlock et al. 2003; Langrish, Chen et al. 
2005). IL-17 is believed to contribute to the pathogenesis of these diseases by acting 
as a potent proinflammatory mediator. The molecular mechanism inducing the 
development of Th-17 cells is still unclear. Recently it has been shown that both 
TGF-β and IL-6 are required for the full differentiation of Th-17 cells from CD4+ T 
cells in vitro. These recent discoveries suggest that nTreg and Th-17 cells have close 
affinity and that both T cells subsets may differentiate from the same precursor 
depending on the type of cytokines present in the local environment (Cua and 
Kastelein 2006). 
 
1.2.1.6.  Memory T cells 
Memory T cells are faster and more effective responders to infection then naïve T 
cells. They also respond to a lower antigen dose and are less dependent on co-
stimulatory signals. In the peripheral blood, two types of memory T cells have been 
described based on the homing molecules they express. Central memory T cells (T 
CM) express L-selectin (CD62L) and the chemokine receptor CCR7 for efficient traffic 
through secondary lymphoid tissues. In contrast, effector memory T cells (T EM) lack 
these migration receptors and are therefore excluded from these organs and are 
found in non-lymphoid tissues (such as the gut, lung and liver) (Lanzavecchia and 
Sallusto 2005; Lefrancois and Marzo 2006). Another important property of memory T 
cells is that after re-exposure to antigen, they specifically home to the site where the 
initial antigen exposure had taken place. This selective migration is due by the 
differential expression of adhesion molecules. In this way memory T cells that home 
to the gut express the integrin α4β7 which bind to the E-cadherin expressed on 
epithelial cells. Instead, cells that home to the skin express the cutaneous 
lymphocyte antigen (CLA), whose ligand is the skin E-selectin. 
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1.2.2.  Normal immune surveillance in the skin 
The cutaneous immune surveillance arises from the interaction of innate and 
adaptive immune systems (Kupper and Fuhlbrigge 2004).  
Langerhans cells (LCs) are the APCs found in the epidermis. They originate from 
the bone marrow and migrate into the skin, where they constitute the 2-4% of 
epidermal cells (Parkin and Cohen 2001). LCs are mainly localized at the suprabasal 
region of the epidermis and are characterized by their dendritic shape and by Birbeck 
granules, which are rod- shaped organelles. 
In non-inflamed epidermis LCs are the only cells which express MHC-ΙΙ molecules 
constitutively. LCs play a double function in the skin immune system as they can 
process antigens by picking up the antigen and migrate to the draining lymph node 
where they activate native T cells. But they can also activate memory/effector T cells 
specific for previously encountered antigens directly in the epidermis. 
Circulating cutaneous lymphocytes antigen (CLA)-positive T cells represent 10-
15% of all circulating memory T cells in peripheral blood and are crucial to the 
initiation and execution of skin immune responses (Robert and Kupper 1999). CLA+ 
T cells may be positive for either CD4 or CD8, and upon activation they may induce 
either a Th1 or a Th2 response. 
E-selectin the endothelial ligand for CLA, and ICAM-1 are constitutively expressed 
at low levels on cutaneous endothelia and may mediate CLA+ T cells trafficking also 
in non inflamed skin. Those cells that encounter the specific antigen presented by 
local APC will be activated to proliferate and carry out their specific functions. CLA+ T 
cells that do not encounter their specific antigen will return to the peripheral blood 
through the lymphatics.  
Recently it has been shown that the majority (80%) of CLA+ memory T cells 
reside in the skin and only a minority (20%) is recalculating.  It has been calculated 
that in the entire non inflamed skin surface there are about 2 x 1010 T cells (1 x 106 T 
cells/cm2), nearly twice the number of T cells in the circulation (Clark, Chong et al. 
2006). This observation suggests that all the components necessary for an adaptive 
immune response (LCs, dermal DCs and memory T cells) are already present in the 
skin and are sufficient to activate an efficient defence against pathogens. On the 
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other hand this scenario may also contribute to the development and perpetuation of 
inflammatory skin diseases. 
After tissue damage or pathogen invasion both resident innate immune cells (LCs, 
dermal DCs and mast cells) and skin cells (keratinocytes and fibroblasts) are 
activated. Keratinocytes play an important role in cutaneous immune responses. 
After an injury they release different types of cytokines, including TNF-α and IL-1α 
which induce the up-regulation of MHC-ΙΙ molecules on LCs and dermal DCs, 
increasing their efficiency as antigen-presenting cells.  These cytokines also act on 
the local endothelia increasing the expression of cellular adhesion molecules (E-
selectin, P–selectin, intracellular adhesion molecule 1(ICAM-1)). The expression of 
all these molecules enables circulating leukocytes (neutrophils, natural killer cells and 
effector T cells) to extravasate to the site of skin injury (Kupper and Fuhlbrigge 2004). 
In this way CLA+ memory T cells by binding to E selectin and other adhesion 
molecules are recruited to the skin in an antigen non-specific manner. Once in the 
skin, T cells respond to chemotactic gradients released by cells in the side of injury. If 
T cells encounter the cognate antigen, they will respond inducing a rapid and 
effective immune response.  
 
1.2.3.  Autoimmunity 
Autoimmunity is the failure of the organism to recognise its own constituent parts 
as no-self, which results in an immune response against its own cells and tissues. 
This aberrant response is due to autoantibodies and/or autoreactive T cells to 
specific antigen within a target organ. In some autoimmune diseases the 
autoantigens have been already identified as in the case of rheumatoid arthritis (RA) 
and systemic lupus erythematousus (SLE). In the case of psoriasis several 
autoantigens (keratin 13, heterogeneous nuclear ribonuclearprotein-A1 and rab 
coupling protein isoform 3) has been proposed, but a definitive final autoantigen has 
not been found yet (Bowcock 2005). However an autoimmune disease becomes 
manifest in less 50% of genetically predispose people indicating that other factors are 
also needed in order to make the disease manifest. In fact environmental factors in 
association with defects in immunoregulatory mechanisms are the additional 
components that can lead to the development of an autoimmune disease in 
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genetically predisposed individual. Several factors are known to trigger the 
immunological process leading to psoriasis including streptococcal infection, trauma 
to the skin, drugs and alcohol consumption, smoking and stress. 
1.3. Psoriasis 
The name psoriasis derives from the Greek, psora, which means to itch. Over the 
centuries psoriasis was described as a variety of leprosy. In the late 18th century an 
English dermatologist, Robert Willan, for the first time recognised psoriasis as an 
independent disease. He identified two categories: Leprosa Greacorum, which 
described the condition when the skin had scale and Psora Leprosa, when the 
disease becomes eruptive. But only in 1841 Ferdinand von Herba, a Viennese 
dermatologist, described the clinical picture of psoriasis which is used today and 
ascribed it the name “psoriasis”. It is during the 20th century that psoriasis was further 
differentiated into specific types (Bologna JL 2003). 
 
1.3.1.  Epidemiologic and genetic features 
Psoriasis affects 2-3% of the population worldwide, with prevalence varying 
according to race and geographic location. Higher rates of psoriasis have been 
reported in people of the Faroe Islands, were 2.8% of the inhabitants were found to 
be affected (Lomholt 1964). By contrast in Japan the prevalence is very low (0.2%) 
and almost absent in American Indians (Bowcock and Barker 2003). 
Males and females are equally affected and based on an important epidemiology 
study, done by Henseler and Christophers, two types of psoriasis have been 
described (Langley, Krueger et al. 2005). Early onset type psoriasis (or type Ι) is the 
most common form and occurs before age 40; late onset type psoriasis (or type ΙΙ) 
begins after the age of 40 years. Early onset type psoriasis has been reported to 
have more genetic susceptibility and hereditary association than late onset of the 
disease. The role of hereditary transmission in the pathogenesis of psoriasis is still 
poorly understood. Epidemiologic studies have confirmed that genetic factors are 
strongly involved in the pathogenesis of this disease and showed that there is a 
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threefold increased risk of psoriasis in monozygotic twins compared to fraternal twins 
(Farber and Nall 1974; Elder, Nair et al. 1994). However, as the concordance for 
psoriasis is never 100% among monozygotic twins these studies suggest that 
environmental factors also play an important role. So far at least six different 
susceptibility loci (designed PSORS1-PSORS6) have been identified (Nickoloff and 
Nestle 2004), however only two of these loci, PSORS1 and PSORS2, have been 
replicated in more then one study (Table Ι). PSORS1 is located in the MHC region on 
chromosome 6p21 and has been estimated to account for 30-50% of psoriasis cases 
(Trembath, Clough et al. 1997). For many years the HLA-Cw*0602 allele (most 
important gene of the PSORS1 locus) has been considered the major predisposing 
factor in this region. However,, due to the linkage disequilibrium in the PSORS1 
region, it is difficult to ascertain that HLA-Cw6 is the relevant candidate gene. Other 
candidate genes in the PSORS1 region include corneodesmosin (CDSN) and α−helix 
coiled coil rod homolog (HCR), which are expressed in skin cells (Elder 2006). 
PSORS2 is located on human chromosome 17q24-q25 and different family studies 
have shown its involvement in psoriasis (Nair, Henseler et al. 1997; Samuelsson, 
Enlund et al. 1999; Helms, Cao et al. 2003). In this region two genes, called 
SLC9A3R1 and NAT9, may be candidate genes for psoriasis.  SLC9A3R1 (solute 
carrier family 9, isoform 3 regulator 1) encodes a protein involved in actin 
cytoskeleton reorganization. It is implicated in negative selection of T cells in the 
thymus and may lead to the development of autoreactive T cells. NAT9 (N-
acetyltransferase family member 9), is involved in the glycosylation of 
immunoregulatory proteins, such as MHC-Ι molecules and components of the 
immunological synapse (Nickoloff and Nestle 2004). Moreover, between the two 
genes SLC9A3R1 and NAT9 lies an intragenic region also of interest for psoriasis. 
This region contains several runx-related transcription factor (RUNX) binding sites 
which are involved in haematopoietic cell development, development of T cells in the 
thymus and gene silencing. In psoriatic patients genetic analyses of this region have 
identified an associated single nucleotide polymorphism (SNP) that consequently 
abolishes a binding site for the transcription factor RUNX1. Alteration in RUNX1 
binding may lead to dysregulated self-tolerance and perturbation of T cell 
development or activation. Aberrant RUNX1 expression has also been correlated with 
other two autoimmune diseases: systemic lupus erythematosus and rheumatoid 
Chapter 1  General introduction 
 
 
 
30 
arthritis (Tokuhiro, Yamada et al. 2003) (Alarcon-Riquelme 2004) suggesting an 
important role of RUNX family members in the development of autoimmunity. 
Psoriasis may not be classified as a classical autoimmune disease, however there 
are some common features between autoimmune conditions and psoriasis. For 
example the presence of autoreactive T cells (Nestle, Turka et al. 1994), numerous 
oligoclonally expanded T cells, immunosuppressing drugs such as cyclosporine are 
effective against psoriasis and appearance or disappearance of psoriasis after bone 
marrow transplantation (Snowden and Heaton 1997) (Valdimarsson, Baker et al. 
1995). 
 
Table 1.1  PSORS Loci associated with psoriasis 
PSORS LOCUS CHROMOSOME  
LOCATION 
ASSOCIATED GENE STUDY POPULATION 
PSORS1 6p21 MHC class I Many 
PSORS2 17q25 SLC9A3R1 and NAT9 
American 
American and British 
PSORS3 4q ND - 
PSORS4 1q21 
Epidermal differentiation 
complex 
Italian and American 
(unpublished) 
PSORS5 3q21 SLC12A8 Swedish 
PSORS6 19p13 ND - 
                  Adaptation from Bowcock et Krueger (Bowcock and Krueger 2005) 
 
1.3.2. Clinical and histopathological aspects 
Psoriasis is a chronic skin disease characterised by the presence of dry red, 
raised, scaly plaques, which can be several centimetres in diameter. Usually, the skin 
is covered with many individual lesions, separated by normal appearing skin, 
whereas in severe cases all the skin can be affected. The most specific 
histopathological changes that distinguish psoriasis from other inflammatory skin 
diseases are dramatic hyperplasia of the epidermis (acanthosis) with loss of the 
granular layer, regular elongation of the rete ridges, thickening of the cornified layer 
(hyperkeratosis) and incomplete keratinocyte differentiation (parakeratosis), 
infiltration of many different leukocytes and increased vascularity in the dermis 
(Bologna JL 2003).   
Psoriatic lesions can be very variable in morphology, distribution and severity. 
Despite the classical presentation described above, psoriasis may be classified in 
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three main types: non-pustular psoriasis, pustular psoriasis and psoriatic arthritis. 
Each of these types can further be subdivided in other clinical variants (Figure 1.3) 
and the most common forms are outlined below. 
 
1.3.2.1. Non-pustular psoriasis 
Plaque-type psoriasis or psoriasis vulgaris is the most frequent type of psoriasis 
(80-90% of cases).  The classical sites of involvement are elbows, knees, scalp, 
buttocks and the lumbar region, but all areas of the body may be affected. The lesion 
may initially begin as small red papules that subsequently scale as they grow larger. 
These plaques tend do be symmetrical with clearly defined edges.  
A
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Figure 1.3  Clinical aspects of psoriasis. A) Psoriasis Guttate. B) Psoriasis palmo plantar pustulosa. 
C) Plaque type Psoriasis. D) Psoriasis Erythrodermie E) Psoriasis capillitii. F) Psoriasis Arthritis. G) 
Nail psoriasis. 
 
The second most common clinical form is the guttate phenotype which more 
commonly affects children or young adults and often follows a streptococcal infection. 
The lesions, round to oval in shape, have a very small diameter and usually spread 
over the trunk and the proximal limbs. This type of psoriasis has a more acute clinical 
course and may dissolve spontaneously. However it may eventually progress into 
plaque phenotype (Langley, Krueger et al. 2005). 
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Other less common variants are: inverse psoriasis, with non-scaling lesions 
located in groin and axillary regions and erythrodermic psoriasis, covering the entire 
body surface (Griffiths, Christophers et al. 2007). 
 
1.3.2.2. Pustular psoriasis 
Pustular psoriasis is an uncommon form of psoriasis consisting of widespread 
pustules on an erythematous background. Cutaneous lesions characteristic of 
psoriasis vulgaris may be present before, during, or after an acute pustular episode. 
It can affect the areas of the feet and the hands (palmo-plantar pustulosis) or be 
generalised and usually manifests itself as small sterile bumps or pustules on the 
surface of the skin. 
 
1.3.2.3. Psoriatic arthritis 
About 10-30% of people with psoriasis also develop psoriatic arthritis, which 
causes pain, stiffness and swelling in and around the joints. The onset of psoriatic 
arthritis generally occurs in the fourth and fifth decades of life. Males and females are 
affected equally. The skin disease (psoriasis) and the joint disease (arthritis) often 
appear separately. In fact, the skin disease precedes the arthritis in nearly 80% of 
patients. The arthritis may precede the psoriasis in up to 15% of patients. 
 
1.3.3. Immunopathogenesis 
Psoriasis is classified as an immune-mediated disease, characterised by a 
chronic and persistent inflammation. Typical alterations in psoriasis are 
hyperproliferation and abnormal differentiation of keratinocytes, lymphocyte 
infiltration consisting mostly of T lymphocytes, and various endothelial vascular 
changes in the dermal layer, such as angiogenesis and capillary dilatation. However 
the precise mechanism and sequence of interactions triggering the inflammatory 
cascade are still unknown. In the last years, different experimental findings and 
clinical observations have shown a central role for T cells in psoriasis pathogenesis. 
The first evidence supporting this idea came from the use of cyclosporine, a 
generalised T-cell immunosuppressant, whose administration to psoriatic patients led 
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to a remarkable improvement of the disease (Ellis, Gorsulowsky et al. 1986). 
Subsequently, administration of monoclonal antibodies or other specific approaches 
targeting T cells (Weinshenker, Bass et al. 1989; Prinz, Braun-Falco et al. 1991; 
Gottlieb, Gilleaudeau et al. 1995) confirmed the pivotal role of T lymphocytes in 
psoriasis. Moreover, experiments with immunodeficent mice transplanted with non 
involved skin from patients with psoriasis provided support for the concept of T cell 
mediated pathogenesis (Nickoloff and Wrone-Smith 1999). Finally, in the last years, it 
has been shown that tissue-resident immune cells in psoriasis may be sufficient to 
induce the epidermal changes typical of the disease (Boyman, Hefti et al. 2004; 
Boyman, Conrad et al. 2006). All these evidence are further supported by the fact 
that increased levels of activated T lymphocytes are present in psoriatic skin plaques 
and blood of patients (Bata-Csorgo, Hammerberg et al. 1995; Ellis and Krueger 
2001).  
 
1.3.3.1.  Development of skin lesions and the local immune system 
Although the initial event triggering a psoriatic lesion is still unknown, many 
environmental factors have been shown to play a role in the pathogenesis of 
psoriasis. External triggers such as physical trauma (known as the Köbner 
phenomenon), infections, stress, drugs, alcohol and smoking can all trigger an initial 
episode of psoriasis in those individuals who already have a genetic predisposition  
(Bowcock and Krueger 2005). These triggers also worsen the disease and can 
induce a severe relapse. Among all the external triggers mentioned above the only 
one which has consistently been associated with initiation of psoriasis is 
streptococcal infection. Group A streptococci have been related to the onset of 
psoriasis, especially acute guttate psoriasis, by inducing cutaneous lymphocyte 
associate antigen (CLA) expression on T cells, thereby facilitating T cell migration in 
the skin (Leung, Gately et al. 1995). It is also postulated that bacterial endotoxins can 
act as superantigens, activating T cells, macrophages and Langerhans cells 
(Swerlick, Cunningham et al. 1986). In fact streptococcal M proteins have epitopes 
common to some human keratins which are up-regulated in psoriatic lesions, but 
usually absent in healthy skin (Gudjonsson, Johnston et al. 2004). Hence psoriasis 
may be induced and exacerbated in susceptible individuals by M-protein specific Th1 
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cells that cross-react with human epidermal keratin (Valdimarsson, Sigmundsdottir et 
al. 1997). 
Even if the real antigen which triggers psoriasis has yet to be identified, 
researchers highlight three key steps in the development of psoriatic plaque. The first 
event driving psoriatic inflammation is the migration of CLA+ activated T cell into the 
dermis. Progressive accumulation of leukocytes and progressive epidermal 
hyperplasia characterise the evolution to an acute lesion. During this step some T 
cells, DCs and neutrophils start to infiltrate the epidermis and release 
proinflammatory cytokines, which in turn stimulate keratinocytes inducing epidermal 
hyperplasia. An acute lesion rapidly evolves to a chronic plaque characterised by a 
continuous migration of cells, especially CD8+T cells, to the epidermis and the 
accumulation of mature DCs together with T cells around dermal blood vessels 
(Bowcock and Krueger 2005).  
The events described above depict a multi-step process, which requires the 
recruitment of recirculating immune cells to the skin in order to develop a new 
psoriatic lesion. However, it is recently been proposed that once the very first 
episode inducing psoriasis has occurred, a subsequent inflammatory lesion can be 
triggered and sustained by the local skin immune system (Figure 1.1) (Boyman, 
Conrad et al. 2006). The evidence supporting this concept arises from the use of an 
established mouse model of psoriasis (Boyman, Hefti et al. 2004), which will only 
briefly be described in this section. Highly immunosopressed mice strains (AGR 129 
mice, which lack both type Ι and type ΙΙ IFN receptors and the recombination 
activating gene necessary for the immunoglobulin and T receptor gene 
recombination (RAG2-/-)) were transplanted with symptomless psoriatic skin of 
patient with psoriasis. Upon transplantation the grafts developed in typical psoriatic 
lesion, without requiring injection of activated T cells. The explanation for this 
phenomenon was that skin resident cells already present in the graft were necessary 
and sufficient for disease development. In fact, no T cells were found in the lymph 
nodes or in the spleen of grafted mice, showing that the cells present in the graft 
were sufficient to generate the lesion. Moreover the failure to generate a psoriatic 
lesion after administration of an anti-CD3 mAb, demonstrated that T cells and not 
KCs alone were necessary to generate the psoriatic phenotype. The theory that skin-
resident immune cells are sufficient to maintain and re-induce a psoriatic lesion 
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during the chronic relapsing course of the disease, is reinforced by the work of Clark 
et al (Clark, Chong et al. 2006 24). They propose that the majority of skin-homing 
lymphocytes reside in normal skin and that there are twice so many cells resident in 
the skin than are present in the circulation. The majority of these cells are memory T 
cells that are Th1 polarized and involved in cutaneous immunosurvelliance. 
Considering these two studies into account the development of a psoriatic lesion 
could be explained as follows (Figure 1.4). Once a patient has developed his first 
psoriatic lesion, his symptomless skin may be activated in a much faster manner due 
to the strategic positioning of pDCs, dermal DCs and T cells. Thus, an innocuous 
trigger could activate the resident cells, eliciting the inflammation cascade typical of 
psoriatic lesion, without recruitment of cells form the recirculation. After the initial 
trigger, one of the earliest events driving the inflammatory eruption are the secretion 
of INF-α from pDCs and the production of TNF-α by cells of the innate and adaptive 
immune system. High amounts of IFN-α released by pDCs induces the activation of 
the local immune effector cells that become capable of secreting cytokines that 
further promote the inflammatory cascade. TNF-α is a highly active cytokine of the 
inflammatory infiltrate and is an important pro-inflammatory factor in the development 
of psoriasis. Its important role in the pathogenesis of this skin disease has been 
demonstrated by the efficacy of anti- TNF-α–therapies (Infliximab and Etanercept) in 
patient with psoriasis (Kleyn and Griffiths 2006). TNF-α is mainly released by 
activated macrophages, dermal DCs and in a lesser extent by KCs and T cells. The 
high amounts of this released cytokine have mainly two direct consequences in the 
skin. Firstly, TNF-α leads to the maturation of DCs into more powerful APCs, 
secondly, in conjunction with other cytokines TNF-α up-regulates the expression of 
endothelial E-selectin and ICAM-1 on skin vessels. In this way, more and more CLA+ 
T cells will extravasate into the skin and take part in the inflammatory process 
(Guenther and Ortonne 2002). The panel of cytokines released by T lymphocytes is 
also responsible for potent stimulation of epidermal keratinocytes. They trigger 
keratinocyte hyperproliferation and induce the expression of ICAM-1, CD40 and 
MHC-ΙΙ, which favour the migration of T cells in the epidermis through LFA-1/ICAM-1 
interactions.  
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Figure from: The pathogenic role of tissue-resident immune cells in psoriasis. Boyman, Conrad, Tonel, Gilliet and 
Nestle, Trends in Immunol 2006 
Figure 1.4  Local skin immune system in psoriasis. Psoriatic patients who have already 
experienced a psoriatic lesion may quickly develop a second one.  Individuals with a genetic 
predisposition might develop psoriasis after an external trigger (physical trauma, infection, stress, 
etc.). During this first event (priming), dermal DCs (DDCs) migrate to the local lymph node and 
activate (auto)antigen-specific T cells (T). Subsequently, T cells migrate to the skin where they induce, 
together with PDCs and DDCs, the formation of a psoriatic skin lesion. After resolution of this inflamed 
state these patients might develop a second lesion more quickly (elicitation). The skin cells already 
present are necessary and sufficient to reinduce an inflamed state, without the requirement of 
recirculating cells. 
 
 
Finally, the cytokine milieu seems to be also responsible of the characteristic 
vascular changes observed in the dermis of psoriatic lesions, such as dilatation and 
tortuosity of capillaries, angiogenesis and high endothelial venule (HEV) formation. 
Angiogenesis and hyperpermeabilty are also a direct consequence of the high levels 
of VEGF/VPF (vascular permeability factor) produced by keratinocytes (Guenther 
and Ortonne 2002). 
From this scenario it becomes clear that cytokines play a central role in the 
initiation, maintenance and recurrence of psoriasis. Beside the already mentioned 
cytokines, IL-1, IL-2, IL-6, IL-8, IL-15, IL-22 and IL-23 have also been demonstrated 
to amplify the inflammatory reaction, which finally ends to the characteristic features 
of psoriasis. 
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1.3.3.2. T cells in chronic plaques 
As mentioned before, the number of T cells present in psoriatic lesions is highly 
increased when compared to the skin of healthy individuals. Moreover, large number 
of lymphocytes populates the epidermis of a chronic psoriatic lesion, while in normal 
skin no T cells are found at this level. The majority of T lymphocytes localised in the 
dermis are CD4+ Th cells, while those migrating to the epidermis are mainly CD8+ 
Tc cells. The majority of T cells in psoriatic plaques are CD45RO+ subtype, indicating 
that they are memory T cells that migrate into skin in recognition of a yet 
undetermined antigen. Moreover, these cells are persistently activated T cells, as 
identified by the surface expression of activation-associated molecules CD69 and 
CD25 (Ferenczi, Burack et al. 2000). Some investigators have reported an 
oligoclonal expansion of CD8+ T cells in psoriatic lesions, suggesting that these T 
cells have been clonally expanded by an antigen present in the skin (Chang, Smith et 
al. 1994; Lin, Norris et al. 2001). However, no consistent data have been reported 
regarding TCR clonality and further studies have to be done in order to confirm the 
real presence of psoriasis-specific T cell clones. 
Three other types of T cells might be important in psoriasis: interleukin 17 
producing T cells (Th-17), Treg and NK T cells.  
Th-17 cells are a recently identified lineage of effector CD4+T cells characterised 
by production of IL-17. Mouse models suggest that TGF-β and IL-6 mediate de novo 
differentiation of these cells from naïve precursors (Bettelli, Carrier et al. 2006; 
Mangan, Harrington et al. 2006). Survival and expansion of Th-17 cells on the other 
hand, seems to depend on IL-23, a cytokine produced by DCs and keratinocytes. IL-
23 has been shown to have a critical role in the development of several classic 
autoimmune inflammatory diseases in mice (Cua, Sherlock et al. 2003; Murphy, 
Langrish et al. 2003). Recent studies have also shown that both IL-17 and IL-23 are 
increased in psoriatic skin (Teunissen, Koomen et al. 1998; Lee, Trepicchio et al. 
2004). An interesting study by Sugiyama at al.(Sugiyama, Gyulai et al. 2005) showed 
that Treg cells are both functionally and numerically impaired in psoriasis, and as a 
result they cannot restrain the ongoing chronic inflammation. In this regard, it has 
been suggested that Treg and Th-17 may differentiate from the same precursor, 
depending on the balance of cytokines present in the surrounding milieu. Therefore, 
Treg and Th-17 cells may arise in a mutual fashion, depending whether they are 
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activated in the presence of TGF-β alone or TGF-β plus IL-6 respectively. In 
autoimmune diseases, as well as in psoriasis, the high amounts of IL-6 produced by 
the activated innate immune system would suppress the generation of Treg cells and 
induce a pro-inflammatory response dominated by Th-17 cells (Bettelli, Carrier et al. 
2006). Whether this scenario is of relevance in human pathology, future studies will 
show. 
Finally, there are few studies assessing the presence of NK T cells in plaques of 
psoriasis (Nickoloff, Bonish et al. 2000)(Cameron, Kirby et al. 2002). The exact 
function of these cells is still unclear, although they may inhibit or modulate 
inflammation as a reduced NK-T activity in animals appears to predispose to 
autoimmunity. 
 
1.3.3.3. DCs in chronic plaques 
Beside T cells, large amounts of DCs are also present in the psoriatic plaque. 
Both epidermal LC and dermal dendritic cells are increased in psoriatic skin lesions. 
Many of the dermal DCs display a mature or activated phenotype as identified by the 
expression of mature DC markers like CD80, CD83 and DC-LAMP. In contrast, few 
mature DCs are found in healthy skin or uninvolved psoriatic skin (Krueger and 
Bowcock 2005). Interestingly, Nestle at al showed that dermal DCs, derived from 
psoriatic plaque, strongly stimulated autologous T proliferation. Moreover they 
showed that these cells were six times more potent in inducing T cell proliferation 
compared to psoriatic blood-derived DCs or normal skin derived DCs (Nestle, Turka 
et al. 1994).  
Beside dermal DCs and LCs, another subset of DCs has been identified in the 
dermal psoriatic skin. Plasmacytoide DCs (pDCs) are absent in the skin of healthy 
individuals, but it has been shown to be extremely increased in the skin of patients 
with psoriasis (Nestle, Conrad et al. 2005). The activation of these cells trough TLRs 
and the resulting secretion of IFN-α may activate immune T cells in psoriatic skin, 
leading to the development of new psoriatic lesions. Indeed, it has been shown that 
the high amounts of IFN-α released by pDCs can induce myeloid DCs activation and 
maturation, increasing the presentation of autoantigens to the local autoimmune T 
cells (Blanco, Palucka et al. 2001). Finally, high concentration of IFN-α could also be 
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responsible of the impaired migration of LCs shown in psoriasis, not attributable to 
the lack of cytokine signals (TNF-α and IL-1β) normally required for migration 
(Cumberbatch, Singh et al. 2006). 
 
1.3.3.4. Keratinocytes in psoriasis  
Over the last 20 years it has been continuously discussed whether psoriatic skin 
lesions arise from a primary alteration in epidermal KCs or in immunocytes. As 
mentioned before the current dogma is that infiltrating T cells initiate and maintain 
psoriasis. In this view, cytokines released by T cells and other inflammatory 
components (as DCs, macrophages and neutrophils) would trigger KC 
hyperproliferation. Some inflammatory cytokines (e.g. IL-1, IL-6 and IFN-γ) have been 
shown to directly induce epidermal hyperplasia (Krueger 2002). Recently, IL-23, 
whose expression is increased in psoriatic lesion compared to healthy and psoriatic 
non-lesional skin (Piskin, Sylva-Steenland et al. 2006), has been implied in the 
development of epidermal acanthosis, most likely through the induction of IL-22 
(Chan, Blumenschein et al. 2006; Zheng, Danilenko et al. 2006). Injection of this 
cytokine into mouse ear or into the dermis induces epidermal hyperplasia and dermal 
inflammation similar to features seen in psoriasis (Chan, Blumenschein et al. 2006). 
Acanthosis may be a direct consequence of the observed increase of KCs STAT-3 
(signal transduction and activation of transcription 3), a pathway already shown to be 
critical for the development of psoriasis (Sano, Chan et al. 2005). An additional 
explanation for the chronic epidermal hyperplasia in psoriatic lesions has been 
suggested by Krueger (Krueger 2002), referring to an unpublished study done 
together with L Austin. The migration of T cells in the epidermis would first break the 
basement membrane, which has been shown to have large gaps or areas with 
reduced staining intensity for collagen IV and laminins (Fleischmajer, Kuroda et al. 
2000), and secondly disrupt desmosome connection between KCs. These two events 
could be interpreted by KCs as an injury and therefore induce a wound repair 
response. As a consequence a lot of mitogenic cytokines would be released by KCs 
triggering a regenerative epidermal growth. Hence, T lymphocytes in psoriatic 
epidermis would be responsible for the chronic hyperplasia both by releasing pro-
inflammatory cytokines and by disrupting epidermal integrity. 
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However, other studies are highlighting the central role of KCs in the induction of 
psoriasis. From the histological aspect, it has been claimed that psoriasis does not 
look like a T-cell skin disease, as i.e. lichen planus or lupus erythematosus (Nickoloff, 
Schroder et al. 2000), and also that the Koebner phenomenon can not be explained 
only by T cell aetiology. Moreover, some drugs that are used to treat psoriasis, e.g. 
cyclosporine A, not only interact with T cells activity, but also inhibit KC proliferation. 
Another evidence against the fundamental role of T cells in psoriasis arise from the 
observation that patient infected by HIV (human immunodeficiency virus), who have 
a reduced number of CD4+T cells, develop psoriasis with the same frequency as the 
rest of the population. However, patients with HIV infection often present with more 
severe clinical manifestations of psoriasis than the non-HIV population. (Namazi 
2004). Finally, in 2005 Zenz and al. reported an interesting animal model with 
psoriasis-like features (Zenz, Eferl et al. 2005). The authors knocked out JunB and c-
Jun, two components of the AP-1 transcription factor, which control cell proliferation 
and differentiation, cytokine production, and stress responses in the skin. 
Interestingly, these mice developed not only inflammatory skin lesions but also a 
form of destructive arthritis. This evidence suggested that alteration in the epidermal 
Jun-pathway may be sufficient to induce inflammatory reactions in the skin as well as 
in the joints. At the skin level these mice showed typical hallmarks of psoriasis: 
hyperkeratosis, enlarged blood vessels, infiltration of CD3+ cells and neutrophilis, as 
well as upregulation of several cytokines. Finally, the importance of this animal model 
lies in the fact that JunB is located in the PSORS6 locus, which has been shown to 
be a psoriasis susceptibility region on chromosome 19 (Hensen, Windemuth et al. 
2003). The above described transgenic animal model shifted again the interest 
towards KCs as first initiator in psoriasis. However, in order to confirm this hypothesis 
a better characterization of this mice model is required. In this context Brian Nickoloff 
(Nickoloff 2006) has raised some interesting questions with respect to this new 
animal model. Firstly, he argues if the epidermal thickening seen in the animal model 
of Zenz et al (Zenz, Eferl et al. 2005) can really be classified as a psoriatic lesion or 
could it be also attributed to other skin inflammatory disorders, such as atopic 
dermatitis. In fact there are a lot of human skin diseases in which epidermal 
hyperplasia is a consequence of a wound healing process. Secondly, even if in this 
model T cells were not necessary for disease development, Nickoloff believes that a 
better characterization of the CD3+ cell population in this psoriasis model is 
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mandatory. Nickoloffs observations in turn imply that before using animal models to 
study psoriasis rigorous testing is required in order to conclude that the model of 
interest truly resembles this unique human skin disease. 
 
1.3.4. Animal models of psoriasis 
Psoriasis seems to be a uniquely human disease (Conrad and Nestle 2006). 
Therefore, due to the lack of a natural occurring animal model, most of the research 
regarding the pathogenesis of psoriasis has been done on transgenic and 
xenotransplantation animal models. Through these models the pathogenic function of 
several cytokines and genes could be defined as well new insights into the 
immunology of psoriasis could be gained. 
 
Table 1.2  Animals models for psoriasis 
MODEL EPIDERMAL  
HYPER 
PROLIFERATION 
INCREASED 
VASCULARITY 
INFLAMMATORY 
CELLS 
T CELL 
INFILTRATE 
ANTIPSORIATIC  
TREATMENT 
REFLECTS 
HUMAN 
SITUATION 
Transgenic mice       
K14/KGF 
K14/IL-6 
K14/amphiregulin 
Yes Yes Yes No No data No 
K14/VEGF Yes Yes Yes No data No data No 
K14/IL-1α 
K14//TGF-α 
Yes No data Yes Few animals No data No 
Involucrin/IFN-γ Yes Yes Yes Yes, not 
epidermal 
No data No 
STAT-3C Yes Yes Yes Yes No data Yes 
       
Knockout mice       
Epidermal IKK2 Yes Yes Yes Yes, no 
functional role 
No data No 
Epidermal Junb/c-jun Yes Yes Yes Yes, marginal 
role 
No data No 
       
Xenotransplantation       
SCID Yes Yes Yes Yes Yes Yes 
AGR129 Yes Yes Yes Yes Yes Yes 
      Adaptation from Conrad and Nestle (Conrad and Nestle 2006) 
 
Different inflammatory mediators or growth factors, which have been proposed to 
participate in the development of psoriasis, have been overexpressed or knocked-out 
in order to make a genetically modified mouse model resembling this skin disease 
(Table ΙΙ). For example, transgenic mice with epidermal overexpression of IL-1α 
(K14/IL-1α) developed a spontaneous skin disease characterised by scaling and 
focal inflammatory skin lesions (Groves, Mizutani et al. 1995). Lesional skin of these 
animals presented histologically with a mixed cellular infiltrate, acanthosis and 
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parakeratosis. The effect on keratinocyte differentiation appeared to be modest, 
indicating that there are also other factors in psoriatic lesion that were absent in this 
animal model. On the other hand the IL-1α transgenic animal model showed a 
primary role of this cytokine during cutaneous inflammation. In order to study the role 
of IFN-γ in the pathogenesis of inflammatory skin disease, Carroll at al created a 
transgenic mice overexpressing IFN-γ in the superbasal layers of the epidermis 
(Carroll, Crompton et al. 1997). The skin of affected mice was characterised by 
keratinocyte hyperproliferation, enlarged dermal capillaries and dermal infiltration 
consisting of T cells and monocytes. The absence of T cells and LCs in the epidermis 
suggested that IFN-γ does not influence the migration of cells as seen in human 
psoriasis. Taken together, all these transgenic mice models fail to generate skin 
lesions with all the hallmarks of psoriasis, suggesting that a single cytokines is 
apparently not sufficient to induce the full phenotypic appearance of the disease.  
In recent years, some new genetically modified mice models, showing many 
characteristic features of psoriasis, have been published. Sano et al. generated a 
mouse model that constitutively overexpressed activated STAT-3 in the basal stem-
cells of the epidermis (Sano, Chan et al. 2005). Within two weeks after birth, animals 
developed reddened, scaling, thickened skin lesions on the tail and paws. Lesions 
progressed overtime to the trunk. Histolotgically the lesions showed a marked 
hyperplasia of the epidermis, loss of the granular layer, inflammatory infiltrates and 
angiogenesis. Furthermore, by blocking STAT-3 with a decoy oligonucleotide (which 
competes for binding of STAT-3 and interferes with its transcriptional activity) the 
disease could no longer progress. Finally, the authors showed the presence of 
activated STAT-3 in keratinocytes of uninvolved skin of psoriatic patients, implying 
pivotal role of this pathway in the development of psoriasis.  Another important 
observation is that the development of psoriatic lesions required not only STAT-3 
activation in keratinocytes but also the presence of activated T cells. These data 
suggests that the development of a full psoriatic lesion may depend from the co- 
presence of a signalling defect in keratinocytes and an inappropriate immunocytes 
activation state (Nickoloff 2006). 
Zenz and colleagues developed another interesting new mouse model by double-
knockout JunB and c-Jun (Zenz, Eferl et al. 2005). JunB, belongs to a family of 
transcription factors and is known to regulate cell proliferation, differentiation and 
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stress responses (Zenz, Eferl et al. 2005). Its activity is greatly reduced in lesional 
psoriatc skin, however, mice lacking JunB did not show any signs of psoriasis. Only 
through the combined deletion of JunB and c-Jun, a closely related gene proposed to 
antagonise JunB function (Zenz, Eferl et al. 2005), the typical symptoms of the 
disease could be induced. Animals mutated for JunB/c-Jun developed scaly plaques 
on their ears, paws and tails that closely resembled the characteristic lesions of 
human psoriasis. On histological examination, the epidermis was thickened and had 
prominent rete ridges, with hyperkeratosis and parakeratosis in the upper layers. 
Dermal vascularization was increased. Strictly the mice also developed arthritic 
lesions, with periostitis and massive bone destruction, similar to the psoriatic arthritis 
seen in humans. Interestingly, the  deletion of epidermal JunB and c-jun in Rag2-
deficeint mice (mice lacking T and B cells) still led to the development of skin lesions, 
though they were milder than those in the mice with normal Rag2 activity, suggesting 
that T and B cells make a minor contribution to the development of skin symptoms in 
psoriasis. In these Rag2-knockout mice joint inflammation and bone destruction were 
strongly reduced, leading to the conclusion that functional immune cells are 
necessary for the development of psoriatic arthritis (Zenz, Eferl et al. 2005) but not 
skin inflammation. However, conflicting data about the role of JunB in psoriasis are 
derived from another study showing that mRNA and protein levels of JunB were 
increased and not reduced in psoriatic lesions (Haider, Duculan et al. 2006). 
Moreover, this study showed that genes depending on the transcriptional activation 
of JunB were up-regulated, showing that JunB was biologically active in psoriatic 
lesions.  
Compared to transgenic mouse models, xenotransplantation models for psoriasis 
are very attractive because of their relatedness to human situation. Initially, 
investigators focused on human skin grafted onto nude mice. Using this approach, 
psoriasis could be maintained for more then 2 months without further manipulations 
(Fraki, Briggaman et al. 1983). Subsequently, uninvolved psoriatic skin was 
engrafted onto SCID (severel combined immunodeficiency disease) mice, which 
cannot make T and B cells but retain the capacity to produce neutrophils and NK 
cells. Therefore, they have been extensively used as host for tissue transplants. By 
using this immunodeficient animal model the pathogenic link between T cells isolated 
from psoriatic patients and the induction of skin alterations characteristic of psoriasis 
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has been demonstrated (Nickoloff, Schroder et al. 2000). Basically, when T cells from 
psoriatic patients were activated (using different stimuli such as bacterial 
superantigens, IL-2, etc) and injected into non involved psoriatic skin, consistent 
phenotypic conversion to a psoriatic plaque lesion was observed. Interestingly, only 
lymphocytes from psoriatic patients could promote plaque formation, and not 
immunocytes from healthy individuals. Moreover, only CD4+ T cells, but not CD8+, 
cells were able to induce psoriatic plaques formation (Nickoloff and Wrone-Smith 
1999). The mentioned animal model has also been successfully used as an 
experimental tool for preclinical screening of potential anti-psoriatic treatments 
(Nickoloff and Nestle 2004). Besides the SCID mice another new psoriasis xenogenic 
model has been evaluated recently (Boyman, Hefti et al. 2004). In this new approach, 
AGR129 mice were used as acceptor of human skin grafts. AGR129 mice have no 
functional receptors for type Ι (IFN-α/β) and type ΙΙ IFN (IFN-γ) and therefore show 
immature NK cells with impaired cytotoxic activity. Moreover they carry a third 
deletion (RAG) that enables the production of T and B cells. Upon transplantation on 
these mice, uninvolved psoriatic skin grafts spontaneously converted to psoriatic 
lesion without injection of any exogenous factor. Such spontaneous development of a 
full psoriatic phenotype indicates that the local environment present in the 
symptomless psoriatic skin is sufficient to drive psoriasis plaque formation. By using 
this new psoriasis mouse model new insights into the immunopathogenesis of 
psoriasis have been provided. Firstly, the model highlighted the importance of 
resident T cells for the development of the psoriatic lesion as by treating engrafted 
skin with anti-CD3 antibodies or TNF-α inhibitors the conversion into a psoriatic 
phenotype could be prevented. Secondly, this model showed that during 
development of psoriatic lesion T cell proliferation takes place in the dermis that is 
followed by a decrease of T cells in the dermis and a concurrent increase of T cells in 
the epidermis (Boyman, Hefti et al. 2004). 
A recent study has demonstrated that pDCs infiltrate uninvolved skin of psoriatic 
patients and become activated to produce IFN-α in the early phase of the disease 
development (Nestle, Conrad et al. 2005). Consequently, pDC-derived IFN-α would 
activate and expand the pathogenic T cell population already present in the skin, 
causing formation of psoriatic skin lesions. When the production of INF-α was 
blocked or prevented, the development of psoriasis was likewise blocked. This study 
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provided the first evidence for a role of pDCs-derived IFN-α in the pathogenesis of an 
autoimmune disease and presented IFN-α as a key cytokine in the development of 
psoriasis. The presented mouse model is the first in which psoriasis appeared 
spontaneously after skin engraftment and which allows the study of very early events 
leading to the development of psoriasis. However, there are limitations in the use of 
xenografts models.Upon transplantation no human bone marrow derived cells can 
participate in lesion formation, which precludes studies of trafficking between 
circulating cells and skin.  
1.4. Overview 
This thesis sought to delve deeper into the immunopathogenesis of psoriasis. In 
particular this work shows that cytokines, T cells and integrins are essential elements 
of psoriatic lesion formation. Chapter 2 provides functional evidence for a crucial role 
of the IL-23 axis in cutaneous inflammation and demonstrates the beneft of blocking 
the p19 subunit of IL-23 in the treatment of psoriasis. Chapter 3 provides evidences 
that although IL-17-producing cells take part in the inflammatory reaction during the 
formation of a psoriatic lesion, the inhibition of IL-17 function is not sufficient to block 
the onset of disease.. The first part of Chapter 4 is taken from an article published in 
Nature Medicine (Conrad, Boyman et al. 2007). This part shows the importance of 
extracellular matrix/T cell interactions in psoriasis and demonstrates that collagen IV 
binding integrin α1β1 is essential for expansion of epidermal T cells and the 
manifestation of the disease. The second part of chapter 4 focuses on the role of 
another integrin, α2β1, during psoriasis onset. It demonstrates that interaction of α2β1 
with collagen I causes KCs and ECs hyperproliferation and presents a T-cell 
independent mechanism for inhibiting the development of psoriatic lesions. Chapter 5 
contains concluding remarks of the data presented throughout this thesis work, 
outlines possible future experiments and opens further questions in the field of 
psoriasis research. 
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2. IL-23 promotes the development of new 
psoriatic skin lesions  
2.1. Introduction 
The heterodimeric cytokine IL-12 promotes IFN-γ production by NK cells and 
thereby resistance to intracellular infections, especially bacteria, protozoa and fungi. 
It also induces the differentiation of IFN-γ-secreting Th1 cells and has been 
implicated in chronic inflammatory disorders characterised by excessive Th1 
response (Trinchieri, Pflanz et al. 2003). In 2000, Kastelein and Bazan identified the 
new p19 subunit and showed that it dimerized with IL-12p40, to form a cytokine that 
they called IL-23 (Oppmann, Lesley et al. 2000). IL-12 and IL-23 belong to the IL-12 
family of heterodimeric cytokines and are composed of the identical p40 subunit plus 
a unique p35 and p19 subunit respectively. IL-12 and IL-23 receptors share the 
common IL-12Rβ1 (IL-12 receptor beta 1), for binding of p40, but require IL-12β2 and 
IL-23R respectively to induce signal transduction. These two cytokines activate a 
JAK-STAT (Janus kinase/signal transducer and activator of transcription) signal 
transduction cascade, which subsequently induces the activation of target genes in 
the nucleus (Trinchieri, Pflanz et al. 2003). The main difference between the 
signalling pathways of IL-12 and IL-23 is that IL-12 leads to the phosphorylation and 
activation of STAT-4 homodimers, whereas IL-23 mainly induces the formation of 
STAT-3/STAT-4 heterodimers (Figure 2.1). DCs and monocytes/macrophages are 
the major producers of these two cytokines (Trinchieri, Pflanz et al. 2003). IL-23p19, 
in the same manner as the p35 subunit of IL-12, is poorly secreted until the same cell 
produces the p40 subunit. An explanation for this tightly regulated secretion may be 
that an aberrant release can lead to severe inflammation (Hunter 2005). In this 
context it has been shown that mice ubiquitously overexpressing IL-23p19 develop 
systemic inflammation and die prematurely due to impaired growth (Wiekowski, 
Leach et al. 2001). Similarly, a constitutive overexpression of p40 in basal 
keratinocytes leads to the development of cutaneous inflammation with the 
characteristic of an eczematous skin disease (Kopp, Kieffer et al. 2001)(Kopp, Lenz 
et al. 2003).  
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Figure 2.1  IL-12/IL-23 structure and signal transduction. IL-12/IL-23 are covalently linked 
heterodimers composed of a unique light chain (IL-12p35/IL-23p19) and a common heavy chain (IL-
12p40). IL-12Rβ1 heterodimerizes with IL-12β2 to form the IL-12 receptor, whereas the dimerization of 
IL-12Rβ1 with IL-23R creates the IL-23 receptor. Engagement of these two cytokines with their 
receptor activate a similar spectrum of JAK-STAT molecules. IL-12 preferentially induces STAT-4 
homodimers, whereas IL-23 induces STAT-3/ STAT-4 heterodimers. Through activation of STAT-4 the 
primary action of IL-12 is to induce differentiation of naïve T cells and the production of IFN-γ, while IL-
23 may support the proliferation of memory T cells and the secretion of IL-17.   
 
The receptor complexes for IL-12 and IL-23 are primarily expressed on T and NK 
cells, but also on DCs and macrophages suggesting that these cytokines also act in 
an autocrine manner (Bastos, Marinho et al. 2004). Due to their structural similarities 
it was expected that IL-12 and IL-23 have overlapping activities. However, several 
studies published in the last years have shown that these two cytokines show very 
distinct functions. IL-12 induces the production of IFN-γ from T and NK cells and 
promotes the differentiation of naïve T cells into Th1 effector cells. Whereas IL-23 
acts on CD4+ memory T cells and promotes the expansion and survival of previously 
differentiated Th-17 cells (Bettelli, Oukka et al. 2007). In the last years it has also 
been demonstrated that chronic inflammatory diseases, especially in mice, previously 
attributed to IL-12 (Leonard, Waldburger et al. 1995)(Malfait, Butler et al. 1998), are 
indeed caused by IL-23. Perhaps the most compelling evidence for the fundamental 
role of IL-23 in the development of autoimmune disorders derives from studies done 
in the experimental autoimmune encephalomyelitis model (EAE). Cua et al, by using 
gene-targeted mice lacking only IL-23 and cytokine replacement studies, were the 
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first to demonstrate that IL-23, but not IL-12, is the critical cytokine in this disorder 
(Cua, Sherlock et al. 2003). In this work the authors compared the induction of EAE 
in mice lacking only either IL-23 (p19-/-) or IL-12 (p35-/-), or both cytokines (p40-/-). 
After injection of the encephalitogenic myelin oligodendrocyte glycoprotein (MOG) 
only p19-/- and p40-/- mice were resistant to EAE. Moreover, the delivery of IL-23 into 
the central nervous system (CNS) reconstituted EAE in both p19-/- and p40-/- mice. 
The mentioned study demonstrates that during disease onset IL-12 promotes the 
development of naïve T cells, whereas IL-23 mediates late stage inflammation by 
activating memory T cells and macrophages to produce pro-inflammatory cytokines. 
Consistent with the dominant role for IL-23 in the CNS inflammation, further studies 
demonstrated that this cytokine is an essential mediator also for joint autoimmune 
inflammation (CIA) (Murphy, Langrish et al. 2003) and inflammatory bowel disease 
(IBD) (Kullberg, Jankovic et al. 2006).  
In psoriasis, as in the disease mentioned before, IL-12 was thought to be the 
driving force behind the persistent inflammatory reactions. MRNA for the p40 subunit 
of IL-12 as well as expression of IL-12p70 protein was shown to be increased in 
psoriatic lesions as compared with normal and non lesional psoriatic skin (Yawalkar, 
Karlen et al. 1998). Moreover, the administration of an antibody against IL-12 in a 
psoriasis mouse model inhibited the development of the disease (Hong, Chu et al. 
1999). However, with the identification of IL-23 and its role in many autoimmune 
diseases researchers argued for a possible role of this cytokine also in psoriasis. The 
first who confirmed this hypothesis were Lee and co-workers who showed a 
consistent increase in IL-23 production in psoriatic lesional skin, as compared to non 
involved psoriatic skin or skin from healthy volunteers. They showed a strong 
upregulation of both p40 and p19 subunits, but not of p35, indicating that IL-23 rather 
then IL-12 may be involved in the pathogenesis of psoriasis (Lee, Trepicchio et al. 
2004). A subsequent study demonstrated that not only DCs and macrophages can 
produce IL-23, but also human keratinocytes constitutively express the p40 and p19 
subunits of IL-23. Moreover, the keratinocyte-secreted IL-23 was shown to be 
biologically active and capable to induce IFN-γ production in memory T cells (Piskin, 
Sylva-Steenland et al. 2006). Recently, two independent studies demonstrated that 
intradermal injection of IL-23 induced the development of epidermal acanthosis in 
mice (Zheng, Danilenko et al. 2006)(Chan, Blumenschein et al. 2006). Additionally, 
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Zheng et al demonstrated that also IL-12 injection led to an increase in epidermal 
thickening, however at a much lower level then the one seen with IL-23. The 
infiltrating lymphocytes of both IL-12 and IL-23 treated mice were composed by 
CD4+ and CD8+ cells, but the two treatments induced different cytokines profiles. 
The injection of IL-12 induced an increase only of IFN-γ levels, whereas IL-23 led to 
the production also of IL-17 and IL-22, which were already shown to be increased in 
psoriatic lesions (Chan, Blumenschein et al. 2006)(Wolk, Kunz et al. 2004). 
Moreover, binding of IL-22 to its receptor, whose expression in the skin is confined to 
KCs, mediates epidermal acanthosis through the activation of STAT-3. These 
observations potentially explain the increased STAT-3 expression in the epidermal 
compartment of the previous mentioned IL-23 treated mice (Zheng, Danilenko et al. 
2006) and in the skin of psoriatic patients (Sano, Chan et al. 2005).  
Recent studies have supplied genetic evidence that the IL-23 pathway may be 
critical for the pathogenesis of psoriasis. The identification of two psoriasis-
susceptibility genes, i.e. variants of IL-12B and IL-23R associated with psoriasis, 
underscore the importance of this pathway (Capon, Di Meglio et al. 2007; Cargill, 
Schrodi et al. 2007). The same variant in the IL-23R has been observed in IBD 
(Duerr, Taylor et al. 2006), suggesting that the IL-23R locus may play a key role in 
the development of chronic inflammatory diseases.  
Promising data about the relevance of IL-23 in the immunology of psoriasis also 
come from a clinical study using a neutralizing antibody to IL-12p40 in patients with 
moderate to severe psoriasis vulgaris. Phase-Ι and -ΙΙ studies showed the safety and 
the prolonged efficacy of a single intravenous injection of the human neutralizing 
antibody to IL-12p40 and demonstrated a concentration dependent efficacy in the 
treatment of psoriatic lesions (Kauffman, Aria et al. 2004; Krueger, Langley et al. 
2007). Additional studies will define the potential of this compound in psoriasis. 
Nevertheless all these data together show the importance of studying the IL-23 
pathway in psoriasis and provide the evidence that IL-23 or downstream cytokines 
may be a good target for psoriasis treatment. 
The studies mentioned above showed a dysregulation of the IL-23 axis in lesional 
skin of patients with psoriasis and unequivocally demonstrated that the direct 
injection of this cytokine into murine skin induces dermal inflammation and 
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acanthosis resembling psoriasis. However, the functional role of IL-23 in human 
psoriatic lesions remains to be determined.  
To better understand the function of IL-23 in the pathogenesis of this chronic 
inflammatory skin disorder the following experiments were performed. First, analyses 
were done on blood and tissues of psoriasis patients. A statistically significant 
increase of the IL-23 receptor was seen in peripheral CD3+ cells of psoriasis patients 
compared to healthy controls. In contrast, peripheral DCs and B cells of these two 
groups had similar levels of IL-23R expression. The next step was to determine the 
expression of IL-23R in the skin. In line with the results obtained in the blood with 
immune cell subpopulations, overexpression of IL-23R was detected on T cells and 
also on DCs of psoriatic patients compared to healthy donors. When IL-23R 
expression was analysed on the surface of KCs a similar pattern of expression was 
seen on cells isolated from the skin of psoriatic patients compared to that of healthy 
individuals. Subsequently, lesional psoriatic skin sections were stained with a 
monoclonal antibody specific for IL-23. Dendritic appearing cells in the dermis of 
psoriasis stained positive for this antibody, indicating that DCs are the main producer 
of IL-23 in this disease, as already shown by other groups (Lee, Trepicchio et al. 
2004). However, in accordance with previous data presented by Piskins et al. (Piskin, 
Sylva-Steenland et al. 2006), further analyses showed the presence of IL-23 also in 
the epidermis of psoriatic lesion, indicating that also KCs are able to produce this 
cytokine. Finally, in order to put the tissue expression data in a functional context the 
role of IL-23 was analysed in a humanized psoriasis mouse model (the AGR 
xenotransplantation psoriasis mouse model). Administration of a neutralizing Ab 
against human IL-23 inhibited psoriasis development in a manner comparable to the 
use of anti-TNF-α blockers, the current “gold standards” of anti-psoriatic therapy. 
Anti-IL-23 monoclonal Ab (mAb) treatment also blocked human epidermal and 
dermal T cell expansion, typically seen during psoriasis development. In a final step, 
IL-23 kinetics during development of psoriatic lesions was monitored. This analysis 
showed that the appearance of IL-23 correlated with the increase of T cells in the 
skin and with epidermal hyperplasia during development of a psoriatic lesion 
.
Chapter 2  Results 
 
 
53
 
2.2. Results 
2.2.1. Analysis of IL-23R expression in the blood and in the 
skin of psoriatic patients 
 
An IL-23R variant has been found to be associated with psoriasis in whole 
genome association studies (Capon, Di Meglio et al. 2007; Cargill, Schrodi et al. 
2007). Specifically, the allele for the R381Q single nucleotide polymorphism 
conferred protection against psoriasis. The same variation has also been reported to 
strongly associate with Crohn’s disease (Duerr, Taylor et al. 2006), suggesting that 
common genetic variants may contribute to the pathogenesis of chronic epithelial 
disorders, such as Crohn’s disease and psoriasis. It is unknown whether IL-23R is 
differently expressed in psoriatic patient compared to healthy donors. The aim of the 
first part of this study was to analysed the IL-23R expression in the blood and in the 
skin of psoriatic patient and compare it with that of healthy volunteers.   
 
2.2.1.1. Increased expression of IL-23R on psoriatic blood T cells 
IL-23R+ PBMCs of psoriatic patients (n=12) and healthy individuals (n=13) were 
detected using a specific antibody against the IL-23R chain and subsequently 
analysed by flow cytometry (Figure 2.2C). T cells of patient with psoriasis showed 
higher levels of IL-23R expression compared to healthy donor’s lymphocytes. A more 
detailed analysis of T cell subpopulations demonstrated that there was a statistically 
significant increase in CD3+ and CD4+/IL23R+ T cells in psoriatic patients compared 
to healthy controls (Figure 2.2A). In contrast, psoriatic CD8+ T cells had only a 
slightly increased expression of the IL-23 receptor when compared to the same 
subpopulation in the blood of healthy donors. DCs, identified as CD11c+/HLA-DR+ 
cells, were also expressing the IL-23R, but no statistical significance was seen in the 
two analysed groups. Three colour staining with IL-23R, CD19 and CD40 revealed 
that B cells also express the receptor for IL-23, but only a slight increase was seen 
by comparing these cells in psoriatic patients versus healthy donors (Figure 2.2B).  
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Figure 2.2  Increased interleukin-23 receptor expression in psoriatic blood cells. Expression of 
IL-23R on blood T cells of psoriatic patients and healthy controls (A). IL-23R expression showed a 
statistically significant increase on CD3+ (p=0.02) and CD4+ (p=0.01) T cells of psoriatic patients 
compared to CD3+ and CD4+ T cells of healthy controls. (B) IL-23R expression on DC and B cells. No 
significant difference was seen in the expression of IL-23R, neither for DCs or B cells, on psoriatic 
patients compared to healthy controls. (C) Examples of expression of IL-23R on cells freshly isolated 
from blood of healthy controls or psoriasis patients. The antibodies used for analysis are indicated on 
the x and y axes. Third and fourth column represent IL-23R expression in healthy controls or psoriatic 
patients respectively. The numbers in quadrants indicate percentage of cells staining positive for IL-
23R. Dot plot shown are gated either on lymphocytes or DCs. Data represent mean of 12 (psoriatic 
blood) or 13 (healthy donors) respectively experiments performed on different donors.  
* p= 0.02, ** p=0.01 
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2.2.1.2. IL-23R expression in lesional psoriatic skin 
Experiments shown in paragraph 2.2.1.1 demonstrated that peripheral T cells of 
psoriatic patients had a significant increase of IL-23R compared to the same 
subpopulation in the blood of healthy donors. In contrast, only a slight increase in the 
level of IL-23R expression was seen in DCs and B cells of patients with psoriasis 
compared to healthy individuals. The next step was to investigate the expression of 
this receptor directly in the skin. For this purpose three biopsies of patients with 
chronic-plaque –type psoriasis and three skin samples from healthy volunteers (NN 
skin) were analysed. Split-thickness skin was obtained using a dermatome. 
Epidermal and dermal sheets were separated and cell suspensions, obtained after 
enzymatic treatment of epidermal or dermal sheets, were afterwards used for 
cytofluorimetric analysis. Psoriatic tissue T cells showed a significantly higher level of 
IL-23R expression compared to lymphocytes isolated from the skin of healthy 
individuals (Figure 2.3A). CD8+ lymphocytes had an increase, although not 
significant, of the receptor for IL-23. In contrast CD4+ T cells of psoriatic patients had 
similar expression of IL-23R compared to CD4+ cells isolated from the skin of healthy 
individuals. An explanation for these results could be that during separation of 
epidermal/dermal sheets an enzymatic step is required. Some enzymes, such as 
trypsin, have a proteolytic effect on CD4 (Lynch, Slaytor et al. 2003), which could 
explain the low levels of CD4+ cells found in the biopsies and also the few CD4/IL-
23R double positive T cells present in both PP and NN skin. Upon examination of IL-
23R on epidermal Langerhans cells (LCs) and dermal DCs of healthy individuals a 
lower expression level was observed when compared to the same cell population 
present in the tissue of patient with psoriasis (Figure 2.3B). The final part of this study 
focused on the expression of IL-23R on KCs, the main cells of the skin epidermis. 
KCs isolated from the skin of psoriatic patients (n=3) showed a similar pattern of 
expression to that observed in the epidermal cell suspensions of healthy individuals 
(n=3) (Figure 2.4). These data suggest that KCs constitutively express the IL-23R on 
their surface and that they do not increase the levels of this receptor in response to 
the inflammatory environment of a psoriatic lesion. 
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Figure 2.3  Expression of IL-23R in psoriatic and normal human skin. Significant increased levels 
of IL-23R expression were seen in epidermal and dermal psoriatic CD3+ (p=0.03) and CD8+ (p=0.03) 
cells when compared to CD3+ and CD8+ lymphocytes of healthy individuals (A). Dermal DCs and 
epidermal LCs isolated from NN skin presented significant less IL-23R levels on their surface 
compared to the same cells in the skin of psoriatic patients (B). Representative example of IL-23R 
expression on cells freshly isolated from the epidermis and dermis of psoriatic skin biopsies (C-D). 
Flow cytometry analysis revealed that approximately 12% of T cells in the epidermis and in the dermis 
as well were positive for IL-23R (C). Among the LCs in the epidermis and DCs in the dermis 14% and 
30% respectively stained positive for the IL-23R (D). Graph C-D: Epidermal/dermal T cells and DCs 
data are gained from 2 distinct patients and are representative of three independent experiments.          
* p≤0.03, ** p=0.009 
 
 
 
Figure 2.4  IL-23R expression in keratinocytes. Representative flow cytometry analysis of IL-23R 
expression in epidermal cell suspension isolated from psoriatic plaque lesions. Percentage of IL-23R+ 
KCs is indicated in the plot.  
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2.2.1.3. Identification of IL-23 expressing cells 
Immunohistochemical stainings of skin sections done by Schering-Plough 
Biopharma showed that the IL-23 protein was localized in dendritic appearing cells in 
the dermis of psoriasis (Figure 2.5). 
 
 
 
Figure 2.5  Presence of IL-23 in dendritic appearing cells. Expression of IL-23 protein (mAb 
12F12) is demonstrated on dendritic appearing cells in the dermis of psoriasis. Isotype control staining 
is negative.  
 
Interestingly, when immunohistochemical stainings of psoriatic sections were 
performed in our laboratories, the same Ab showed a diffuse positive pattern also in 
the epidermis, indicating that not only DCs, but also keratinocytes produced and 
secreted this cytokine (Figure 2.6). Similar staining pattern were already shown by 
Piskin and al. (Piskin, Sylva-Steenland et al. 2006). This group further analysed the 
biological activity of keratinocyte-produced IL-23 and demonstrated that the secreted 
cytokine was able to enhance IFN-γ expression by memory T cells. Therefore it is 
likely that KCs release IL-23, which in turn may affect infiltrating T cells, inducing the 
production of proinflammatory cytokines such as IL-17.  
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Figure 2.6  Immunohistochemical staining of IL-23. (A) Anti-IL23 showed an intense positive 
pattern in the epidermis. Arrow indicates IL-23 expression also in dermal cells. (B) Isotype control 
specimens.  
 
 
2.2.2. In vivo evidence for a functional role of IL-23 in psoriasis 
2.2.2.1. Injection of anti-IL-23 antibody inhibits development of psoriasis in the 
AGR psoriasis mouse model 
The next step was to investigate whether the blockade of IL-23 signalling in vivo 
was sufficient to prevent the spontaneous conversion of uninvolved skin (PN) in 
psoriatic skin lesions (PP) in the AGR xenotransplantation psoriasis mouse model. 
Anti human-IL-23 neutralizing mAb, provided by Schering-Plough Biopharma, was 
injected subcutaneously at day 7 and day 21 and histological analyses of the grafts 
were performed at day 35. The effect of the anti-IL-23 mAb was compared to isotype 
control treatment and the current benchmark anti-TNF-α (Infliximab). Skin grafts from 
mice receiving isotype mAb developed a fully fledged psoriatic phenotype, showing 
an epidermal hyperplasia similar to the one observed in the lesional psoriatic skin of 
the donor patient (Figure 2.7B and D). In contrast, treatment with anti-IL-23 
significantly inhibited the development of psoriasis, with grafts presenting a 
histological picture nearly indistinguishable from the uninvolved skin before 
transplantation. (Figure 2.7A and C). Acanthosis and papillomatosis indices were 
quantified in skin grafts of three independent experiments with PN skin from three 
different patients. There was a statistically significant reduction of psoriasis 
acanthosis (p=0.0005) and papillomatosis indices (p=2.3x10-6) in grafts of mice 
injected with anti-IL-23 compared to isotype control treated mice (Figure 2.7E and F). 
Moreover anti-human IL-23 antibody demonstrated to have a similar inhibitory effect 
on psoriasis development as the well established anti-psoriatic drug anti-TNF-α 
(Infliximab).  
A B 
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The described results clearly indicate that IL-23 is required for the development of 
lesional psoriatic skin and that the neutralization of this cytokine can significantly 
prevent the onset of a psoriasiform chronic inflammatory reaction. 
 
 
 
Figure 2.7  Blockade of IL-23 prevents development of psoriasis in a psoriasis 
xenotransplantation mouse model. Microscopic view of uninvolved psoriatic (PN) skin on the day of 
transplantation (A) and lesional psoriatic skin of the same patient (B). Uninvolved skin 5 weeks after 
transplantation onto AGR129 mice treated with anti-human IL-23 antibody (C) or isotype control 
antibody (D). Acanthosis (E) and papillomatosis indices (F) in skin grafts before transplantation onto 
AGR129 mice and after 35 days treatment with either anti-human IL-23 or isotype-matched control 
antibody. There was a statistically significant reduction of psoriasis acanthosis and papillomatosis 
indices in grafts of mice treated with anti-human IL-23 compared to isotype control mice. The efficacy 
of the treatment with anti-human IL-23 in inhibiting psoriasis development was comparable to anti-
TNF-infliximab), the „gold standard“ in psoriasis treatment. (F). Data in panel E and F were pooled 
together from three independent experiments with PN skin from three different patients. Dots 
represent independently grafted mice samples. Scale bars in A-D represent 20µm. P-values were 
calculated using the unpaired Student‘s t test. * p≤ 0.01,** p≤ 0.001, *** p≤0.0001 
 
2.2.2.2. Anti-IL-23 therapy inhibits inflammatory T cell expansion 
There is a strict relationship between the presence of T cells in a pre-psoriatic skin 
and the development of a psoriatic lesion. In fact previous work showed that the 
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blockade of T cell function after transplantation of PN skin onto AGR mice inhibited 
the development of a psoriatic lesion (Boyman, Hefti et al. 2004; Boyman, Conrad et 
al. 2006). Hence, the capacity of an antibody to block the proliferation of T cells 
reflects the efficacy of the treatment. In order to asses the impact of IL-23 blockade in 
this context, the number of CD3+ T in the engrafted skin on the day of transplantation 
and after 35 days were analysed. Transplants of mice treated with anti-IL23 mAb 
showed a significant reduction (p< 0.001) of total T cells number compared to grafts 
injected with isotype control mAb (Figure 2.8A). Moreover by analysing the 
distribution of these lymphocytes, isotype control treated mice showed an increase of 
the T cell epidermal to dermal ratio, whereby both anti-IL23 and anti-TNF-α treatment 
led to a reduction of this ratio (Figure 2.8B). Injection of anti-IL23 mAb therefore 
blocked the proliferation and the migration of T cells into the epidermis with an 
efficacy comparable to anti-TNF-α treatment, the “gold standard” in anti-psoriatic 
therapy.  
 
 
Figure 2.8  IL-23 blockade reduces the number of inflammatory T cells (A) Total human CD3+ T 
cell count in PN skin grafts before transplantation and 35 days after transplantation and treatment with 
either anti-human IL-23, isotype-matched control or anti-TNF-α (infliximab) antibody. There was a 
statistically significant reduction of CD3+ total T cells in grafts treated with anti-human IL-23  
compared to isotype control treated mice. (B) Number of CD3+ T cells present in the epidermal and 
the dermal compartment. Treatment with anti-human IL-23 led to a significant reduction of CD3+ T 
cells in both the epidermis and dermis of grafted skin. Dots in panels A represent independently 
grafted mice samples and are representative of three independent experiments with PN skin from 
three different patients. P-values were calculated using the unpaired Student‘s t test. 
* p≤0.003, ** p≤7x10-4, *** p<7x10-6. 
 
2.2.2.3. Increase in IL-23p19 mRNAs parallels the typical psoriatic changes in 
the epidermis 
The advantage of the xenotransplantation mouse model used throughout this 
thesis is that uninvolved psoriatic skin engrafted on these mice spontaneously 
converts into a typical psoriatic plaque lesion within 35 days. This allows to 
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investigate all the immunological and phenotypical changes that occur during the 
conversion of uninvolved prepsoriatic skin (PN) into a fully-fledged psoriatic lesion 
(PP). In a recent work we showed that during the formation of a psoriatic lesion there 
is an increase and redistribution of CD3+ T cells in graft transplanted on the AGR 
mouse model (Conrad, Boyman et al. 2007). Specifically, during the first 2 weeks 
only a proliferation of dermal T cells was observed in the grafts in the absence of 
visible changes in the epidermis. Afterwards, around day 21, the migration and 
proliferation of T cells in the epidermal compartment induced the typical psoriasiform 
changes such as an increase in the papillomatosis and acanthosis indices. Based on 
the results of the previous paragraphs, which showed the importance of IL-23 during 
the formation of a psoriatic lesion, the next step was to investigate IL-23 production in 
relation to the development of a psoriatic plaque. Prepsoriatic skin of two different 
patients was engrafted on the AGR mice and analysed on day 0 and after 7, 21 and 
35 days upon transplantation. RNA was extracted from grafts and quantitative RT-
PCR was performed using human specific primers for IL-23p19. This experiment 
showed an increase of IL-23p19 mRNA levels during the course of the disease 
reaching a peak at day 35. By correlating the kinetics of mRNA expression for this 
cytokine with the proliferation of pathogenic T cells, a slight delay in IL-23p19 
expression levels was seen compared to the expansion of CD3+ T cells (Figure 2.9A, 
C). This observation is in agreement with previous work which showed that IL-23 is 
not necessary for the proliferation of T cells, but is important for the induction and 
survival of the recently discovered Th-17 subpopulation, which have been associated 
with different autoimmune diseases, including psoriasis (Zheng, Danilenko et al. 
2006). Moreover, IL-23p19 mRNA levels approximately paralleled the typical 
epidermal hyperplasia seen during the development of a psoriatic lesion (Figure 
2.9B, D). A result that supports the observation of Zheng at al, who showed that IL-
23 promotes the thickening of the epidermis through the induction of IL-22 and 
activation of Stat3 in KCs, a pathway critical for psoriasis development (Zheng, 
Danilenko et al. 2006). 
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Figure 2.9  IL-23p19 mRNA expression during psoriasis development in the AGR-/- xenograft 
mouse model. Kinetics of human IL-23p19 mRNA expression (normalized to human GAPDH) during 
psoriasis development was compared to the number of total CD3+ T cells (A, C) and papillomatosis 
indices (B, D). Grafts were analysed on the day of transplantation and after 7, 21 and 35 days. RNA 
was extracted from grafts and quantitative RT-PCR was performed using human specific primers for 
IL-23p19. Experiments were repeated twice, with A, B representing one patient and C,D the second 
patient. 
 
 
2.3. Discussion 
IL-23 is a heterodimeric cytokine, belonging to the IL-12 family, and is mainly 
secreted by DCs and macrophages (Trinchieri, Pflanz et al. 2003). In the last years 
several studies have demonstrated the essential role of IL-23 in the regulation of cell 
mediated immune responses, with at least one of its activities being to support the 
survival of Th-17 cells. In different models of autoimmune disease, such as IBD, CIA 
and EAE, it was shown that the neutralization of IL-23 function significantly 
ameliorated disease pathogenesis (Kullberg, Jankovic et al. 2006)(Cua, Sherlock et 
al. 2003; Murphy, Langrish et al. 2003; Langrish, Chen et al. 2005). More recently, IL-
23 was also found to be an essential mediator in skin inflammation. In fact, the direct 
injection of IL-23 in mouse skin was shown to induce psoriasisform changes like 
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dermal inflammation, erythema, and epidermal hyperplasia (Chan, Blumenschein et 
al. 2006)(Zheng, Danilenko et al. 2006). Finally, there are at least three different 
direct evidences for the involvement of IL-23 in the pathogenesis of psoriasis. First, 
psoriatic lesions have an increased expression of IL-23 mRNA and protein compared 
to uninvolved psoriatic skin and the skin of healthy donors (Lee, Trepicchio et al. 
2004)(Piskin, Sylva-Steenland et al. 2006)(Chan, Blumenschein et al. 2006). 
Secondly, a humanized mAb targeting the p40 subunit of both IL-12 and IL-23 
already reached the phase ΙΙ of a clinical trial, demonstrating the efficacy of inhibiting 
IL-23 function in psoriasis (Kauffman, 2004; Krueger, 2007}. Finally, two single 
nucleotide polymorphisms in the IL-23R gene locus have been reported to highly 
associate with psoriasis (Capon, Di Meglio et al. 2007; Cargill, Schrodi et al. 2007). 
Although all these studies suggest an imporatance of the IL-23 pathway in psoriasis, 
no data are available regarding the specific role and function of this cytokine during 
disease development. 
The first part of this study focused on the expression of IL-23R in tissues of 
patients with psoriasis. The analyses were done on cells freshly isolated from the 
peripheral blood and stained with a specific mAb to the IL-23R chain. Flow cytometry 
analyses demonstrated a significant increase in IL-23R expression on CD3+ and 
CD4+ cells of patients with psoriasis (n=12) compared to healthy donors (n=13). 
Approximately 30% and 10% of peripheral monocytes/DCs and B cells respectively 
stained positive for IL-23R, with psoriatic patients having a slight increases in the 
levels of expression on both populations.  
As psoriasis is mainly a skin disease the next step was to analyse cells isolated 
from the epidermal and dermal compartment of psoriatic lesions (n=3). Dermal DCs 
and T cells showed the highest levels of IL-23R with a significant increase compared 
to the same cells residing in the skin of healthy individuals. In contrast, no difference 
in the pattern of expression was detected among psoriatic and healthy KCs. 
Collectively, these data indicate that in psoriasis there is a dysregulation of IL-23R 
expression, which may lead to the aberrant activation of immune cells and induce a 
pro-inflammatory cascade leading to the typical psoriasiform changes.  
One typical feature of psoriatic lesions is the large increase of mature DCs 
compared to the immature state of these cells in the symptomless psoriatic skin 
(Nestle, Turka et al. 1994; Lee, Trepicchio et al. 2004). During this study 
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immunohistochemical staining of psoriatic skin section showed expression of IL-23 
on dendritic appearing cells in the dermis, a result that agrees with other studies 
where human mature DCs were shown to secrete IL-23 in response to different TLR 
agonists (Vanden Eijnden, Goriely et al. 2006). Taken together these two results 
indicated that IL-23 may be produced by dermal DCs as a consequence of a still 
undefined external trigger. The fact that an excessive production of IL-23 can lead to 
an overreaction of the immune response has been shown in different mouse models. 
For example, mice constitutively expressing the p40 subunit of IL-12/IL-23 in the 
basal layer of the epidermis had an enhanced production of IL-23, but not IL-12, and 
spontaneously developed an inflammatory skin disease with increased numbers of T 
cells, neutrophilis and macrophages (Kopp, Lenz et al. 2003). Moreover, transgenic 
mice expressing mouse IL23p19 mRNA in multiple tissues showed systemic 
inflammation, impaired growth, and premature death (Wiekowski, Leach et al. 2001).  
In order to study the in-vivo relevance of IL-23 in psoriasis, keratomes from 
uninvolved psoriatic skin were xenografted in an established mouse model of 
psoriasis (Boyman, Hefti et al. 2004; Nestle, Conrad et al. 2005; Conrad, Boyman et 
al. 2007). Previous studies have shown that after engraftment, transplants developed 
a typical psoriatic lesion over the course of 5 weeks, characterised by epidermal 
hyperplasia (acanthosis,) elongation of the rete ridges (papillomatosis) and increased 
number of dermal and epidermal T cells. During this study transplanted mice were 
treated with either neutralizing mAb to IL-23 or isotype matched control Ab and grafts 
were then analysed after 35 days. Immunohistochemestry evaluation of acanthosis 
and papillomatosis indices demonstrated that IL-23 treatment had the same efficacy 
in inhibiting psoriasis development, as TNF-α, the “gold standard” in anti-psoriatic 
therapy. Mice treated with isotype mAb instead developed into a full-fledged psoriatic 
lesion, with epidermal hyperplasia reaching similar levels as the lesional psoriatic 
skin of the donor patient. IL-23 neutralization significantly reduced also the activation 
and expansion of pathogenic T cells, thereby confirming the importance that this 
cytokine has on the immune components and on the skin environment as well.  
Our results are in agreement with previous finding in the EAE animal model, 
which showed that IL-23 is important during the development and recruitment of 
inflammatory cells to the CNS (Thakker, Leach et al. 2007). A similar scenario can 
therefore be postulated in psoriasis. It is likely, that IL-23 is important during the 
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development of the psoriatic plaque as it triggers a proinflammatory cytokine cascade 
responsible for epidermal hyperplasia and the survival of Th-17 cells. In line with 
these findings, IL-23 mRNA levels were shown to slowly increase during the 
development of a psoriatic lesion, reaching a peak five weeks after transplantation. 
The kinetics of this cytokine paralleled the development of epidermal hyperplasia 
demonstrating the important role of this cytokine in relation to psoriatic epidermal 
hyperplasia. IL-23 expression levels coincided or slightly followed the increase of 
CD3+ T cells in the transplanted skin, suggesting that IL-23 could have a role in 
supporting the survival of lesional Th-17 cells and thereby also their pathogenic 
function, primly mediated by the release of IL-17 and IL-22 (Acosta-Rodriguez, Rivino 
et al. 2007)(Zheng, Danilenko et al. 2006)(Liang, Tan et al. 2006).  
All these data together point to a fundamental role of IL-23 during the 
pathogenesis of psoriasis. Moreover the in vivo data presented in this chapter, 
together with the encouraging results obtained in initial clinical trials with anti-IL-
12p40 in psoriasis suggest that IL-23 may be a good candidate for the treatment of 
psoriasis. However, it will be important to determine the long-term effects of IL-23 
neutralization in terms of efficacy and safety.   
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3. Role of IL-17 in psoriasis 
3.1. Introduction 
The putative role of IL-23 in the induction of autoimmune disease has already 
been discussed. However, the exact mechanism by which IL-23 may cause the 
development of chronic inflammatory diseases is still unclear. Several recent studies 
suggested that T helper (h)-17 T cell subpopulation, whose survival and expansion 
seems to depend on IL-23, may account for the generation and/or maintenance of 
autoimmune disorders.  
Th-17 cells are a type of Th cells committed to produce IL-17. This cytokine, 
originally called CTLA-8 (cytotoxic T lymphocyte-associated 8) was isolated from a 
murine CTL hybridoma cDNA library (Rouvier, Luciani et al. 1993), and subsequently 
renamed IL-17. Five homologous cytokines were later identified through database 
homology searches and were called IL-17 B-E (Weaver, Hatton et al. 2007). These 
cytokines, together with IL-17 (sometimes also called IL-17A) form the IL-17 cytokine 
family. Mouse and human IL-17 members display significant homology as shown in 
Table 3.1. 
Table 3.1  Human IL-17 family members. 
Family 
member  
Alternative 
names 
Chromosomal 
location 
Homology 
of murine 
to human 
(%) 
Cellular sources Receptor 
IL-17A CTLA-8 6p12 62 Memory T cells IL-17R 
IL-17B IL-20 5q32-34 88 pancreas, small intestine, stomach IL-17RB 
IL-17C Cx2 16q24 75  unknown 
IL-17D IL-27 13q12.11 82 pancreas, small intestine, stomach IL-17R 
IL-17E IL-25 14q11.2 76 
several tissues( 
brain, kidney, lung, 
prostate, testis) 
IL-17RB 
IL-17F ML-1/IL-24 6p12 54 Activated CD4 cells IL-17R  
 
IL-17 was initially described as a cytokine produced by activated/memory CD4+ T 
cells. However, further studies demonstrated that also CD8+ memory T cells, γδ T 
cells, NK cells and neutrophils secrete this protein (Weaver, Hatton et al. 2007). The 
human receptor for IL-17 has a broad distribution, suggesting that IL-17 has the 
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capacity to induce different biological activities depending on which type of cells it is 
acting on (Afzali, Lombardi et al. 2007). In particular, IL-17 induces macrophages, 
fibroblasts, endothelial and epithelial cells to secrete proinflammatory cytokines and 
prostaglandins, which in turn mediate chemotaxis of neutrophils and monocytes to 
the sites of inflammation. Finally, this cytokine acts as a bridge between innate and 
adaptive immunity inducing the expression of the co-stimulatory molecule ICAM-1, 
which supports T cell activation (Afzali, Lombardi et al. 2007). 
At the same time when Cua et al. reported that IL-23 and not IL-12 was crucial for 
autoimmune inflammation in the brain (Cua, Sherlock et al. 2003), the group of 
Aggarwal et al demonstrated that IL-23 induces the production of IL-17 from memory, 
and not naïve, T cells (Aggarwal, Ghilardi et al. 2003). Further studies demonstrated 
that these IL-17 producing cells were responsible for the development of autoimmune 
inflammation (Langrish, Chen et al. 2005). It was shown that Th-17 cells primed for 
reactivity to the central nervous system and cultured in vitro with recombinant IL-23, 
induced EAE once transferred into recipient mice. In contrast, primed Th1 cells 
expanded with IL-12 were not pathogenic. In a subsequent step, the gene expression 
profile of IL-12-driven Th1 and IL-23-driven Th-17 cells were analysed. Whereas Th1 
cells were preferentially expressing genes associated with cytotoxicity and host 
defence, such as IFN-γ, granzymes and FasL, the IL-23 stimulated cells were mainly 
producing IL-17, IL-17F, TNF-α and IL-6 which are expressed during organ-specific 
inflammation, but not during immune surveillance (Langrish, Chen et al. 2005). 
Finally, to prove the direct contribution of IL-17 and not of IFN-γ to EAE, mice were 
treated with either anti-IFN-γ or anti-IL-17 mAbs. The neutralization of IFN-γ led to 
disease exacerbation due to the high levels of IL-17 in the serum. Whereas anti-IL-17 
treatment partially protected the mice from EAE, confirming previous works which 
showed that IL-17 deficient mice were resistant to induced EAE and CIA (Nakae, 
Nambu et al. 2003). In the following months, further studies, confirming the reciprocal 
interaction between IFN-γ and IL-17 were published (Harrington, Hatton et al. 2005; 
Park, Li et al. 2005). These studies showed that Th1 and Th2 cytokines strongly 
inhibited the generation of Th-17 cells, whereas the neutralization of IFN-γ and IL-4 
were increasing IL-17 production. Additionally, IFN-γ knock-out mice had enhanced 
IL-17 production caused by loss of IFN-γ suppression (Chu, Swart et al. 2007). All 
these data together supported the hypothesis that IL-17 producing cells might 
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develop via a lineage distinct form Th1 and Th2. In fact, this hypothesis was soon 
confirmed by three independent groups (Bettelli, Carrier et al. 2006; Mangan, 
Harrington et al. 2006; Veldhoen, Hocking et al. 2006), which showed that, in mice, 
TGF-β and IL-6 were required for the development of IL-17 secreting cells. It was 
demonstrated that TGF-β alone induced the production of Treg cells, while the 
synergy of TGF-β and IL-6 promoted the differentiation of Th-17 cells. Thus, it is 
current belief that naïve T cells will differentiate to Th-17 cells in the presence of 
TGF-β and IL-6 and that IL-23 will maintain and/or expand already differentiate Th-17 
cells. However, the exact mechanism by which IL-23 promotes Th-17 response 
remains to be established.  
IL-17 producing cells have been extensively studied in mice but much less is 
known about their identity and properties in humans. The group of Lanzavecchia 
(Acosta-Rodriguez, Rivino et al. 2007) provided the first detailed characterisation of 
human Th-17 cells. They distinguished human memory Th-17 cells from Th1 and Th2 
on the basis of selective expression of chemokine receptors. In particular, Th-17 cells 
co-expressed CCR6, a mucosa-homing receptor, and CCR4, a skin-homing receptor. 
In contrast CCR6+/CXCR3+ cells identified a heterogeneous population mainly 
composed of Th1 cells and to a lesser extent of T cells producing both IL-17 and IFN-
γ. They also investigated the signals driving human Th-17 differentiation and found 
that TGF-β alone or together with IL-6 failed to induce differentiation of IL-17 cells. IL-
1β induced the differentiation of IL-17 producing cells and synergised with IL-6 to 
promote Th-17 development. Accordingly, IL-1β up-regulated the transcription factor 
RORγT (retinocic-acid-receptor-related orphan receptor-γT) which is known to be 
required for the differentiation of mouse Th-17. Recently these results were 
confirmed and extended by several other groups (Acosta-Rodriguez, Napolitani et al. 
2007; Annunziato, Cosmi et al. 2007; Wilson, Boniface et al. 2007; Yang, 
Panopoulos et al. 2007). In particular Annunziato and co-workers provided the first 
detailed characterisation of human Th-17 cells isolated from the gut of patients with 
Crohn’s disease. They demonstrated the existence of both Th-17 and IFN-γ-
producing Th-17 cells in the gut mucosa and identified IL-23R, CCR6 and RORγT as 
Th-17 specific markers (Annunziato, Cosmi et al. 2007).  
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Th-17 cells play an important role in sustaining autoimmune disorders, such as 
EAE and CIA. Moreover IL-17 has been implicated in a variety of other chronic 
human inflammatory diseases. Increased levels of this cytokine have been 
demonstrated in respiratory diseases, ulcerative colitis, Crohn’s disease, multiple 
sclerosis and psoriasis (Steinman 2007). During skin inflammation IL-17 may act 
alone or together wit IFN-γ and/or TNF-α to enhance the production of IL-6, IL-8, GM-
CSF and adhesion molecules on keratinocytes which in turn promotes the 
chemotaxis of leukocytes (Teunissen, Koomen et al. 1998; Albanesi, Cavani et al. 
1999).  
In this chapter the regulation and the function of IL-17 producing cells in vitro and 
in vivo was studied. In the first part of this work Th-17 cells were analysed in the 
blood and in the skin of psoriatic patients and compared to healthy volunteers. Blood 
PBMCs were analysed by flow cytometry in order to investigate the cytokine profile of 
lymphocytes. In particular, IFN-γ and IL-17 production by CD3+ T cells were 
investigated. Considering that psoriasis is mainly a skin disease and that all the 
major phenotypical and morphological changes take place in this tissue, the same 
flow cytometry analyses were performed in cells isolated from the skin. Finally, to 
confirm the results obtained in the previous experiments, the mRNA expression of IL-
17 and IFN-γ were also analysed by real time polymerase chain reaction (RT-PCR). 
All these experiments show an enhanced expression of IL-17 in both blood and skin 
of psoriatic patients relative to healthy controls and suggest a dysregulation in the 
production and probably function of this cytokine in psoriasis. In order to analyse the 
functional role of IL-17 during the development of a psoriatic lesion, AGR mice were 
transplanted with uninvolved psoriatic skin and treated with a neutralizing antibody 
against IL-17. Although anti-IL-17 treatment did not ameliorate psoriasiform lesion 
formation in a significant manner, the increased production of IL-17 in the blood and 
especially in the skin of psoriatic patients lends support to the argument that Th-17 
cells may play an important role in psoriasis. 
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3.2. Results 
3.2.1. Th-17 cells in psoriasis 
3.2.1.1. Increased production of IL-17 by psoriatic T cells  
In the previous chapter I have demonstrated the importance of the IL-23 pathway 
in psoriasis. DCs and T cells were both positive for the IL-23R and psoriatic patient 
had an enhanced level of expression in the blood and the skin, compared to healthy 
donors. Based on the evidence that IL-23 is required for the effector functions and 
the recruitment of Th-17 cells at the site of inflammation the next step was to analyse 
the effect of IL-23 on IL-17 production on activated CD3 T cells.  
 
Figure 3.1  Increased production of IL-17 by psoriatic T cells (A) T cells freshly isolated from the 
blood of healthy donors (n=6) were treated with anti-CD3/CD28 monoclonal antibodies in the presence 
or absence of recombinant IL-23 (100ng/ml) over 3 days. Addition of IL-23 did not increase the 
secretion of IL-17 over the 3 days of analysis. (B) Psoriatic T cells showed increased production of IL-
17 as compared to T cells of healthy donors. CD3+ T cells were isolated from the blood of healthy 
donors and treated with anti-CD3/CD28 monoclonal antibodies in the presence of recombinant IL-23 
(100ng/ml) over 3 days. Immediately after isolation, T cells from blood of psoriatic patient (PP) 
produced similar levels of IL-17 as normal T cells after 1 day of stimulation. Graph represent mean of 
eleven or six experiments performed on different psoriatic patients and healthy donors respectively.  
* p=0.006, ** p=0.015 
 
In a first step T cells from the peripheral blood of healthy donors were isolated by 
magnetic depletion. These cells were then stimulated over 3 days with anti-CD3 and 
anti-CD28 mAbs in the presence or absence of human recombinant IL-23 (hrIL-23) 
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(100 ng/ml). By using flow cytometry, the levels of IL-17 production were analysed on 
the day of extraction and after stimulation. Freshly isolated T cells already showed 
production of IL-17 and this secretion was enhanced after 1 day of stimulation and 
progressively decreased over the 3 days of analysis. Interestingly, under these 
culture conditions the rates of IL-17 production were not altered by hrIL-23  (Figure 
3.1A). Based on several studies published in the last years, this result is not 
surprising. In fact, it has been demonstrated that IL-23 do no effect the production of 
IL-17, but may rather function in the maintenance of Th-17 committed cells 
(Aggarwal, Ghilardi et al. 2003; Suryani and Sutton 2007). When analysing freshly 
isolated psoriatic T cells (n=11), significantly higher levels of this cytokine were 
detected compared to T cells isolated from healthy donors (n=6). IL-17 production of 
freshly isolated psoriatic T cells was comparable to IL-17 production of normal T cells 
after 1 day of stimulation with hrIL-23 and anti-CD3/CD28 (Figure 3.1B). Among the 
CD3+ cells, the CD4+ subpopulation had the highest levels of IL-17 production.  
 
3.2.1.2. Cytokine profile of activated T cells in the blood and in the tissue  
To investigate if the previously identified Th-17 cells were able to produce Th1 
type cytokines, flow cytometry analyses were done on peripheral T cells. The 
cytokine profile of CD3+ T cells from the blood of psoriatic patients (n=9) were 
compared to that of healthy individuals (n=8). The majority of the cells secreted either 
IFN-γ or IL-17, with only few cells producing both cytokines at the same time (Figure 
3.2C). T cells from psoriatic patients produced higher levels of IFN-γ and IL-17 
compared to healthy donors (Figure 3.2A). Especially psoriatic CD4+ T cells had a 
higher percentage of IL-17 producing T cells compared to healthy donors (Figure 
3.2B). This experiment demonstrates that the majority of T cells contain either IFN-γ 
or IL-17, suggesting a dichotomy of IFN-γ and IL-17 producing T cells in the blood of 
psoriatic patients and healthy individuals. 
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Figure 3.2  Cytokine profile of peripheral blood T cells. (A-B) CD3+ and CD4+ T cells freshly 
isolated from peripheral blood of psoriatic patient had an increased production of IL-17 and IFN-γ 
when compared to healthy donor cells. (C) Representative flow cytometry analysis of IL-17 and IFN-γ 
production by CD3+ T cells present in the peripheral blood (n=9 for psoriatic patient, n=8 for healthy 
volunteers). Plots are gated on lymphocytes as identified by using forward and side scatter settings. 
*p≤ 0.005, **p=0.0001, ***p=2x10-5 
 
 
The following step was to analyse the secretion levels of these two cytokines in 
skin lymphocytes. When CD3+ T cells were freshly isolated from the skin of psoriatic 
patients (n=7), epidermal CD3+ T cells produced significantly higher amounts of both 
IFN-γ and IL-17 compared to lymphocytes extracted from the dermis of a psoriatic 
lesion and of healthy skin (n=3) (Figure 3.3A). CD3+ T cells present in the dermis of 
psoriatic lesions were secreting higher amounts of IFN-γ compared to the 
lymphocytes residing in the skin of healthy individuals, albeit not reaching statistical 
significance. Interestingly, in the epidermal compartment, in addition to the either 
IFN-γ or IL-17 producing cells a consistent major subpopulation secreting both of 
these two cytokines was identified. In contrast, in the dermis of psoriatic patients and 
healthy controls the amounts of “double producers” was very low. These results 
suggest that IL-17 producing cells preferentially migrate into the psoriatic epidermis, 
where they exert their pathogenic effect by secreting IL-17 (and in a significant 
proportion IFN-γ). This cytokine upregulates the expression of chemokines on 
epithelial tissues, thereby attracting further immune cells to the epidermis (Weaver, 
Hatton et al. 2007).  
Taken together, these results show that psoriasis correlates with increased 
frequencies of IFN-γ and IL-17-producing cells in the skin, suggesting that both Th1 
and Th-17 cells may contribute to the propagation of the disease. Support for this 
hypothesis comes from two studies performed on intestinal inflammation models 
(Hue, Ahern et al. 2006; Kullberg, Jankovic et al. 2006). Herein it was demonstrated 
that both Th1 and Th-17 cells were present during the development of colitis, which 
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let the authors arguing that the two cell responses may synergize to exacerbate 
disease pathology. 
 
 
 
Figure 3.3  Cytokine profile of CD3+ cells present in the skin. Cells were freshly isolated from the 
epidermal and dermal compartment of psoriatic patients (PP, n=7) and healthy individuals (NN, n=3). 
(A) Percentage of CD3+ cells producing either IFN-γ or IL-17. (B) Representative flow cytometry 
analysis of total Th-17 and Th1 cells present in the epidermal compartment. (C) Better 
characterisation of the cytokine profile of CD3+ cells present in the skin of psoriatic patients and 
healthy individuals. (D) Representative flow cytometry analysis of IL-17 and IFN-γ production by CD3+ 
T cells present in the epidermal and dermal compartment of a psoriatic lesion. (B and D) Numbers in 
quadrant indicate percentage of positive cells as assessed by intracellular cytokine staining. Plots are 
gated on lymphocytes as identified by using forward and side scatter settings. *p≤ 0.03, **p≤0.008 
 
3.2.1.3. Characterization of IL-17 producing T cells 
To better characterise the Th-17 population, peripheral T cells were analysed 
according to their expression of surface markers for activated/memory T cells. 
Classically, T cells with different specificities are continually produced in the bone 
marrow in order to maintain an efficient T cell repertoire, capable of responding to 
any antigen. Lymphocytes that survive thymic selection are released in the periphery 
in a naïve state. After encountering the appropriate antigen, T cells undergo clonal 
expansion and differentiation into effector and memory T cells. Two types of memory 
T cells are present in the peripheral blood and are characterised by different 
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migratory capacities. “Central” memory T cells (TCM) expressing the chemokine 
receptor CCR7 and representing a pool of cells that home to secondary lymphoid 
organs. Effector memory T cells (TEM) do not express this receptor and 
predominantly migrate to peripheral tissues to mediate inflammatory reactions. 
Human naïve T cells in addition to the CCR7 receptor also express the human 
leukocyte antigen, CD45RA.  
To investigate the phenotype of the Th-17 population, peripheral cells of healthy 
donors and psoriatic patients were stained with mAbs directed against IL-17, 
CD45RA and CCR7 and subsequently analysed using flow cytometry (Figure 3.4A - 
D). Within the IL-17–cell population, most cells were CCR7+CD45RA- or CCR7-
CD45RA-, indicating that these cells had the phenotype that has been associated 
with central memory (CCR7+CD45RA-) or effector memory cells (CCR7-CD45RA-). 
The Th-17 population in the blood of healthy donors (n=7) and psoriatic patients 
(n=11) displayed similar expression of surface markers for activated/memory T cells.  
 
 
 
Figure 3.4  Characterization of IL-17 producing T cells. (A ,C) Representative example of IL-17 
producing CD3+ and CD4+ T cells freshly isolated from peripheral blood of psoriatic patients (n=11). 
Numbers in quadrants represent percentage of cells staining positive for IL-17. To further define the 
Th-17 subpopulation, cells were analysed according to their CD45RA and CCR7 phenotype (B, D). IL-
17 is mainly produced by memory T cells (CD45RA- CCR7-/+). (E) Representative example of surface 
markers for activated/memory T cells expressed by epidermal and dermal Th-17 cells extracted from 
the same lesional psoriatic skin. Cells were extracted from the epidermal and dermal compartment of 
psoriatic lesions (n=2) and subsequntially stained with mAb to IL-17, CD3, CD45RA and CCR7. Plots 
are gated on lymphocytes as identified by using forward and side scatter settings.  
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Subsequently, the expression of these surface markers was investigated in the 
Th-17 population found in the in the skin of psoriatic patients (n=2). Both IL-17 
producing cells of the dermal and epidermal compartment show to be CCR7-
/CD45RA-, indicating that they were all effector memory T cells as expected (Figure 
3.4E).  
 
3.2.2. Pro-inflammatory cytokines in human psoriatic skin 
In order to analyse IL-17 and IFN-γ mRNA expression in lesional and non lesional 
psoriatic skin samples quantitative RT-PCR was performed. Both IL-17 and IFN-γ 
mRNA expression was increased in lesional psoriatic skin compared to non lesional 
skin from psoriatic patients (Figure 3.5). TNF-α, a validated target in many 
inflammatory diseases, was also expressed at significant higher levels in lesional 
psoriatic skin compared to non lesional skin from psoriatic patients. The relative 
amounts of TNF-α mRNA were at least a thousand times higher than the ones 
observed for IL-17 and IFN-γ, indicating the key role of this cytokine in the 
inflammatory process of psoriasis and explaining the efficacy of TNF-α blockers in 
the treatment of this skin disease.  
 
Figure 3.5  Quantification of pro-inflammatory cytokines expression in psoriatic skin. IL-17, 
IFN-γ and TNF-α mRNA expressions were increased in lesional psoriatic skin (PP) compared to non 
lesional skin (PN) from psoriatic patients. mRNA levels of each cytokine were normalised to their 
correspondent hGAPDH concentrations. 
 
 
3.2.3. Blockade of IL-17 in vivo does not prevent the 
development of a psoriatic lesion 
One of the final steps was to investigate if the high amounts of IL-17 at mRNA and 
protein level detected in the lesional psoriatic skin were responsible for the chronic 
inflammation seen in psoriasis. Injection of a human IL-17 specific mAb did not inhibit 
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the development of a psoriatic lesion in significant manner when using the AGR 
xenograft psoriasis model. For this experiment keratomes of non lesional psoriatic 
skin from 3 different patients were transplanted onto AGR mice and injected with 
anti-IL-17 mAb and matched isotype control mAb starting at day 7.  
 
 
 
Figure 3.6  Neutralization of IL-17 function does not prevent the development of psoriasis.  
Acanthosis and papillomatosis indices in skin grafts before transplantation (PN) onto AGR129 mice 
and after 35 days treatment with either anti-human IL-17 or isotype-matched control antibody. There 
was no statistically significant reduction of psoriasis acanthosis (A) and papillomatosis indices (B) in 
grafts of mice treated with anti-human IL-17 compared to isotype control mice. Mice treated with anti-
TNF-α (infliximab), had a statistically significant reduction of both acanthosis and papillomatosis 
compared to mice injected with anti-human IL-17 and isotype-matched control antibody. Microscopic 
view of uninvolved psoriatic (PN) skin on the day of transplantation (C) and lesional psoriatic skin (PP) 
of the same patient (D). Uninvolved psoriatic skin 5 weeks after transplantation onto AGR mice and 
after treatment with either anti-IL17 (E) or isotype-matched control mAb (F). (A-B) Data were pooled 
together from three independent experiments with PN skin from three different patients. Dots 
represent independently grafted mice samples. Scale bars in C-F represent 20 µm. P-values were 
calculated using the unpaired Student‘s t test. *p≤ 0.03, **p≤ 0.009, *** p≤ 0.0007 
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Anti-TNF-α (infliximab) was administered as positive control. At day 0 and 35 days 
after transplantation grafts were evaluated for their psoriatic phenotype, defined by 
the typical epidermal hyperplasia involving thickening of the epidermis (acanthosis) 
and the elongation of epidermal papillae (papillomatosis index) (Figure 3.6 A-B). The 
psoriatic phenotype was confirmed by immunohistochemestry (Figure 3.6 C-F). Mice 
treated with anti-IL-17 mAb and isotype control group presented similar values of 
both acanthosis and papillomatosis indices. Treatment with anti-TNF-α led to a 
statistically significant reduction of epidermal hyperplasia when compared to anti-
IL17 or isotype control intervention. Numbers of total T cells and epidermal T cells 
were present in the human grafts treated with anti-IL17 or isotype control mAbs 35 
days after engraftment onto AGR mice (Figure 3.6 G-H). These results suggest that 
IL-17 blockade alone is not sufficient to inhibit psoriasis development.  
 
3.3. Discussion 
The present study provides evidence that although Th-17 cells take part in the 
inflammatory reaction during the formation of a psoriatic lesion, the inhibition of IL-17 
function is not sufficient to significantly block disease onset. Interestingly, in some 
models of inflammatory diseases, such as EAE and CIA, the neutralization of IL-17 
function was efficacious in inhibiting the disease manifestation. For example, in the 
EAE model anti-IL-17 mAbs was shown to reduce the incidence and the severity of 
disease, even though cells extracted from the lymph nodes and the spleen retained 
their capacity to produce pro-inflammatory cytokines (IL-17, TNF-α, IL-2 and IFN-γ). 
However, these cells were not able to induce any pathogenic effect as only few 
lymphocytes and macrophages were found in the CNS, where the disease takes 
place. Blockade of IL-17 inhibited the upregulation of chemokines, which are 
important for T cell and macrophages migration (Park, Li et al. 2005). 
The exact role of the Th-17 population in psoriasis is still unknown. The results 
presented in this chapter clearly show that peripheral T cells of psoriatic patients 
secrete higher levels of IL-17 compared to healthy control volunteers, and that the 
major producer of this cytokine was a subset of memory CD4+ T cells. Furthermore, 
the incubation of CD3+ T cells with anti-CD3 and anti-CD28 enhanced the secretion 
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of IL-17 with maximum levels reached after 1 day of stimulation. Since psoriasis is a 
skin inflammatory disease, where T cells have been reported to be the main effector 
cells promoting disease onset (Boyman, Hefti et al. 2004; Nickoloff and Nestle 2004; 
Boyman, Conrad et al. 2006; Conrad, Boyman et al. 2007), IL-17 and IFN-γ 
production in CD3+ skin T cells population was further investigated. These analyses 
showed a functional heterogeneity, in that a major population produced IFN-γ but not 
IL-17, a minor subset only IL-17 and a third population both cytokines together. This 
scenario differs from that seen in the blood where IFN-γ and IL-17 production was 
almost mutually exclusive. The three above mentioned subpopulations were 
particularly evident in the epidermal compartment of psoriatic lesions, whereas in the 
dermis IFN-γ- producing cells were the main subset. The Th1 cells were also the 
main population present in the dermal compartment of healthy individuals, however 
containing less IFN-γ producing cells then the dermis of psoriatic patients. A similar 
scenario was already presented in a model of systemic autoimmune disease and 
EAE (Lohr, Knoechel et al. 2006; Suryani and Sutton 2007). Specifically, it was 
shown that early during disease onset all three populations were present, with higher 
amounts of IFN-γ+/IL-17+ cells. Over time, the continuous decrease of IL-17 and 
double producing cells was compensated by the rise of IFN-γ+/IL-17- cells until 
disease stabilization. In this context, the authors suggested that the IFN-γ+/IL-17+ 
cells could be a pre-Th1 intermediate subset that further differentiates into an 
exclusively IFN-γ-producing population. Therefore, it could be argued that the 
variable IFN-γ/IL-17 cytokine proportions seen when analysing the skin of different 
psoriatic patients reflected the stage of disease progression at the point were the 
biopsy was taken. However, the double producing cells (IFN-γ+/IL-17+) could also 
represent already differentiated Th-17 cells, able to produce both cytokines due to a 
particular environment or situation, a scenario already seen for cells producing both 
IL-4 and IFN-γ (Acosta-Rodriguez, Rivino et al. 2007).  Finally, consistent with 
published works (Langrish, Chen et al. 2005; Park, Li et al. 2005), IL-17 was mainly 
produced by memory T cells. In the blood IL-17 was secreted by both central and 
effector memory cells, while in the skin Th-17 cells were confined to the effector 
memory subset.  
To explore if the increased IL-17 concentrations seen in the skin of psoriatic 
patients were directly responsible for disease pathogenesis, the effects of IL-17 
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blockade was investigated in the AGR psoriasis mouse model. Injection of IL-17 
mAbs did not block T cell expansion and psoriasis development seen in the 
xenotransplantation mouse model. Instead, the use of anti-TNF-α, the “gold 
standard” in psoriasis treatment, specifically inhibited psoriasis development and T 
cell proliferation. These results confirmed previous work performed on a mouse 
model where epidermal hyperplasia was induced by injecting IL-23 in mice skin 
(Chan, Blumenschein et al. 2006). Also in this mouse model pre-treatment with anti-
IL17 did not ameliorate epidermal hyperplasia. Additionally, it was shown that the 
direct injection of IL-17 into murine skin had minimal effects on epidermal 
hyperplasia. These results demonstrate that even though Th-17 cells may play an 
important role in psoriasis, IL-17 on its own is not a “master cytokine” in psoriasis 
pathology and that other effector mechanisms may synergize with IL-17 for disease 
outcome. A similar scenario has also been suggested in a model of T-cell-mediated 
colitis (Hue, Ahern et al. 2006; Kullberg, Jankovic et al. 2006). Here, it was shown 
that intestinal inflammation was associated with increased development of 
pathogenic Th-17 cells, however the neutralization of IL-17 alone was not enough to 
attenuate the disease. Interestingly, a significant amelioration of colitis was observed 
with anti-IL-6 and anti-IL-17 combination therapy, suggesting that both cytokines 
participate to the IL-23-driven intestinal inflammation. As discussed above for 
psoriasis, also during intestinal inflammation concomitant with the high levels of IL-17 
there was a strict increase of IFN-γ, indicating that Th-17 and Th1 responses may 
synergize to elicit maximal pathologic effects. Based on these data it can be argued 
that psoriasis and intestinal inflammation present a similar pathological scenario that 
differs from that seen in the EAE and CIA model. In these latter animal models it has 
been proposed that the major pathogenic cell population might be the IL-17-secreting 
T cells alone, whereas Th1 cells, by secreting IFN-γ might rather inhibit the Th-17 
subset (Harrington, Hatton et al. 2005; Park, Li et al. 2005; Mangan, Harrington et al. 
2006). Based on these results it can be concluded that IL-17 is a critical cytokine in 
many autoimmune disease, but that its contribution during disease development 
varies for each disorder. In some diseases, like EAE, IL-17 may account for most of 
the pathological effects downstream of IL-23, but in other disorders like psoriasis and 
intestinal inflammation the blockade of IL-17 alone is not sufficient to inhibit disease 
onset and additional factors may also participate to the inflammatory reaction. In this 
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context, IL-22 has recently been proposed to be a major player in the pathogenesis 
of psoriasis. This cytokine is secreted by Th-17 cells and is involved in the 
proliferation and differentiation of keratinocytes (Wolk, Witte et al. 2006). High levels 
of IL-22 were found in the blood and in the diseased skin of patients with psoriasis. 
Interestingly, when comparing the cytokine amounts of psoriatic patients with healthy 
donors the differences in IL-22 levels were greater then the ones seen for other 
cytokines such as IFN-γ, IL-1 or IL-23 (Wolk, Kunz et al. 2004). Recently, it has also 
been shown that IL-22 is responsible of the acanthosis and dermal inflammation 
observed in the mouse skin after intradermal injection of IL-23 (Zheng, Danilenko et 
al. 2006). Therefore, theses results suggest that the increased number of Th-17 cells 
observed in psoriasis may exert their pathogenic effect by the release of both IL-17 
and IL-22 and that these two cytokines may then synergize to regulate local tissue 
inflammation. A possible scenario could be that the release of IL-17 by Th-17 cells 
would induce the production of proinflammatory cytokines and chemokines by 
different cellular targets, including epithelial cells, endothelial cells and macrophages 
and thereby recruiting inflammatory cells to the damaged tissue (Acosta-Rodriguez, 
Rivino et al. 2007; Weaver, Hatton et al. 2007). IL-22, instead, would induce 
epidermal acanthosis through STAT-3 activation in keratinocytes, a pathway already 
shown to be critical for psoriasis development (Sano, Chan et al. 2005). 
In conclusion this study suggests that the development of a psoriatic lesion 
depends on the presence of both IFN-γ and IL-17 cells and potentially other pro-
inflammatory cytokines that act in concert in order to produce the typical tissue 
inflammatory reaction seen in psoriasis. The exact contribution of each T helper cell 
populations to this skin pathology remains to be determined. Thus, further work is 
required to delineate the effects of the IL-12/IFN-γ versus IL-23/IL-17 axis in the 
pathogenesis of psoriasis. 
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4. Functional importance of integrin expression 
during the development of psoriasis 
4.1. Introduction 
During an immune and inflammatory responses, the interaction of immune cells 
with other cells and with the extracellular matrix (ECM) is mediated by adhesion 
molecules. These molecules are mainly transmembrane proteins, which provide a 
link between cells and their environment and are of fundamental importance to many 
cellular functions such as regulation of cell motility, gene expression and 
differentiation (Parks 2007). The loss of adhesive interactions as well as an aberrant 
expression of adhesion molecules may result in disease states (e.g. pemphigous 
vulgaris, leukocyte adhesion deficiency-1, arteriosclerosis, diabetic vasculopathy) 
(Petruzzelli, Takami et al. 1999). Cell adhesion molecules can be classified in 4 
major groups which include integrins, cadherins, selectins and members of the 
immunoglobulin superfamily (Petruzzelli, Takami et al. 1999). Among these four 
major groups the one with highest affinity to ECM components is the integrin group. 
Integrins are a large family of transmembrane heterodimeric glycoproteins containing 
two non-covalently associated α and β subunits, which combine to form more then 20 
different receptors (Pozzi, Wary et al. 1998). A single β chain can interact with 
different α chains, forming integrins that bind different ligands. Integrins relay 
information via out-side-in signalling and regulate a vast array of cellular functions 
including proliferation, migration, gene expression and survival (Watt 2002). 
Therefore, they are involved in tissue homeostasis and play a critical role during 
injury, infection and inflammation (Parks 2007). The importance of these proteins is 
further stressed by the dramatic consequences of genetics defects in the integrins 
genes. For example, diminished or absent expression of the β2 integrin chain lead to 
a disease called leukocyte adhesion deficiency-1 (LAD-1). Patients bearing this 
mutation suffer from impaired wound healing with high risk of bacterial infections. 
Similarly, mutations in the α or in the β subunit of the gpIIbβ3 integrin increase the 
susceptibility to bleeding, as seen in patients with Glanzmann thrombasthenia 
(Petruzzelli, Takami et al. 1999). An aberrant expression of integrins can, on the 
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other hand, induce pathological conditions. During the formation of an atherosclerotic 
plaque one pathological event is the dramatic increase in platelet adhesiveness. 
Antibodies directed against platelets integrins have been shown to ameliorate 
atherosclerotic vascular changes (Petruzzelli, Takami et al. 1999).  
In skin, the most prevalent integrins belong to the β1 subfamily. This group 
includes adhesion molecules with high affinity for many ECM proteins such as 
fibronectin, collagens and laminins. In healthy skin, β1 integrin expression is confined 
to the basal layer and has a fundamental role in anchoring KCs to the basement 
membrane. The loss of integrin β1 expression at this level leads to blistering and 
failure in basement membrane organisation (Raghavan, Bauer et al. 2000). A 
suprabasal integrin expression is a feature of hyperproliferative epidermis and is 
seen during wound healing or psoriasis (Watt 2002).  
Collagens are the most abundant proteins in the ECM and they account for 75% 
of skin’s dry weight (de Fougerolles, Sprague et al. 2000). The major cell surface 
receptors for collagen are the α1β1 and α2β1 integrins. α1β1 preferentially binds 
collagen IV, the major component of the basement membrane and is mainly 
expressed on mesenchymal cells, fibroblasts, hepatocytes and endothelial cells. α2β1 
shows a preference for binding to collagen I and is preferentially expressed in the 
epithelial compartment (de Fougerolles, Sprague et al. 2000). Both integrins show 
very low expression on peripheral blood lymphocytes. However long term activation 
of T cells induces expression of both α1β1 and α2β1 integrins, consistent with the initial 
description of α1β1 and α2β1 as very late antigens (VLA). Finally, both integrins were 
shown to play a role in cell migration (Dustin and de Fougerolles 2001), and in 
reorganization and contraction of collagen fibres during wound healing (Schiro, Chan 
et al. 1991).  
Psoriasis is a skin disorder characterized by epidermal hyperplasia, inflammation 
and neoangiogenesis. Two of the most prominent phenotypical changes during the 
formation of a psoriatic lesion are the increased turnover of KCs and the intense 
infiltration of activated T cells in the epidermal compartment. The fact that suprabasal 
integrin expression is a characteristic of hyperproliferative epidermis and that 
infiltrating T cells in chronically inflammatory diseases express α1β1, suggested that 
integrins may be of importance in psoriasis. Based on these two observations a 
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closer analysis of integrin expression, in particular α1β1 and α2β1, during the 
development of psoriasis was performed. The first part of this chapter will be 
dedicated to the relationship of α1β1 expression on effector T cells and the 
development of psoriasis. The second part will refer to the functional role of α2β1 
expression in the epidermal compartment of psoriatic lesions. 
 
4.2. A critical role for α1β1 (VLA-1) in accumulation of 
epidermal T cells and the development of psoriasis 
 
The aetiology of autoimmune inflammatory disorders such as rheumatoid arthritis, 
Crohn’s disease and psoriasis is complex and many aspects are still unclear. A 
common characteristic of these diseases is a permanent inflammatory process within 
lymphoid organs and involved tissue. In the last years, increasing number of studies 
suggested a strong correlation between the expression of α1β1 on tissue infiltrating T 
cells and the development of chronic inflammatory disorders (de Fougerolles, 
Sprague et al. 2000). In particular, the importance of α1β1 integrin was demonstrated 
in animal models of hypersensitivity, arthritis and experimental colitis.  
α1β1 is a major cell surface receptor for collagen with a preference for collagen IV. 
α1β1 is expressed on mesenchymal cells, including smooth muscle cells, fibroblasts 
and microvascular endothelium (Krieglstein, Cerwinka et al. 2002). Naïve T cells 
express only low levels of α1β1, whereas long term activation (4-6 weeks) significantly 
increases the levels of this integrin, hence the alternative name VLA-1 (very late 
antigen- 1). Finally, α1β1 positive T cells belong to a restricted subset of lymphocytes, 
the memory T cells, and are all IFN-γ producing T cells (Goldstein, Ben-Horin et al. 
2003). Given the functional importance of the ECM environment during the migration 
of T cells in a psoriatic lesion and the fact that chronic activated T cells express the 
VLA-1 receptor, the role of α1β1 function during the onset of psoriasis was 
investigated. In the first part (results 1) of this chapter, a summary of the most 
relevant results, performed by other member of our group, will be presented. The 
main focus of this part are the relationship of epidermal accumulation of α1β1 memory 
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Th1 cells and psoriasis onset, and the prevention of psoriasis development by 
blocking α1β1 with a monoclonal antibody in a clinically relevant psoriasis mouse 
model. In the second part (results 2), a more detailed description of the experiments 
performed during my PhD thesis that also complement the previous part will be 
shown.  
 
4.2.1. Results 1 
4.2.1.1. Exclusive expression of α1β1 integrin on epidermal but not dermal T 
cells 
Based on the fact that in inflammatory skin disorders infiltrating T cells express 
α1β1 integrins (de Fougerolles, Sprague et al. 2000), the first step was to investigate 
the expression of this receptor on psoriatic T cells. Staining of psoriatic skin sections 
with an anti-α1 mAb revealed the presence of α1β1 on leukocytes in the epidermis but 
not dermis of lesional psoriatic skin (Figure 4.1A). In contrast, mononuclear cells 
positive for α1β1 could not be detected either in uninvolved skin from psoriatic 
patients or in the skin of healthy donors (data not shown). Dual colour 
immunofluoresence was then performed to better characterise the VLA-1+ cell 
population (Figure 4.1B and C). 20-50% of epidermal infiltrating CD3+ cells (red) co-
expressed α1β1 integrin (green), while no α1-integrin could be detected on dermal T 
cells. α1β1 positive cells observed in the dermis represent mesenchymal cells such as 
smooth muscles cells and vascular endothelium. A closer analysis of α1β1 epidermal 
T lymphocytes demonstrated that these cells were predominantly effector memory T 
cells with a type 1 cytokine profile. In fact, when cells were freshly isolated from 
lesional psoriatic skin biopsies most of the α1β1/CD3+ T cells were CCR7-/CD45- 
(Figure 4.1E), a phenotype compatible with effector memory cell differentiation 
(Sallusto, Geginat et al. 2004). Moreover, intracellular cytokine staining showed that 
the majority of epidermal CD3+ cells secreted IFN-γ but not IL-4, and that nearly all 
IFN-γ+ cells expressed α1β1 integrin receptors (Figure 4.1F-H).  
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Figure 4.1  Expression of α1β1 on human epidermal but not dermal T cells in psoriasis. (A) 
Cryosesctions of lesional psoriatic skin were stained for α1 integrin and revealed the presence of α1β1 
positive cells only in the epidermal compartment (black arrows). (B and C) Two-colour 
immunofluoresence staining of psoriatic lesions with α1-integrin (green) and CD3 (red). (B) Several 
epidermal T cells appeared yellow as a consequence of co-localization of CD3 and α1β1 (white arrow). 
(C) Green dermal staining reflects the expression of α1β1 on mesenchymal cells.  (D-H) Flow 
cytometry analysis of epidermal lymphocytes freshly isolated from the epidermis of lesional psoriatic 
skin. (D) On average 63% +/- 6.2% of CD3+ cells co-expressed the α1β1 integrin receptor (n=5). (E) 
The majority of epidermal CD3+/α1β1 cells were CCR7-/CD45RA-, indicating an effector memory 
phenotype.(F-G) Flow cytometry analysis (n=3) demonstrated that almost 60% of epidermal T cells 
secreted IFN-γ and that nearly all of these cells were α1β1+ . Not any CD3+ cell produced IL-4 (H). 
Scale bar in A represent 50µm. Dashed line indicate border between epidermis above and dermis 
below. Ep, epidermis; De, dermis. Dot plots shown are gated on lymphocytes. 
 
4.2.1.2. Migration of T cells into epidermis parallels psoriasis onset 
In order to study the expansion of T cells during the development of a psoriatic 
lesion, a time course experiment was performed. Uninvolved human psoriatic skin 
was transplanted on the AGR xenotransplantation mouse model and skin sections 
were obtained after 0, 7, 21 and 35 days. Sections were stained for CD3 and T cell 
expansion was analysed. At day 0 no T cells were present in the epidermis and only 
few T cells could be detected in the dermis. 7 days later an accumulation of dermal 
CD3+ T cells took place, while the epidermis remained unaltered. At day 21 the 
entrance of dermal T cells into the epidermis correlated with a thickening of the 
epidermis (acanthosis) and some papillomatosis. At day 35, beside numerous 
epidermal T cells, the typical histological signs of psoriasis, acanthosis and 
papillomatosis, were evident. Taken together this experiment revealed an early 
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proliferation of T cells in the dermis followed by a considerable migration into the 
epidermis (Figure 4.2A). Interestingly, dermal T cells (dashed line) showed marked 
proliferation until day 14 and thereafter a progressive reduction, while in the 
epidermal compartment only around day 21 the first T cells could be detected (solid 
black line). From these results it could be concluded that in developing psoriatic 
lesions expansion of dermal T cells precedes typical psoriasisform changes and that 
accumulation of epidermal T cell correlates with the development of psoriatic 
epidermal hyperplasia (Figure 4.2B). 
Figure 4.2  Expansion of epidermal but not dermal T cells correlates with epidermal 
psoriasisform changes. (A) Quantification of T cell expansion on grafts transplanted on the AGR 
mouse model (d0, d7, d14, d21 n=2, d35 n=1). In contrast to the number of dermal T cells (dashed 
line) the expansion of epidermal CD3+ T cells (solid black line) parallels the onset of histological 
psoriatic features represented by the papillomatosis index (red line). (B) Significant correlation of 
epidermal CD3+ cells and papillomatosis index. Data points shown (n=41) represent grafts of different 
PN skin, PN skin with active immune compartments, and psoriasis developing PN skin treated or 
untreated taken at different time points including d0, d7, d14, d21, d28 and d35. Data shown in A are 
representative of two independent experiments with PN skin from two different psoriatic patients. 
 
4.2.1.3. Effects of α1β1 blockade in vitro and in vivo  
The basement membrane, which separates the dermis from the epidermis, is rich 
in collagen IV, the main ligand for α1β1. Therefore, when T cells migrate into the 
epidermal compartment they come in contact with these collagen fibers. To test if T 
cells need α1β1 integrin to attach and migrate through this structure an in vitro 
transmigration assay was performed. Peripheral T cells were cultured with 
phytohemagglutinin (PHA) plus IL-2 and as soon as α1β1 expression exceeded 60% 
(after approx. 4-6 weeks), T cells were isolated by depletion of non-T cells. Migration 
of α1β1 T cells trough collagen IV-coated transwells, using SDF-1α (stromal cell-
derived factor 1 or CXCL12) as chemoattractant was significantly blocked by adding 
anti-α1 mAbs compared to isotype control mAb (Figure 4.3A).  
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To determine the consequences on T cell migration after blocking α1β1 in vivo, 
uninvolved psoriatic skin was transplanted on AGR mice and treated with either anti-
human anti-α1 (n=7) or isotype control mAbs (n=5). CD3+ T cells were quantified in 
skin grafts excised 35 days after transplantation and stained with anti-CD3 mAb. 
Treatment with anti-α1 mAb almost completely inhibited expansion of epidermal T 
cells compared to skin grafts treated with isotype control mAb. The number of 
epidermal T cells found in the transplants of anti-α1 treated mice were comparable to 
that counted in non-lesional pre-psoriatic skin (PN) from the same psoriatic patient 
(Figure 4.3B).  
 
Figure 4.3  α1β1 blockade inhibits T cell migration through collagen IV matrices in vitro and 
accumulation of epidermal T cell in vivo. (A) Migration of cultured T cells trough collagen IV-coated 
transwells using SDF-α as a chemoattractant. Numbers of T cells were measured by flow cytometry 
analysis of each sample counted for 3 minutes. Data graphed represent mean values +/- standard 
error of the mean (SEM) deviation for SDF-1α at 0, 5, 20 and 50 ng/ml. Depicted migration assay was 
performed in triplicates and is representative for data obtained from three independent experiments. 
(B)  Counts of epidermal T cells in human skin sections taken 35 days after transplantation on AGR 
mice. Injection of anti-α1 mAb significantly reduced the number of epidermal T cells compared to 
isotype control treatment. *, p<0.05; **, p=0.0005 
 
Anti-α1 treatment was also efficacious in inhibiting the development of psoriatic 
lesion, in 7 out of 7 mice grafted with uninvolved skin from three different psoriatic 
patients. Histological evaluation of grafts injected with anti-α1 mAb revealed 
significant reduction of both acanthosis and papillomatosis index compared to isotype 
control mAb (Figure 4.4A). Moreover, the treatment with anti-α1 mAb was as effective 
as the blockade with anti-TNF-α mAb, the current “gold standard” of anti-psoriatic 
therapy. Taken together, these data demonstrate that blocking the interference of 
α1β1 integrin with collagen IV inhibits the migration of T cells into the epidermis and 
thereby prevents the development of psoriatic lesions (Conrad, Boyman et al. 2007).
Chapter 4  Results α1β1 
  
 
 
91
 
 
 
Figure 4.4  Blocking α1-integrin inhibits psoriasis development. (A) Uninvolved psoriatic skin 
transplanted on AGR mice developed fully-fledged psoriasis 35 days after engraftment and treatment 
with isotype control mAb (representative of n=5) and presented same histological features as lesional 
psoriatic skin of the same patient (B). (C) Graft treated with anti α1-integrin mAb (representative of 
n=7) presented a histological picture indistinguishable from uninvolved psoriatic skin on day 0 of the 
same patient (D). (E) Acanthosis (open bars) and papillomatosis (solid bars) indices on day 0 and 5-6 
weeks after transplantation on AGR mice treated either with anti-α1 (n=7) or isotype control mAb 
(n=5). (F) Treatment with anti-α1 mAb induced a reduction of the papillomatosis index comparable to 
the treatment with anti-TNF-α (n=2). Scale bares (A-D) represent 100µm. Dashed line (A-D) indicates 
border between epidermis above and dermis below. Data depicted represent mean values plus 
standard error of the mean (SEM) (E), and mean values of triplicates (F). *, p≤ 0.003 
 
 
4.2.2. Results 2 
4.2.2.1. Characterisation of intraepidermal α1β1 T cells 
In the previous section it has been shown that α1β1 was exclusively expressed on 
IFN-γ T cells in the epidermis and that these cells were effector memory T 
lymphocytes (CCR7-/CD45RA-). Subsequent immunofluoresence staining performed 
on lesional psoriatic skin sections, revealed that the majority of α1β1+/CD3+ 
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epidermal T cells belong to the CD8+ subset, and only few of them were CD4+ 
(Figure 4.5A-D). Identical results were seen when immunofluorescence staining was 
performed on grafts excised after development of the psoriasiform lesion (d35). 
Again CD3+ T cells were expressing α1β1 integrin and were mainly of the CD8+ 
phenotype (Figure 4.5E and F). 
 
 
Figure 4.5  CD3+/CD8+ and CD3+/CD4+ epidermal T cells express α1 integrin. Three-color 
immunofluorescence staining using FITC-conjugated mAb to CD49a (α1) (green), PE-conjugated mAb 
to CD3 (red), and APC-conjugated mAb to CD8 (A-C) or CD4 (D) (blue) was performed on lesional 
psoriatic skin. (A) Several epidermal T cells appeared in yellow as a consequence of co-localization of 
CD3 and α1β1. (B) The majority of epidermal T cells showed co-localization of CD3 and CD8 and 
therefore, appeared in magenta (white arrows). (C) A subpopulation of both epidermal CD8+ (white 
arrows) and CD8- (yellow, arrow heads) CD3+ T cells expressed α1β1. (D) A subpopulation of 
CD4+/CD3+ T cells (magenta, white arrows) appeared in white (arrow heads) as a consequence of 
co-localization of CD3, CD4, and α1β1. CD4-/CD3+ epidermal T cells representing CD8+ T cells 
appeared in yellow showing expression of α1 integrin. (E and F) Grafts excided (d35) after 
development of a psoriasiform phenotype in the AGR mouse model. (E) Epidermal T cells appeared in 
yellow as a consequence of co-localization of CD3 and α1β1 (yellow, arrow heads). (F) The majority of 
epidermal T cells in xenografts showed co-localization of CD3 and CD8 and therefore appeared in 
magenta (white arrows). Location of several α1β1 expressing epidermal T cells (e, arrow heads) 
corresponded to CD8+/CD3+ T cells (f, white arrows) indicating co-expression of α1β1/CD8/CD3. 
Dashed line (a-f) indicates border between epidermis and dermis. 
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In order to even better characterise this intraepidermal subpopulation of T cells, 
flow cytometry analysis was performed on cells freshly isolated from lesional psoriatic 
skin of psoriasis patients. Epidermal T cells were stained with mAb to CD3 and to 
α1β1 in conjunction with other antibodies against different surface markers. These 
analyses showed that the majority of α1β1+/CD3+ T cells were CD8 positive (Figure 
4.6B), thereby confirming the immunofluorescence results, and that almost no cells 
were positive for Vγ9 and Vδ1, two markers present on unconventional γδ T cells 
(Figure 4.6C and D). Further staining demonstrated that a significant number of 
intraepidermal α1β1+ T lymphocytes also expressed the αEβ7 integrin (CD103), which 
mediates the adhesion to E-Cadherin on keratinocytes and favours the retention of T 
cells in the epidermis (Figure 4.6E). Another receptor highly expressed on 
intraepidermal α1+ T cells was NKG2D, a C-type lectin like protein normally 
expressed on NK cells, CD8+ T cells and γδ T cells (Saez-Borderias, Guma et al. 
2006); whereas no expression of the skin-homing-associated receptor CCR4 could 
be detected (Figure 4.6F and G). The analysis of the total epidermal cell suspension 
revealed that no α1β1+/CD56+ NK cells were present in the epidermis of psoriatic 
patients (Figure 4.6H).  
 
Figure 4.6  Extended Phenotype of freshly isolated α1β1+ psoriatic T cells. Flow cytometry 
analyses of epidermal T cells freshly isolated from lesional psoriatic skin. (A and B) Approximately 
60% of epidermal CD3+ cells and even 75% of the CD8+ subpopulation were also positive for α1β1 
integrin. The expression of Vγ9 (C) and Vδ1 (D), was barely or not detectable on CD3+/α1β1+ 
epidermal T cells. Further analysis of the α1β1 population revealed that the majority of intraepidermal 
CD3+ cells were expressing CD103 (E) and NKG2D (F), whereas no expression of the skin-homing 
marker CCR4 (G) could be detected. Analysis of the total epidermal lymphocyte population 
demonstrated that almost no α1β1+/CD56+ cells were present in the epidermis of lesional psoriatic 
skin (H). Data depicted are representative of 3 independent experiments. 
Chapter 4  Results α1β1 
  
 
 
94
 
 
4.2.2.2. Contact with collagen IV induces expression of α1β1 integrin on T cells 
Epidermal T cells but not dermal T lymphocytes seem to express the α1β1 
receptor. This implies that collagen IV present in the basement membrane of the skin 
might induce the up-regulation of this integrin, when T cells emigrate from the dermis 
to the epidermis. This hypothesis was confirmed by an in vitro transmigration assay 
using freshly isolated human T cells. α1β1 expression on CD3+ cells was measured 
before and after 4 hours migration through collagen IV-coated transwells using SDF-
1α (CXCL12) as a chemoattractant (Figure 4.7). Interestingly, percentage of α1β1 
positive T cells increased significantly after migrating through collagen IV as 
compared to the expression at the beginning of the experiment. These data 
demonstrate that the interaction of T cells with collagen IV induces the expression of 
α1β1 integrin on their surface. 
 
 
Figure 4.7  Collagen type IV increases α1β1-expression on T cells in vitro. Percentage of α1β1 
expression of freshly isolated T cells before and after migration through collagen IV-coated transwells 
using SDF-1α (CXCL12) as a chemoattractant. Graph displays three independent experiments with T 
cells from three different healthy donors. Migration assays were performed in triplicates. Data points 
t=4h represent mean values of triplicates +/- standard deviation (SD) for SDF-1α at 50ng/ml after 4 
hours. *, p<0.01 
 
4.2.2.3. Anti-α1 mAb treatment does not induce T cell apoptosis 
In paragraph 4.2.1.2 it was shown that treatment with anti-α1 mAb significantly 
reduces the number of CD3+ T cells in the AGR xenograft mouse model. This 
epidermal T cell reduction could also be attributed to non-specific cytotoxic effects of 
the antibody. In order to address this hypothesis an in vitro test evaluating the direct 
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effect of anti-α1 mAb on T cells was performed. α1β1+ T cells, obtained as already 
described in paragraph 4.2.1.3, were incubated at various concentrations of anti-α1 
mAb and different time-points. Percentage of cells undergoing apoptosis was 
measured by flow cytometry after staining them with annexin V and propidium iodide 
(PI) (Figure 4.8C-E). While irradiation with single dose of 4200 rad readily induced T 
cell apoptosis, none of the indicated concentration of monoclonal antibody to α1β1 led 
to an increase of apoptosis as compared to isotype control antibody or medium alone 
(Figure 4.8A and B). Moreover cell apoptotic rate did not increase with longer 
incubation times. Based on these results it could be concluded that anti-α1 mAb 
blocks the emigration of dermal T cells into the epidermis, rather than inducing a 
cytotoxic effect on α1β1+/CD3+ T cells. 
 
Figure 4.8  No induction of apoptosis via monoclonal antibody to α1. Graphs A and B show 
percentage of T cells undergoing early apoptosis (cells single positive for annexin V) and percentage 
of total early and late apoptotic cells and necrotic cells (cells double positive for PI and annexin V) 
respectively. Figure C, D and E are representative for data obtained from 2 independent experiments. 
Early apoptotic cells staining positive for annexin, but not PI, appear in the upper left quadrant of dot 
plots. Late apoptotic/necrotic cells appear in the upper right quadrant, staining positive for both PI and 
annexin V. Double negative staining represents live cells. Small boxes (C-E) represent percentage of 
early apoptotic T cells, large boxes (C-E) represent percentage of total apoptotic and necrotic T cells. 
 
4.2.2.4. Effect of anti-α1β1 treatment on lesional psoriatic skin. 
The final step of this study was to investigate the efficacy of α1β1 treatment on 
fully developed psoriatic skin transplanted on AGR mice. Injection of anti-α1 mAb 
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(n=4) only slightly reduced the acanthosis (data not shown) and papillomatosis index 
as compared to isotype control (n=2) or skin prior to transplantation (n=3) (Figure 
4.9). In contrast, anti TNF-α therapy was still able to significantly reduce epidermal 
hyperplasia. An explanation for these results may be in the fact that anti-α1 mAb 
prevents the development of a psoriatic lesion by inhibiting the migration of dermal T 
cells into the epidermis. Therefore, in an established psoriatic lesion, where a 
significant number of T cells are already present in the epidermis, α1β1 blockade is 
not able to ameliorate the disease. However, in our previous study (Conrad, Boyman 
et al. 2007), when psoriatic skin harbouring an active immune compartment (defined 
by increased numbers of dermal T cells with few T cells already present in the 
epidermis) was transplanted on AGR mice, anti-α1 treatment could still show an 
inhibitory effect on the development of psoriasis. In fact, α1β1 blockade inhibited the 
emigration of new T cells into the epidermis and few T cells already present in the 
epidermal compartment were not sufficient to induce psoriasisform changes. 
Subsequent staining with anti-CD3 mAb clearly showed the effect of the anti-α1 
treatment. Although total T cell numbers remained unchanged in all grafts and 
throughout all the experiment, a difference in the distribution of these cells was 
observed. Anti-α1 treated grafts presented an accumulation of T cells beneath the 
basal membrane with almost no cells in the epidermis. In contrast, isotype control 
treated grafts showed a significant reduction of dermal T cells and instead an 
increase of epidermal T lymphocytes. Thus, this experiment confirmed the effect of 
anti-α1 mAb in inhibiting the movement of resident T cell in the epidermis and 
excluded its putative cytotoxic effect. 
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Figure 4.9  α1β1 blockade in established psoriatic skin. (A) Papillomatosis index of lesional 
psoriatic skin 3 weeks after transplantation onto AGR mice and injected with either isotype control 
mAb (n=2), mAb to α1 (n=4) (anti VLA-1) or mAb to TNF-α (n=3). (B-D) Microscopic view of PP skin 3 
weeks after transplantation onto AGR mice treated with isotype control (B), monoclonal antibody to α1 
(C), and monoclonal antibody to TNF-α, (infliximab) (D). Data depicted represent mean values plus 
standard deviation (SD) (a). Dashed line (B-D) indicates border between epidermis above and dermis 
below. *,p<0.05; n.s. not significant  
 
 
4.2.3. Discussion 
 
Experiments performed in section “Results 2” confirmed and extended the initial 
study regarding the critical role of α1β1 integrin in the development of psoriasis. A 
more detailed characterisation of the α1β1 epidermal T cell subpopulation could be 
given by analysing the expression of different surface markers. In addition of being 
effector memory Th1 cells, the majority of α1β1+ T lymphocytes were shown to be 
CD8+, but not CD56, Vδ1 or Vγ9 positive. Moreover, a consistent number of α1β1+ T 
cells was also expressing the integrin αEβ7, which is the ligand for KCs E-cadherin, 
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and therefore can possibly explain the retention of T cells in the epidermis. Based on 
these results a simplified two step scenario has been proposed (Conrad, Boyman et 
al. 2007). During their migration from the dermis to the epidermis, effector T cells 
would interact with collagen IV and therefore induce the expression of α1β1 integrin. 
Once in the epidermis, T lymphocytes would up-regulate integrin αEβ7 and 
progressively downregulate α1β1 expression. In fact, in the epidermis, in addition to 
α1β1+/αEβ7+ T cells also α1β1-/αEβ7+ cells have been observed. An additional 
experiment confirmed the critical role of collagen IV on α1β1 T cell expression. In fact, 
when freshly isolated T cells migrated trough collagen IV coated transwells an 
increase in α1β1 expression could be detected. Previous experiments performed on 
AGR mice showed that blockade of α1β1 inhibited migration of T cells into the 
epidermis and prevented the development of a psoriatic lesion. The reduced number 
of T cells observed after treatment with anti-α1 mAb was shown not to be the 
consequence of an unspecific cytotoxic effect of the Ab. In fact, incubation of α1β1+ T 
cells with different concentration of anti-α1 mAb did not induce any increase in the 
apoptosis rates if compared to isotype antibody or medium alone. While, T cells 
irradiated with a single dose of 4200rad, readily underwent apoptosis. A final 
experiment demonstrated that α1β1 blockade was not able to to significantly 
ameliorate established psoriatic lesions in AGR mice. In fact, anti-α1 mAb has been 
demonstrated to inhibit the development of psoriasiform lesions by blocking the 
migration of T cells in the epidermis. Therefore, in a situation where T cells are 
already present in the epidermis the mAb may not be effective anymore. Though, 
anti-α1 mAbs, by significantly reducing the number of epidermal T cells, eliminate the 
supply of additional T cells needed for chronification of disease and thereby 
effectively improve psoriasis. In addition, a therapy with anti-α1 mAb may be 
considered as a strategy in the long term to avoid disease relapses. 
Taken together this work establishes α1β1+ epidermal T cells as an important subset 
of effector memory lymphocytes in the development of psoriatic lesions. It also 
demonstrates that inhibition of α1 integrin results the blockade of psoriasis 
development as a consequence of T cell migration blockade into the epidermis.
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4.3. Blockade of α2β1 integrin inhibits psoriasis in a T 
cell independent manner 
 
Throughout this thesis psoriasis has been regarded as a T cell- mediated disease. 
T cells were shown to be crucial for the generation of psoriatic lesions and their 
migration into the epidermis was demonstrated to precede psoriasisform changes. 
However, it has to be kept in mind, that psoriasis is a skin disorder, with KCs 
hyperproliferation as one of the most evident phenotypical changes. In this context, 
several reports have already suggested KCs as potential initiator of inflammation, via 
production  of cytokines, growth factors as well adhesion molecules important for the 
disease initiation. In 2005 Zenz et al. published an interesting study considering 
psoriasis as an epidermal disease. By knocking out in the epidermis two components 
of the AP-1 transcription factor (JunB and c-Jun) involved in cell proliferation and 
differentiation in the epidermis, they created a new animal model with psoriasis-like 
features (Zenz, Eferl et al. 2005). At the skin level these mice showed typical 
hallmarks of psoriasis such as hyperkeratosis, enlarged blood vessels, lymphocytic 
infiltration and up-regulation of several cytokines known to be increased in psoriatic 
lesions. By analysing the two JunB and c-jun components in humans, the authors 
observed that JunB was down-regulated and c-jun slightly up-regulated in the skin of 
psoriatic patients. Although many questions arose whether this mouse model truly 
resembles psoriasis, this work shifted again the interest towards KCs as initiator of 
psoriasis. However, it is still a controversial whether psoriasis arises from a primary 
alteration in epidermal KCs or in immunocytes. A reasonable compromise would be 
that the perpetuation of the inflammatory processes in psoriasis originates from the 
mutual interaction and activation between KCs and T cells. This aspect of psoriasis 
biology will be investigated in the last part of this thesis.  
Attachment of KCs to the basement membrane is mediated by integrin receptors, 
including α6β4 integrin, which is a receptor for laminin, and by several β1 integrins, the 
most abundant of which are α2β1 (collagen receptor) and α3β1 (laminin receptor). In 
situations in which the epidermis is hyperproliferative, such as during wound healing 
and psoriasis, all three integrins have been shown to be expressed suprabasally. 
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Carroll et al generated transgenic mice in which human integrins β1, α2 and α5 were 
expressed under the control of the involucrin promoter, thereby limiting their 
expression into skin (Carroll, Romero et al. 1995). Transgenic mice expressing the β1 
subunit alone or in combination with α2 or α5, presented typical features of psoriasis, 
such as epidermal hyperproliferation, capillary dilatation and large numbers of 
epidermal CD8+ and dermal CD4+ cells. While in these mice KCs hyperproliferation 
was observed in the absence of infiltrating leukocytes, epidermal hyperplasia was 
never seen without skin inflammation. Based on this the authors speculated that 
suprabasal expression of β1 integrins in psoriasis may be the cause of psoriasisform 
changes. Among different integrins shown to be abnormally expressed in 
hyperproliferative epidermis, a more detailed analysis of the α2β1 integrin will be 
presented in this section.  
α2β1 (CD49b/CD29) integrin is the major collagen I receptor and is expressed on 
endothelial cells (ECs), KCs, and T cells. This integrin has been shown to participate 
in different cell functions as cell migration and reorganization, vascular 
morphogenesis and in cell survival (Senger, Claffey et al. 1997). On ECs, α2β1 is the 
principal receptor for interstitial collagen I. Senger et al demonstrated that vascular 
endothelial growth factor (VEGF) potently induced α2β1 expression on dermal 
microvascular ECs (DMECs) and that this integrin promoted neovascularisation and 
capillary lumen formation in vitro (Senger, Claffey et al. 1997). α2β1, on the other 
hand, markedly inhibits VEGF-driven angiogenesis in vivo, and has been shown to 
suppress leukocyte infiltration and edema in several mouse models of inflammation 
(de Fougerolles, Sprague et al. 2000; Senger, Perruzzi et al. 2002).  
In the intact epidermis, α2β1 integrin is mostly confined to basal KCs and mediates 
cell-cell adhesion, possibly by interacting with other integrins, such as α3β1 on 
adjacent cells (Symington, Takada et al. 1993). However, the exact function of this 
integrin in healthy skin has not been fully elucidated so far. α2β1 preferentially binds 
to collagen I and in intact skin these two components are separated by the basal 
membrane, which is predominantly composed of collagen IV and laminin. α2β1 can 
also bind to these two proteins, but these interactions are much weaker (Parks 
2007). Moreover, α2 knock-out mice do not present particular skin defects, thereby 
making the role of this integrin even more mysterious in intact skin. A possible 
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explanation for the presence of this integrin in healthy skin may derive from its 
important role in wound healing. It has been shown that after an epidermal lesion 
α2β1 is required for KCs adhesion on dermal collagen I and activation of other factors 
necessary for wound closure. Therefore, in intact skin, α2β1 may be a standby 
condition waiting to respond to injury. In situations where the epidermis is 
hyperproliferative, such as during wound healing or psoriasis (Hertle, Kubler et al. 
1992), aberrant expression of epidermal integrins on suprabasal KCs has been 
observed. Suprabasal α2β1 integrin expression may thus represent the response of 
KCs to an inflammatory state (characteristic of wounds and psoriatic lesions) through 
which KCs are exposed to several pro-inflammatory cytokines. However, when single 
pro-inflammatory cytokines were added to KCs cultures, there was still no suprabasal 
integrin expression (Hertle, Jones et al. 1995). The aberrant expression of α2β1 in 
wounds or psoriatic lesions may likely arise from a complex cascade of events 
including cytokines and multiple cell-cell interactions.  
Regarding T lymphocytes, in vitro α2β1 integrin expression has only been 
observed after long-term activation, and therefore, as for α1β1, this integrin has also 
been called very late antigen (VLA) -2. However, virus infected T cells after an initial 
α2β1 expression become rapidly negative for VLA-2 suggesting that this integrin is 
down regulated after antigen elimination. (Andreasen, Thomsen et al. 2003). 
Most of the studies regarding this integrin have been performed on mice. Given 
the functional importance of integrins in the human setting, a more detailed analysis 
of α2β1 receptor on human KCs and ECs, and in its role in psoriasis has been 
investigated as part of this thesis. 
Initially, α2β1 integrin expression was analysed on psoriatic sections confirming its 
expression on dermal ECs and on basal as well as suprabasal KCs. Subsequently, 
the effects of α2β1 inhibition on keratinocyte hyperproliferation and angiogenesis were 
studied in vitro. Finally, in vivo experiments using the AGR xenotransplantation 
psoriasis mouse model showed that blockade of α2β1 significantly inhibits the 
development of psoriasis.  
These results demonstrated the effect of blocking α2β1 function in psoriasis and 
suggest a T-cell independent mechanism for inhibiting the development of psoriatic 
lesions. 
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4.3.1. Results 
 
4.3.1.1. α2β1 expression on keratinocytes but not on T cells in psoriasis 
Aberrant expression of α2β1 has been observed in conditions characterised by 
epidermal hyperproliferation including wound healing and psoriasis. 
Immunofluorescence staining of lesional psoriatic sections with an anti-α2 mAb 
(green) confirmed that α2β1 integrin was distributed on all sides of basal KCs and 
also around suprabasal epidermal cells (Figure 4.10A and B). This pattern was 
clearly different from that of healthy skin and uninvolved psoriatic skin where α2β1 
was delimitated to basal cells (Figure 4.10C and D). Long term activated T cells as 
well activated T cells in chronic inflammatory settings are known to express the α2β1 
integrin (Andreasen, Thomsen et al. 2003). Thus, the expression of α2β1 on T cells 
resident in psoriatic lesions was investigated. Immunofluorescence double staining 
with mAb to α2 (green) and CD3 (red) revealed plenty of CD3+ T cells in both 
epidermal and dermal compartment of established psoriatic lesions, but none of them 
was expressing the VLA-2 integrin (Figure 4.10A and B). Analyses of symptomless 
psoriatic skin sections revealed only few T cells in the dermal compartment and none 
of them was α2β1+ (Figure 4.10D). To confirm the absence of α2β1 expressing T cells 
in psoriasis, cell suspensions, freshly isolated from lesional and non-lesional psoriatic 
skin biopsies, were stained with mAb directed to CD3 and α2β1 (Figure 4.10E). Flow 
cytometry analyses demonstrated no α2β1+/CD3+ cells in none of the two biopsies 
analysed. Based on these results, the next step was to investigate whether α2β1 was 
present on peripheral blood cells. Flow cytometry analyses performed on cells 
isolated from the blood of psoriatic patients and healthy volunteers revealed that 
peripheral T lymphocytes expressed very low levels of α2β1 integrin and that the two 
groups  had almost the same percentage of VLA-2+/CD3+ cells (Figure 4.10F and 
G). The CD3-/α2β1+ expressing cells found in these experiments most likely 
represented natural killer cells, which are known to express the CD49b chain (Hemler 
1990; Arase, Saito et al. 2001). 
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Figure 4.10  VLA-2 expression in lesional psoriatic skin. Two colour immunofluorescence staining 
using FITC-conjugated anti-CD49b (α2) mAb (green) and PE-conjugated anti-CD3 mAb (red) on 
lesional psoriatic skin (A and B), skin of healthy donor (C) and uninvolved psoriatic skin (D). None of 
the CD3+ T cells (red) present in the psoriatic lesion (A and B) and in the pre-psoriatic skin (D) stained 
in yellow which would be the consequence of co-localization of CD3 and α2β1 integrin. (E) Flow 
cytometry experiment with cells freshly isolated from uninvolved (PN) and involved (PP) psoriatic skin 
biopsies and stained with anti-CD3 and anti-CD49b mAb. (F) Representative example of a flow 
cytometry analysis performed on peripheral blood T cells of healthy donors (n=7) and psoriatic 
patients (n=8) and stained with anti-CD3 and anti-CD49b mAb. (G) Peripheral T lymphocytes in the 
blood of psoriatic patients and healthy volunteers expressed almost the same percentage of α2β1+ 
cells. Data depicted in G represent mean values plus standard error of the mean (SEM). n.s. = not 
significant 
 
4.3.1.2. Blocking α2β1 inhibits KCs proliferation on collagen I matrices. 
Suprabasal integrin expression may not be a direct consequence of inflammation 
since in humans it is not induced by intradermal injection of pro-inflammatory (type 1) 
cytokines (Hertle, Jones et al. 1995). Suprabasal expression may rather correlate 
with KCs hyperproliferation or with alterations in cell-cell and cell-matrix adhesions. In 
this context, it has been shown that psoriatic lesions are associated with a general 
loss of basement membrane integrity (Fleischmajer, Kuroda et al. 2000). In 
particular, the basement membrane showed marked folding and large gaps or areas 
with reduced staining for collagen IV and laminins (Fleischmajer, Kuroda et al. 2000). 
Based on these considerations, it is conceivable that fragmented basement 
membrane allows contact of basal KCs with dermal collagen I and that this 
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interaction causes uncontrolled KCs proliferation. To test this hypothesis a 
proliferation assay with KCs cultivated on collagen I coated wells was performed. 
Firstly, human epidermal KCs, were isolated from foreskin of healthy individuals and 
cultivated in serum-free media in the presence of keratinocytes growth factors. Flow 
cytometric analyses revealed that cultivated KCs expressed high levels (80-90%) of 
α2β1 integrin, as shown in Figure 4.11A. After 2-3 weeks cultivation, KCs were plated 
on collagen I coated wells and let adhere over night. 24 hours later anti-α2 or isotype 
control mAb were added to the coulters. Proliferation rates were measured by 
counting the cells (Figure 4.11C) or using the MTT colorimetric assay (Figure 4.11B) 
on the day of treatment (day 0) and 1, 3 and 5 days after mAb were added. KCs 
cultivated on collagen I and treated with isotype control mAb proliferated much more 
if compared to KCs plated on BSA coated wells (control). Addition of anti-α2 mAb 
significantly reduced KCs proliferation and induced a cell growth similar to cells 
cultivated on BSA. These results suggest that the loss of the basal membrane 
integrity could expose epidermal cell to collagen I and that this interaction induces 
KCs hyperproliferation in a VLA-2 dependent manner.  
 
 
Figure 4.11  Collagen I induces KCs hyperproliferation in a α2β1 integrin dependent manner. (A) 
Representative (n=3) flow cytometry analysis of cultured KCs. 80-90% of KCs expressed VLA-2 (solid 
black line). The grey shaded area represents isotype-matched control staining of the same cells. (B) 
Representative (n=3) MTT proliferation assay performed with KCs cultivated either on collagen I (Coll-
I) or on BSA (Control). Anti-VLA2 or isotype control mAb was added 24h after plaiting. (C) Cell counts 
of cells plated on collagen I or BSA. Anti-VLA2 or isotype control mAb was added 24h (day 0) after 
plaiting (day -1). Absorbance was measured 24h (Day 0) and 1, 3 and 5 days after plaiting.  
*, p =0.048; **, p=0.006 
 
4.3.1.3. α2β1 blockade suppresses dermal microvascular ECs functions 
One typical feature of psoriasis is an abnormal vascular expansion within the dermis, 
principally induced by vascular endothelial growth factor (VEGF), which is produced 
by epidermal keratinocytes (Creamer, Sullivan et al. 2002). Findings reported by 
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Senger et al demonstrated that α2β1 is expressed on VEGF-triggered dermal 
microvascular ECs (DMECs), and that this integrin is involved in ECs migration and 
proliferation, and in the formation of new blood vessels (Senger, Claffey et al. 1997). 
Based on these observations, the next step was to investigate whether α2β1 integrin 
was expressed on the surface of psoriatic blood vessels. Immunofluorescence 
double staining of lesional psoriatic sections demonstrated co-expression of CD31 
(red) and α2β1 (green) on dermal ECs (Figure 4.12A), suggesting that the high 
amounts of VEGF present in psoriatic lesions potently induced DMEC expression of 
α2β1. Previous reports demonstrated that α2β1 integrin present on VEGF-stimulated 
DMECs was important for cell attachment on collagen I and that α2-blockade 
markedly inhibited VEGF-driven angiogenesis in mice (Senger, Perruzzi et al. 2002). 
In order to test the effect of α2β1 blockade on human DMECs two functional in vitro 
experiments were performed. DMECs were cultivated in the presence of VEGF 
(20ng/ml) and thereafter α2β1 expression was measured with flow cytometry. 
Analyses performed after at least one day of stimulation demonstrated that above 
75% of treated cells expressed the VLA-2 receptor (Figure 4.12B). Subsequently, the 
proliferation rate of VEGF-stimulated DMECs was measured after seeding the cells 
on collagen I coated wells in the presence of anti-α2 or isotype control mAbs. Cell 
proliferation was measured 1, 3 and 5 days after seeding using the MTT colorimetric 
assay. Blockade of α2β1 integrin inhibited attachment of DMECs on collagen I and 
thereby significantly reduced ECs proliferation compared to isotype control treated 
cells. DMECs seeded on BSA coated wells presented even more reduced cell growth 
(Figure 4.12C). Given the importance of α2β1–collagen I interactions during EC 
migration and tube formation the effect of α2-blockade on DMECs grown in a 
tridimensional collagen gel were investigated. Therefore, VEGF-stimulated DMECs 
were plated on collagen I gels in the presence of α2-blocking mAb or isotype control 
mAb. As shown in Figure 4.12D, after 2 days of incubation with isotype control mAb 
DMECs nicely organised in tube-like structures, whereas addition of anti-α2 mAb 
strongly inhibited cell spreading and tube formation. Thus, these data together with 
the one presented in the previous paragraph established α2β1 as an important 
integrin for KCs and DMECs functions and suggested its direct involvement during 
psoriasis development.  
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Figure 4.12  α2β1 integrin expression and inhibition on DMECs. (A) Two colour 
immunofluorescence staining using FITC-conjugated anti-CD49b (α2) mAb (green) and PE-conjugated 
anti-CD31 mAb (red) on lesional psoriatic skin. Blood vessel cells appeared in yellow as a 
consequence of co-localization of CD31 and α2β1 integrin. (B) Flow cytometry analysis of cultured 
DMECs. 75% of DEMCs expressed VLA-2 (solid black line). The grey shaded area represents 
isotype-matched control staining of the same cells. (C) Representative (n=3) MTT proliferation assay 
performed with DMECs cultivated either on collagen I (Coll-I) or on BSA (Control). Anti-α2β1 or isotype 
control mAb was added one day of seeding. Absorbance was measured 1, 3 and 5 days after plaiting 
the cells. (D) DMVEc were growth in a tridimensional collagen I gel in the presence of either anti-α2 or 
isotype-matched mAb.  
 
By analysing the formation of new blood vessel during psoriasis development in 
grafts transplanted on AGR mice a final interesting result was obtained. In order to 
survive human transplants after engraftment onto mice had to be fed by mouse 
blood. For this purpose both human and mouse vessels had to proliferate at the base 
of the wound caused during the transplantation and had to fuse in order to form new 
functional vascular tubes. By staining isotype-control treated grafts excided at day 35 
with both anti-human (red) and anti-mouse (green) CD31, the fusion of human and 
mouse blood vessels could be clearly demonstrated (Figure 4.13). 
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Figure 4.13  Fusion of mice and human blood vessel in the AGR mice model. Immunofulorescence 
staining using FITC-conjugated anti-human CD31 mAb (green) and PE-conjugated anti-mouse CD31 
mAb on isotype-control treated grafts obtained 35 days after transplantation. 
 
 
4.3.1.4. Antagonism of α2β1 integrin in vivo suppresses psoriasis development 
To directly test the importance of collagen I/α2β1 integrin interaction in psoriasis α2β1 
function was neutralized during the spontaneous conversion of uninvolved skin into 
psoriatic skin lesions in AGR xenotransplantation mouse model. Transplanted mice 
were treated with either neutralizing Ab to the α2 integrin subunit or isotype-matched 
control Ab. 5 weeks after transplantation animals were sacrificed and grafts were 
processed for immunohistochemical analyses. Transplants injected with anti-α2 mAb 
presented acanthosis and papillomatosis indices similar to grafts treated with anti-
TNF-α, a current standard in anti-psoriatic treatment, and to uninvolved PN skin of 
the same patient (Figure 4.14), whereas skin grafts from mice receiving isotype-
matched control Ab developed into full-fledged psoriatic lesions. Treatment with 
neutralizing anti-α2 mAb significantly reduced skin inflammation. Likely, inhibition of 
epidermal hyperproliferation caused the release of less pro-inflammatory cytokines 
by KCs and consequently reduced the expansion and the migration into the 
epidermis of pathogenic T cells. These results indicate the critical role of collagen 
I/α2β1 integrin interaction for the development of psoriasis and demonstrates that 
psoriasis can also be blocked using a T cell-independent approach.
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Figure 4.14  Anti-α2β1 treatment inhibits development of psoriasis. (A and B) Acanthosis and 
papillomatosis indices in skin grafts before transplantation (d0) onto AGR129 mice and after 35 days 
treatment with either anti-α2 or isotype-matched control antibody. There was a statistically significant 
reduction of psoriasis acanthosis and papillomatosis indices in grafts of mice treated with anti-α2 
compared to isotype control mice. The efficacy of the treatment with anti-α2 in inhibiting psoriasis 
development was comparable to anti-TNF-α (infliximab), the „gold standard“ in psoriasis treatment. (C) 
Total and (D) epidermal human CD3+ T cell count in PN skin grafts before transplantation (d0) and 35 
days after transplantation and treatment with either anti-human anti-α2, isotype-matched control or 
anti-TNF-α (infliximab) mAb. There was a statistically significant reduction of both total and epidermal 
CD3+ T cells in grafts treated with anti-α2 compared to isotype control treated transplants. Graphs A-D 
represent mean values of three independent experiments with PN skin from three different patients. P-
values were calculated using the unpaired Student‘s t test *, p= 0,0003 **, p= 0,0008. Scale bar 
represent 20µm. 
 
4.3.2. Discussion 
Collectively the data presented in this section demonstrate that interaction of α2β1 
integrin with collagen I causes KCs and ECs hyperproliferation and that this integrin 
is directly involved in psoriasis development. 
α2β1 integrin is the major receptor for collagen I and is expressed on a variety of 
cells including ECs, KCs, fibroblasts and platelets (de Fougerolles, Sprague et al. 
2000). In healthy skin α2β1 is abundantly expressed by basal KCs and may function 
in cell-cell adhesion possibly interacting with α3β1 (laminin receptor). In vitro studies 
performed in human skin demonstrated that α2β1 was part of the epidermal repair 
machinery and that anti-α2 mAb inhibited cell migration on collagen I and across 
wounded dermis (Parks 2007). Interestingly, two recent in vivo studies performed on 
α2 integrin-deficient mice instead demonstrated that epidermal wound healing was 
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not impaired in these animals, suggesting that in mice KCs may not require α2β1  
integrin during wound closure (Grenache, Zhang et al. 2007; Zweers, Davidson et al. 
2007). Two explanations were given to the different results obtained in human in 
respect to that seen in mouse. Firstly, the mAb inhibiting integrin function may 
produce effects different from those due to the lack of integrin expression. Secondly, 
there is a different distribution of dermal collagen between human and mice, whereas 
mouse dermis is rich in loose connective tissue, human dermis is a dense fibrillar 
collagen matrix. Thus, expression of α2β1 integrin in human skin may be more critical 
compared to the mouse setting. Apart from the role that α2β1 may play in wound 
healing, the precise function of this integrin in the epidermis is still unclear. In intact 
skin α2β1 is expressed on basal KCs and may mediate adhesion to collagen IV and 
laminin of the basement membrane. However, α2β1 preferentially binds collagen I 
which is the major collagen component in the dermis. In psoriasis, as in wounding, 
the basement membrane has been shown to be destroyed presenting gaps where 
collagen IV and laminin are missing (Hertle, Kubler et al. 1992; Fleischmajer, Kuroda 
et al. 2000). This finding together with the suprabasal integrin expression observed in 
the two above mentioned skin alterations suggested that dermal collagen I interacting 
with basal KCs may induce epidermal hyperproliferation in an α2β1 dependent 
manner. To specifically address the involvement of the α2β1 collagen I receptor 
during epidermal hyperproliferation, KCs cultured on collagen I were treated with 
anti-α2 mAb or isotype control. The significant growth inhibition by anti-α2 mAb 
indicated that α2β1 binding to collagen I may contribute to the abnormal KCs growth 
of psoriasis and wounding.  
In addition to be important regulators of epidermal homeostasis integrins play a 
key role during inflammation. By promoting cell-matrix and cell-cell interactions 
integrins favour leukocyte migration through the extracellular matrix-rich environment 
of peripheral tissues. In the skin the most abundant extracellular matrix component is 
collagen I, accounting for 75% of skin’s dry weight (Fitzpatrick. TB 1987). During the 
development of a psoriatic lesion resident T cells largely proliferate and migrate from 
the dermal to the epidermal compartment, suggesting that psoriatic T cells may 
express the α2β1 receptor in order to move through the dense collagen I matrix. 
Interestingly, neither in lesional nor in pre-lesional psoriatic skin resident T cell were 
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shown to express the VLA-2 integrin indicating that T lymphocytes do not need 
collagen I receptors to migrate through the dermal matrix.  
Previous studies already demonstrated the importance of α2β1 integrin for 
angiogenesis (Senger, Perruzzi et al. 2002) and in particular for the formation of the 
vascular lumen, as required during vessel maturation (Davis and Camarillo 1996). 
This study demonstrated that α2β1 integrin was highly expressed in the dermal 
vasculature of psoriasis, perhaps as a consequence of the high levels of VEGF 
produced by hyperpoliferative KCs (Creamer, Sullivan et al. 2002). In this study, as 
already demonstrated for KCs, α2β1-collagen I interactions were shown to be the 
cause of ECs hyperproliferation, as anti-α2 mAb markedly reduced the proliferation 
rate of DMECs cultivated on collagen I coated wells. Additionally, α2–blockade 
efficiently inhibited DMECs migration and tube formation, thereby confirming the 
functional role of this integrin during angiogenesis.  
The direct involvement of α2β1 integrin during the development of psoriasis was 
investigated in the AGR xenotransplantation mouse model. Antagonism of α2β1 
function with a specific human mAb demonstrated to markedly inhibit psoriasis 
development, as assessed by reduction of the acanthosis and papillomatosis indices. 
Anti-α2 treatment also significantly blocked the proliferation of T cells and their 
migration in the epidermal compartment compared to grafts treated wit isotype-
matched mAb. Moreover, the efficacy of α2–blockade was comparable to TNF-α 
treatment, a benchmark in the therapy of psoriasis.  
This study demonstrates the critical role of α2β1-collagen I interactions on cell 
proliferation. It proposes that the loss of the basement membrane integrity exposes 
epidermal cells to collagen I and that this interaction induces KCs hyperproliferation 
in a VLA-2 dependent manner. Moreover, the expression of VLA-2 on epithelial and 
endothelial cells, but not on lymphocytes, shows that α2–blockade inhibits psoriasis 
development in a T cell independent manner. The question whether epidermal 
hyperplasia is a direct consequence of altered signal transduction in KCs or whether 
it is mediated by the release of pro-inflammatory cytokines by other resident skin 
cells, such as DCs or T cells is still not completely elucidated. With respect to the 
results reported in the previous sections, stressing the importance of T cells during 
psoriasis pathogenesis and demonstrating that T cell expansion precedes the 
Chapter 4  Discussion α2β1 
 
 
111
development of typical psoriatic changes the more reasonable conclusion is that 
psoriasis is the outcome of an inappropriate immunocyte-based activation event, 
together with a defect in KCs, whose combination results in the full psoriatic 
phenotype. 
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5. Concluding remarks and outlook 
Psoriasis is a chronic inflammatory skin disorder affecting 2-3% of the population 
worldwide. The most important clinical and histological features of psoriasis are 
epidermal hyperplasia, increased dilatation and growth of blood vessels together with 
abnormal T cell proliferation and migration into the epidermis. While psoriasis 
aetiology remains unknown, considerable understanding of the genetics and 
immunopathology has been achieved in the last years. T cells together with their 
secreted cytokines and chemokines are currently believed to be the primary cause of 
psoriasis. The present study sought to investigate psoriasis immunopathology from 
different angles by considering the complex cytokine network with a focus on the 
newly identified IL-23/Th-17 axis and subsequently discussing the importance of the 
interaction of cells with the skin microenvironment.  
Recent discoveries in inflammatory immune diseases are highlighting the role of 
IL-23, rather then IL-12, as master cytokine potentially playing a role in the persistent 
inflammatory reaction observed in these disorders. The respective roles of IL-12 and 
IL-23 in inflammation are likely to be different, as IL-12 stimulates IFN-γ and induces 
a Th1 lineage shift, whereas IL-23 acts on memory T cells and maintains a recently 
described population of CD4+ T cells that produce IL-17 (Th-17 cells). Increased IL-
23 and IL-17 expression has been identified in the skin of psoriatic patients (Lee, 
Trepicchio et al. 2004; Steinman 2007) and blocking antibodies to the common p40 
subunit of IL-12 and IL-23 have been shown to have clinical benefit in psoriasis 
patients {Kauffman, 2004 #106; Krueger, 2007 #107}. The present study provides a 
comprehensive analysis of IL-23 and Th-17 cells and demonstrates their functional 
relevance in the pathogenesis of psoriasis. IL-23 function was found to be altered in 
the skin and blood of psoriatic patients and its levels were shown to parallel 
epidermal hyperplasia implying a functional role for IL-23. Administration of a 
neutralizing anti-human IL-23 monoclonal antibody inhibited psoriasis suggesting that 
the beneficial effect of the anti-p40 antibodies, observed when treating psoriatic 
patients, might be due to the inhibition of IL-23 rather then IL-12. The critical role of 
IL-23 during the pathogenesis of psoriasis as well other autoimmune diseases makes 
this cytokine an attractive target for anti-inflammatory strategies. However, it will be 
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important to determine whether the inhibition of this cytokine will increase the risk of 
infections.  
IL-23 has been shown to play a prominent role in the survival and expansion of 
Th-17 cells. We saw an enrichment of Th-17 cells in the skin and blood of psoriatic 
patients compared to healthy donors. IL-17 blockade did not significantly inhibit the 
development of a psoriatic lesion suggesting that the pathogenic effects of Th-17 
cells are not due to IL-17 alone, but potentially due to other cytokines produced by 
this cell subset. The exact function of IL-17 is to date unclear, but it could include the 
induction of epithelial and endothelial cells to secrete proinflammatory cytokines and 
the recruitment of neutrophilis and monocytes into inflammatory lesions (Afzali, 
Lombardi et al. 2007). Whether any of these mechanisms explains the function of Th-
17 cells in psoriasis warrants further investigations. Acosta-Rodriguez et al have 
recently analysed the Th-17 and the Th1 subsets based on the selective expression 
of chemokine receptors (Acosta-Rodriguez, Rivino et al. 2007). They found that 
CCR6 and CCR4 expression identified a population of human memory T cells 
producing IL-17 but not IFN-γ. Instead, CCR6 and CXCR3 defined a population of 
Th1 cells that are able to secrete IFN-γ but also IL-17. Based on these results, it 
would be interesting to investigate whether the Th-17 and Th1 cells found in the skin 
of psoriatic patients are also expressing these markers. CCR6 has been shown to 
play a role in the recruitment of T cells to lesional psoriatic skin (Homey, Dieu-
Nosjean et al. 2000), whereas CCR4 was found on infiltrating lymphocytes, 
principally within the psoriatic dermis (Rottman, Smith et al. 2001). It is conceivable 
that recruitment of T cells into the epidermis is controlled by the expression of 
specific cell receptors and their respective ligands in the inflamed tissue, rather then 
from proinflammatory cytokines released by an uncontrolled activation of the immune 
system. 
Further studies are required to clarify the initial signal leading to the dominance of 
either IL-12 or IL-23 production by the innate immune cells and thus define the 
functional role and the relative contribution of the Th1 and Th-17 subset in the 
development of psoriasis.  
As mentioned earlier, two typical features of psoriasis are epidermal hyperplasia 
and massive proliferation and infiltration of T cells in the epidermis, but which is the 
link between activated keratinocytes and immunocytes during psoriasis onset? 
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STAT-3 seems to be a major mediator. STAT-3 is essential during wound healing, 
however an uncontrolled activation of STAT-3 can induce the development of 
tumours or psoriasis (Sano, Chan et al. 2005)(Yu, Kortylewski et al. 2007). In fact, 
mice with a constitutive active form of STAT-3 in keratinocytes developed skin 
lesions resembling psoriasis. Interestingly, a recent study demonstrated that IL-22, a 
cytokine secreted by Th-17 cells, induced epidermal acanthosis through the 
activation of STAT-3 and that IL-22-/- mice had significantly less activated STAT-3 
and a decrease of total epidermal thickness. These findings provide a further support 
for the important role of the IL-23/Th-17 axis in psoriasis and suggest that epidermal 
hyperplasia is the result of lymphocyte infiltration and inflammation in this disease. 
Besides the effect of various cytokines in the development of psoriasis, adhesive 
interactions appear to be important by promoting cell attachment and migration 
through the inflamed tissue. In this context, the inhibition of specific receptor/ligand 
interactions may represent another target in the treatment of inflammatory disorders. 
We showed that by blocking the interaction of α1β1 on T cells with collagen IV in the 
basement membrane the migration of lymphocytes into the epidermis could be 
inhibited thereby preventing the development of a psoriatic lesion in the AGR 
xentotranplantation mouse model (Conrad, Boyman et al. 2007). In this study, we 
also demonstrated the relevance of other integrins and cell-matrix interactions in 
psoriasis. Specifically, we showed that interaction of α2β1 with dermal collagen I 
caused keratinocytes and endothelial cells hyperproliferation and that by blocking this 
interaction the development of psoriasis could markedly be inhibited. With these 
findings we introduced a potential T-cell independent mechanism for inhibiting the 
development of psoriatic lesions and demonstrate the importance of cell-matrix 
interactions as a causative factor in psoriasis pathogenesis. We hypothesize that 
abnormal integrin expression, observed in the hyperproliferative epidermis, induces a 
release of proinflammatory cytokines and growth factors contributing to the 
inflammation during psoriasis onset.  
In conclusion, excessive inflammation in psoriasis may be the outcome of different 
aberrant mechanisms in the host defence or tissue repair involving not only one 
single cell or cytokine, but a variety of different factors. The elucidation of specific 
biological pathways as well as other susceptibility genes will provide a solid basis for 
the development of new targets for the treatment of psoriasis.
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6. Material and methods 
6.1.1. Animal experiments  
6.1.1.1. Animals and patients 
Animal experiments were performed using AGR 129 mice, which are deficient in 
type I (A) and type II (G) IFN receptors, in addition to being RAG-2–/–. AGR 129 mice 
show immature NK cells with severely impaired cytotoxic activity in vitro and in vivo 
(unpublished data) due to a deficiency in type I (A) and type II (G) IFN receptors. In 
addition, they lack all B and T cell functions as a result of homozygous deletion of the 
Recombinase Activating Gene 2 (Rag2). AGR mice have been previously described 
as a clinically relevant psoriasis xenotransplantation mouse model (Boyman, Hefti et 
al. 2004; Nestle, Conrad et al. 2005; Conrad and Nestle 2006) (Conrad, Boyman et 
al. 2007). Mice were kept pathogen free throughout the study. Animal studies were 
approved by the Kantonale Veterinaeramt of Zurich and human studies by the Ethical 
Committee of the Kanton Zurich. 
  
6.1.1.2. Patients and transplantation procedure 
Keratomes (6 x 2 x 0.04 cm) of plaque psoriasis or uninvolved prepsoriatic skin 
(approx. 5 cm from the leading edge) were obtained from the buttocks or upper 
thighs of patients with plaque-type psoriasis after informed consent was obtained. 
Patients did not receive topical or systemic therapy for at least 4 weeks before the 
study. Mice were 7 weeks to 9 months of age. The AGR xenotransplantation mouse 
model was performed as published (Boyman, Hefti et al. 2004; Nestle, Conrad et al. 
2005; Conrad, Boyman et al. 2007). During transplantation animals were kept under 
inhalation anaesthesia with Sevoflurane (Sevorane, Abbott AG, Switzerland). After 
plucking the hair from the backs of the mice, human skin samples measuring 0.5 x 
0.5 x 0.04 cm were transplanted using an absorbable tissue seal (Vet-Seal, B. Braun 
Medical AG, Switzerland), (Figure 6.1A). Grafts were covered with an antiseptic non-
adhering dressing (Adaptic, Johnson & Johnson Gateway, England) and fixed with a 
self-adherent tape (Mefix, Mölnlycke Health Care AB, Sweden). Dressings were 
removed after 7 days. Mice were sacrificed 5 weeks after engraftment, and skin 
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transplants snap-frozen in liquid nitrogen and stored at -80°C for histological (Figure 
6.1B-F) or mRNA expression analysis. For time course experiments, mice were 
scarified and grafts were removed 7, 21 and 35 days after transplantation.  
 
Figure 6.1  AGR xenotransplantation mouse model. (A) Uninvolved psoriatic skin of a patient with 
psoriasis is transplanted on the back of AGR mice. (B, C) Macroscopic view and hemalaun/CD3 
staining of PN skin on the day of transplantation and (D and F) 35 days after engraftment. (E) 
Hemalaun/CD3 staining of control skin grafts on day 35 after transplantation. Skin of healthy donor 
fails to convert into psoriasis. In red: CD3+ T cells. Bars B-F: 100 µm 
 
6.1.1.3. Immunohistochemistry staining 
Cryopreserved skin specimens were fixed for 10 min in acetone, stained with 
hemalaun for no longer then 1 min and cleared immediately in sterile water. 
Immunochemistry was carried out on cryostat sections to detect CD3 positive cells 
and isotype matched control antibodies were used to asses unspecific binding. 
Unconjugated mAbs to CD3 or IgG1 isotype control (both obtained from BD, 
Bioscience, USA) were used followed by signal amplification using sequential 
incubations with rabbit anti-mouse IgG xenoantibodies and alkaline phosphatase 
anti-alkaline phosphatase complexes (APAAP). All the stainings were performed as 
previously described (Boyman, Hefti et al. 2004; Nestle, Conrad et al. 2005) (Conrad, 
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Boyman et al. 2007) and performed by the immunohistochemistry laboratory at the 
Dermatological Clinic of Zurich. 
 
6.1.1.4. Immunofluorescence staining 
Cryopreserved skin specimens were fixed for 10 min in acetone and then blocked 
for 15 min with normal serum (using the serum of the animal where the second Ab 
has been generated). Tissue sections were incubated with 200 µl of unconjugated 
mAbs diluted in 0.1% Tween-20/PBS for 1 hour, washed three times in PBS and 
incubated with 200 µl of conjugated mAbs diluted in 0.1% Tween-20/PBS for an 
additional hour. For directly labelled mAbs, acetone fixed tissue sections were 
directly incubated with 200 µl of conjugated mAbs diluted in 0.1% Tween-20/PBS for 
1 hour and washed three times in PBS. Finally, sections were mounted onto cover 
slides with Moviol (Calbiochem. California) and analysed under a confocal laser 
scanning microscope (Leica, Germany). 
 
6.1.1.5. Histological assessment and quantification experiments 
Histological quantification experiments represent the mean of three random fields 
using a 400-fold magnification. Quantification of human CD3+ T cells and α1β1+ 
mononuclear cells in uninvolved and lesional psoriatic skin as well as normal skin 
was performed using immunohistochemistry, while CD3+ T cells in transplantation 
experiments were quantified using immunofluorescence (in the transplant sections 
CD3 cells could not be stained with the immunohistochemistry APAAP method, 
because the transplants were treated with mouse anti-human antibodies). 
Subepidermal T cells were defined as CD3+ T cells less than 20 µm below the basal 
membrane. Typical histopathological features of psoriasis include signs of 
papillomatosis (wavy aspect of the epidermis with upwards extension of dermal 
papillae), acanthosis (thickening of the epidermis), hyperkeratosis (thickening of the 
stratum corneum) and parakeratosis (presence of nucleated cells in the stratum 
corneum). These typical psoriatic features of the epidermis were quantified using the 
papillomatosis and acanthosis indices as previously described (Fraki, Briggaman et 
al. 1983). Acanthosis is defined as the maximal epidermal thickness measured from 
the tip of the rate ridges to the border of the epidermis. The papillomatosis index is 
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defined as the ratio between adjoining maximal and minimal thickness of the 
epidermis (elongation of rete ridges, representing ratio of dermo-epidermal border to 
skin surface). The indicated values of both indices were determined using an ocular 
micrometer and represent the mean of ten random areas of each sample. Criteria for 
PN skin with active immune compartment includes a papillomatosis index > 2.0 and 
the presence of intraepidermal T cells as evaluated in histological sections taken 
from PN skin. 
 
6.1.1.6. Neutralization studies 
Dosage and route of administration of the reagents applied was deduced from 
therapeutic trials in humans and based on previous data with anti-human mAbs 
(Boyman, Hefti et al. 2004; Nestle, Conrad et al. 2005; Conrad, Boyman et al. 2007). 
 
Table 6.1  Treatment applied in the animal experiments 
mAb Isotype Dose (µg) Volume/Route Time Frame 
Anti- IL-23 mIgG1a 1000 0.5 ml/s.c Biweekly 
Isotype anti-IL-23 mIgG1 1000 0.5 ml/s.c Biweekly 
Anti-IL17 rIgG1b 1000 0.5 ml/s.c Biweekly 
Isotype anti-IL-17 rIgG1 1000 0.5 ml/s.c Biweekly 
Anti-TNFα Humanised 
mIgG1 
1000 0.1 ml/i.v. Biweekly 
Anti-α1 mIgG1 1000 0.16 ml/s.c Twice weekly 
Anti-α2 mIgG1 1000 0.16 ml/s.c Twice weekly 
Isotype anti-α1/α2 mIgG1 1000 0.16 ml/s.c Twice weekly 
a mIgG1, murine IgG1. b rIgG1, rat IgG1 
 
Antipsoriatic treatments versus controls were carried out on parallel grafts from 
the same subject and statistically analysed in paired fashion. 
Anti-IL-23, anti-IL-17 and isotype matched mAbs were kindly provided by 
Schering-Plough Biopharma, Paolo Alto, CA. Anti-TNFα (Infliximab) was purchased 
by Centocor, Malvern, Pennsylvania and anti-α1/α2 and isotype matched mAb by 
Biogen Idec, USA.  
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6.1.2. Cells and cell culture 
6.1.2.1. PBMC isolation 
Buffy coats from healthy donors or whole blood from psoriatic patients were 
diluted 1:1 in PBS. Peripheral blood mononuclear cells (PBMCs) were isolated by 
placing 10 ml Ficoll-Paque (Amersham Pharmacia Biotech, Sweden) at the bottom of 
a tube and layering 40 ml diluted blood above. The density gradient was generated 
following centrifugation at 1800g, for 20 min at 20°C. The lymphocyte layer was 
removed and washed three times with PBS at 453g, for 5 min to remove platelets. 
Cells were used either for direct flow cytometry staining or for further applications. 
 
6.1.2.2. Sorting of CD3+ cells  
Freshly isolated PBMCs or α1β1+ cells were isolated by depletion of non-T cells 
using the Pan T Cell Isolation Kit II (Miltenyi Biotec, Germany). Cells were first 
resuspended for 10 min at 4°C in 40 µl of MACS buffer (0.5% BSA, 2mM EDTA in 
PBS) containing 10 µl Biotin-Antibody Cocktail (anti- CD14, CD16, CD19, CD36, 
CD56, CD123 and Glycophorin A) per 107 cells. Afterwards, labelled cells were 
incubated for an additional 15 min at 4°C in 30 µl of MACS buffer containing 20 µl 
anti-biotin Microbeads. After washing, cells were diluted at a concentration of 108 
cells per 0.5 ml of MACS buffer and sorted with AutoMACS. The negative fraction 
was collected. Purity of each T cell population was over 90%, as assessed by flow 
cytometry analysis after staining aliquots of the cell fractions with a FITC conjugated 
mAb to CD3 (BD, Bioscience, USA). 
 
6.1.2.3. Isolation of dermal and epidermal cells from psoriatic skin samples 
Epidermal and dermal cells were isolated from skin keratome biopsies of plaque 
psoriatic lesions, uninvolved psoriatic skin or normal skin specimen. Small skin 
pieces (5 x 5 mm) were first incubated in dispase II (Roche Diagnostics, Switzerland) 
at 4°C overnight. Dermal sheets were then carefully separated from epidermal 
sheets, cut into small pieces (1 x 1 mm), incubated with an enzyme cocktail 
consisting of collagenase, hyaluronidase (Sigma-Chemie, Switzerland), and DNAse 
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(Boehringer-Mannheim, Germany) for 1 h at 37°C on a shaker in order to obtain a 
cell suspension. Epidermal T cells were obtained from epidermal sheets by treatment 
with trypsin 0,05%/EDTA 0,02% for 30 min at 37°C. Cells were stained for cytokines 
and surface markers as described in the Flow cytometry analysis section. 
 
6.1.2.4. Isolation of keratinocytes from foreskin 
Foreskins of newborns were washed in PBS, cut in small (0.5 x 0.5 cm) pieces 
and incubated in dispase II (Roche Diagnostics, Switzerland) at 4°C overnight. 
Epidermal sheets, after separation from the dermis, were digested in trypsin 
0,05%/EDTA 0,02% (Biochrom AG, Germany) for 30 min at 37°C. Cells were washed 
and resuspended in serum-free keratinocyte (KC) medium containing low calcium 
concentration and supplemented with human epidermal growth factor 
(hEGF)(Keratinocyte-SFM, Gibco, Switzerland). Cells were incubated at 37° C in a 
humidified atmosphere with 5% CO2. After one week, medium was removed and 
replaced with fresh medium. Afterwards, medium was changed every 3 days.  
 
6.1.2.5. Dermal microvascular endothelial cells (DMECs) culture 
DMECs were purchased by Cambrex and cultivated in EGM-2-MV medium 
containing the following growth supplements: BBE (bovine brain extract), hEGF, 
hydrocortisone, 5% FBS (fetal bovine serum), VEGF (vascular endothelial growth 
factor), IGF-1 (insulin-like growth factor 1) and ascorbic acid (all purchased from 
Cambrex, USA).  
 
6.1.3. Cell activation and cell analysis 
6.1.3.1. Generation of VLA-1+ cells 
After isolation, PBMCs were cultured in RPMI 1640 medium (Gibco, Switzerland) 
containing L-glutamine (Invitrogen, Switzerland) supplemented with 8% heat-
inactivated human AB-serum, 100 U/ml penicillin and 100 µg/ml streptomycin (Pen-
Strep, Invitrogen, Switzerland). After plating, cells were stimulated with 2 µg/ml 
phytohemagglutinin (PHA) and 50U/ml recombinant human IL-2 (R&D Systems, UK). 
Three days after the initial stimulation, new medium and 50 U/ml recombinant human 
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IL-2 was added, and subsequently replaced twice a week. Cultured cells were 
analyzed weekly for co-expression of CD3 and using flow cytometry. As soon as α1β1 
expression on cultured T cells exceeded 60% (after approx. 4-6 weeks), T cells were 
isolated by depletion of non-T cells using the Pan T Cell Isolation Kit II (Miltenyi 
Biotec, Germany).  
 
6.1.3.2. T cell activation with rhIL-23 
Purified T cells were activated by using the T cell activation/Expansion kit (Miltenyi 
Biotec, Germany). T cells were incubated with anti-Biotin MACSiBead particles 
containing biotinylated antibodies against human CD2, CD3 and CD28 (bead-to-cell 
ratio 1:2) and cultured in Iscove’s modified medium (Invitrogen, Switzerland) with 
20% heat inactivated FCS (Sigma, Switzerland), 1% L-glutamine, 1% penicillin and 
streptomycin and 50mM 2-ME. Human recombinant IL-23 (rhIL-23) (generausly 
provided by Schering-Plough Biopharma, Paolo Alto, CA) was added at the 
beginning of the cell culture at a final concentration of 100 ng/ml. Cells were 
harvested after 1, 2 and 3 days and stained for cytokines and surface markers as 
described in the Flow cytometry analysis section. 
 
6.1.3.3. Flow cytometry analysis 
For flow cytometry staining, cells were resuspended in 50 µl of FACS buffer (2% 
FCS, 0.5 mM EDTA in PBS) containing 1 µl (if not otherwise mentioned) of each 
surface mAb and incubated for 30 min at 4°C. Afterwards, cells were washed twice (2 
min 453g) with FACS buffer and fixed with FACS fix solution (2% formaldehyde 
solution 36% in FACS buffer). For intracellular staining of cytokines, cells were 
incubated with PMA (phorbol-12-myristate-13-acetate, 50 µg/ml) and ionomycin (0.5 
µg/ml) for 5 hours, adding brefeldin A (5µg/ml) after 1 hour. Cells were first surface 
stained and fixed (as described above), and then suspended in 50 µl 
permeabilization buffer (0,1% saponin in PBS) containing mAbs against intracellular 
cytokines and incubated for 30 min at 4°C. Afterwards cells were washed twice (2 
min 453g) with permeabilization buffer, once with FACS buffer and fixed with FACS 
fix solution. Cells were then analyzed using a FACSCalibur flow cytometer and data  
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were processed using CellQuestPro (both Becton Dickinson). mAbs used for flow 
cytometry are listed in appendix I. 
 
6.1.4. In vitro assays 
6.1.4.1. Migration assay 
Migration assays were performed as follows: cell culture inserts with 5 µm pores 
(Transwells, Corning, Netherlands) were coated with 25µg/ml collagen IV (Sigma, 
USA) overnight at 4°C, washed twice with PBS, and blocked with 1% BSA (bovine 
serum albumin) for 30 minutes at 37°C. 600 µl of RPMI 1640 medium without AB-
serum was added to the lower compartment supplemented with SDF-1α (R&D 
Systems, UK) at indicated concentrations. Cells were adjusted to 2x106/ml in RPMI 
medium without AB-serum and 100 µl of cell suspension supplemented with 25 µg/ml 
murine anti-human anti-α1 or isotype control mAb was added to the inserts, 
respectively. After 1 or 4 hours migrated cells were collected and processed for flow 
cytometry analysis.  
 
6.1.4.2. Apoptosis assay 
The Annexin V/ PI assay takes advantage of the fact that phosphatidylserine (PS) 
is translocated from the inner (cytoplasmic) leaflet of the plasma membrane to the 
outer (cell surface) leaflet soon after the induction of apoptosis and that the annexin 
V protein has a strong, specific affinity for PS. Therefore Annexin V is used to 
quantitatively determine the percentage of cells undergoing apoptosis, while 
propidium iodide (PI) is excluded by viable cells with intact membranes and thereby 
distinguishes apoptotic cells with intact membranes from lysed, necrotic cells. For 
this assay the Annexin V FITC Apoptosis Detection Kit I (BD, Bioscience, USA) was 
used. Cells were washed twice with cold PBS and then resuspended in 1x binding 
buffer (10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM Cacl2) at a concentration 
of 1x 106 cells/ml. 1x 105 cells were stained with 5µl of Annexin V-FITC, 10 µl PI (50 
µg/ml PI in 1x PBS) and 1 µl CD3 APC and incubated for 15 min at room temperature 
in the dark. Afterwards, 400 µl of 1x binding buffer were added to each tube and 
analysed within 1 hour with flow cytometry.  
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6.1.4.3. Proliferation assay 
24-well cell culture dishes (Falcon, USA) were coated with 25µg/ml rat-tail 
collagen I (BD Bioscience, USA) in sterile 10 mM acid acetic overnight at 4°C. Wells 
were washed twice with PBS and blocked with 1% BSA for 30 minutes at 37°C. 
Control wells were coated with 1% BSA for 30 minutes at 37°C. 2x104 cells/well were 
seeded on coated wells and 1 day later 25 µg/ml murine anti-human anti-α2 or 
isotype control mAb were added. In order to measure cellular proliferation a MTT 
assay was performed. The MTT proliferation assay is a colorimetric test for the 
measurement of cell metabolism and approximately of cell proliferation based upon 
the reduction of the tetrazolium salt 3,[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT). 1, 2, 4 and 6 days after plating, medium was 
replaced by 250 µl of new medium and 20 µl of MTT solution (5mg/ml; Sigma, USA) 
was added to each well and incubated for 1 hour at 37°C. At the end of the 
incubation period the medium was removed and the reduced salt was solubilised by 
adding 200 µl SDS solution (10% SDS) and 200 µl acid/alcohol solution (5% formic 
acid in isopropanol) to each well and incubating for 5 min at 37°C. Absorbance was 
measured on an ELISA reader at a wavelength of 570 nm with a background 
subtraction at 630 nm.  
 
6.1.5. Angiogenesis assay 
This assay was adapted from that of Montesano et al. (Montesano, Orci et al. 
1983). 48-well cell culture dishes (Falcon, USA) were coated with 25 µg/ml rat-tail 
collagen I (BD Bioscience, USA) in sterile 10 mM acid acetic overnight at 4°C. Wells 
were washed twice with PBS and blocked with 1% BSA for 30 minutes at 37°C. 
Control wells were coated with 1% BSA for 30 minutes at 37°C. 2x104 DMECs/well 
were seeded on coated wells. When cells were 80% confluent, wells were rinsed with 
PBS and given 60 µl of a collagen gel. Gels were prepared by mixing seven parts of 
1.4 mg/ml collagen I stock in sterile 10 mM acid acetic with one part 10x Eagle 
Medium (Gibco, Switzerland) and two parts 11.8 mg/ml sodium bicarbonate stock on 
ice. Cultures were incubated until gels had solidified (10-15 min) and then given 
440µl of EGM-2MV medium with 20 ng/ml VEGF (Peprotech, USA). 
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6.1.6. Genomics 
6.1.6.1. RNA isolation 
Skin specimens were homogenised with an electrical homogeniser using a total of 
1 ml of Trizol extraction buffer (Invitrogen, California). Subsequentially, RNA was 
extracted according to the manufacturer’s protocol (Invitrogen, California, Cat. No. 
15596-026). The RNA was then reverse transcribed into single-strand cDNA using 
the 1st Strand cDNA Synthesis Kit for RT-PCR (Roche, Switerland, Cat. No. 11 483 
188 011) following the protocol of the manufacture. 
 
6.1.6.2. Primer sequence for real time PCR 
In order to obtain human specific primers, the human and mouse mRNA 
sequence for the same gene were first aligned online using the BLAST program 
(http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi). Afterwards, primers were 
designed on the selected human specific mRNA region using the Primer3 online 
program (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Primers were 
ordered by Microsynth (Balgach, Switzerland) and diluted in H20 to a final 
concentration of 20 pmol/µl. IFN-γ and TNF-α were purchased by Search LC, GmbH 
Heidelberg. 
 
Table 6.2  Primers used for IL-23p19 detection 
TARGET PRIMER SEQUENCE (5’- 3’) 
Forward Primer ATTGCCCTCAACGACCACTTTG Human GAPDH (hGAPDH) 
Reverse Primer TTGATGGTACATGACAAGGTGCGG 
Forward Primer CAGCAACCCTGAGTCCCTAA Human IL-23p19 (hIL-23p19) 
Reverse Primer TCAACATATGCAGGTCCCACT 
Forward Primer ATGGTCAACCTGAACATCCA Human IL-17 (hIL-17) 
Reverse Primer TCTCTCAGGGTCCTCATTGC 
Human IFN-γ (hIFN-γ) Primers Unknown (purchased by Search LC) 
TNF-α (hTNF-α) Primers Unknown (purchased by Search LC) 
Chapter 6  Material and methods 
 
 
 
127
 
6.1.7. Quantitative real-time (RT)-PCR 
For the mRNA quantification by RT-PCR, the following reaction-mix components 
were used: 
Table 6.3  RT- PCR component mix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LightCycler FastStart DNA Master Syber Green I was purchased from Roche 
Diagnostic. Mg2+ concentration was optimised for each target. RT-PCR was 
performed on the Light Cycler 2.0 (Roche Diagnostic, Switzerland).  
The detecting run was constructed following the manufacturer’s experimental 
protocol, optimizing the amplification settings for each target.   
 
Table 6.4  RT-PCR amplification protocol 
PRIMER [Mg2+] ANNEALING 
TEMPERATURE (C°)  
ELONGATION 
TIME (Seconds) 
NUMBER OF 
CYCLES 
hGAPDH 2mM 62  15 40 
hIL-23p19 2mM 57 8 48 
hIL-17 3mM 57 5 60 
hIFN-γ 2mM 68 16 55 
hTNF-α 3mM 68 16 55 
 VOLUME/ 
CAPILLARY µl 
Reagents/[Mg2+] 2mM 3mM 
H2O 7.1 6.7 
Mg2+ 0.4 0.8 
Primer forward 0.25 0.25 
Primer reverse 0.25 0.25 
DNA Master SYBER green 
I 
1 1 
cDNA 1 1 
Total Volume 10 10 
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At the end of each run, all the data were analysed using the Standard Curve 
Method. mRNA concentration was determined in relation to an external standard 
curve prepared by amplification of 10-fold dilutions of a given concentration of the 
target gene. Each mRNA concentration was further normalised with the hGAPDH 
concentration of each sample. 
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Monocolonal antibodies used for FACS staining 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FITC, Fluoresceinisothiocyanat; PE, Phycoerythrin; Cy3, CyChrome-3; APC, allophycocyanin;  
PerCP, Peridinin-Chlorophyll-Protein 
 
 
ANTIGEN LABEL DILUTION COMPANY 
CD3 FITC, Cy3, APC 1:50 BD Bioscience 
CD4 PE, Cy3, APC 1:50 BD Bioscience 
CD8 FITC, APC 1:50 BD Bioscience 
CD11c APC 1:50 BD Bioscience 
HLA-DR PE 1:50 BD Bioscience 
CD45RA Cy3 1:50 BD Bioscience 
CD45RO APC 1:50 BD Bioscience 
CD49a PE 1:10 BD Bioscience 
CD49b FITC 1:10 BD Bioscience 
CD56 FITC 1:10 BD Bioscience 
Annexin V FITC 1:10 BD Bioscience 
CCR7 FITC 1:50 R&D System 
IL-23R Biotilayted 1:20 R&D System 
Streptavidin PerCP 1:200 BD Bioscience 
Cytokeratin FITC 1:500 Affinty BioReagents 
CCR4 APC 1:500 BD Bioscience 
NKG2D APC 1:10 BioLegend 
Vδ1 FITC 1:10 Endogen 
Vγ9  Cy3 1:200  Beckman Coulter 
CD1b APC 1:10 Miltenyi Biotec 
CD103 FITC 1:10 Immunotech 
CD1a PE 1:10 Dako 
        
IFN-γ FITC 1:10 BD Bioscience 
IL-17 PE 1:8 Schering-Plough 
        
isotype-matched control mAbs       
        
  145
  Curriculum Vitae 
 146
Curriculum Vitae 
 
Personal 
 
Tonel 
Giulia 
Born in Trieste (Italy), January 26, 1977 
Citizenship: Italian 
 
Education 
1988 - 1991  Primary School, Music Conservatory G.Tartini of Trieste, Italy 
1992 - 1997  Linguistic Secondary School, Liceo F. Petrarca of Trieste, Italy. 
   Linguistic degree  
1998 - 2002  Medical Biotechnology, University of Trieste, Italy,  
    Undergraduate thesis: “Generation of dendritic cells from bone  
   marrow and vaccination of melanoma mice with tumour lysate- 
   pulsed dendritic cells” 
2003 - 2007  PhD at the Department of Dermatology University Hospital of Zürich 
   PhD Thesis: “New Immune Effector Pathways In Psoriasis” 
   Supervisor: Prof. Dr. med. FO Nestle 
   Thesis supervisor at MNF: Prof. Dr Peter Sonderegger 
 
   
 147
  Publications 
 148
Publications 
 
Conrad, C., Boyman, O., Tonel, G., Tun-Kyi, A., Laggner, U., de Fourgerolles, V., 
Gardner, H. and Nestle, FO. A critical role for VLA-1 in accumulation of 
epidermal T cells and the develpoment of psoriasis. Nature Medicine; 13 836-
42 (2007). 
 
Boyman, O., C. Conrad, G. Tonel, M. Gilliet, and F.O. Nestle. The pathogenic role of 
tissue-resident immune cells in psoriasis. Trends Immunol 28:51-57 (2007). 
 
Farkas, A., C. Conrad, G. Tonel, Z. Borbenyi, L. Kemeny, A. Dobozy, and F.O. 
Nestle. Current state and perspectives of dendritic cell vaccination in cancer 
immunotherapy. Skin Pharmacol Physiol 19:124-131 (2006). 
 
Nestle, F.O., G. Tonel, and A. Farkas. Cancer vaccines: the next generation of tools 
to monitor the anticancer immune response. PLoS Med 2:e339 (2005). 
 
   
 149
  Acknowledgments 
 150
Acknowledgments 
 
My thanks go to Prof Frank O. Nestle for the opportunity to do my PhD in his group 
and to work in the fascinating field of psoriasis. 
 
I am especially grateful to Curdin Conrad who first introduced me into psoriasis 
research field and followed me step by step during all my PhD work. Thank you for 
your precious advices, for your excellent supervision and guidance and for the big 
effort in correcting this work. Many thanks, you have been of so much help!  
 
I would like to thank Prof. Peter Sonderegger for his kindness to accept me as an 
external student and to Prof. Nikhil Yawalkar for refereeing my thesis.  
 
I am very grateful to Mirjana Urosevic who had the hard work to read the first draw of 
my thesis. Thank you also for the constant help, support and for the wonderful 
cooking evenings we spent together. 
 
Many thanks to Natalie, Julia and Ossia for the very nice atmosphere in F14, for the 
nice lunch time spent together and for being always there when I needed. I believe 
you were the best PhD colleagues ever. 
 
I also want to thank Prof. Giusto Trevisan who got me to know Prof. Frank Nestle and 
gave me the possibility to do my PhD in Switzerland. Thank you also to the Move 
Science, which supported the first years of my PhD.  
 
I would like to thank DNAX, Shering Plough, which gave me all the antibodies for the 
IL-23 and IL-17 projects and supported part of my PhD.  
 
I also want to thank Christa Dudli for the excellent immunostaining work.  
 
My gratitude goes also to Anatoli Tassis, who was the PhD student before me and 
left me all the templates for preparing the PhD thesis. 
 
Muchas gracias Ana por tu paciencia en enseñarme a hablar español, por la ayuda 
con los ratones y sobre todo por tu amistad. 
 
Un immancabile ringraziamento va a tutti i miei amici. In particolare a Raffy, Michela, 
Micky australiana ed Emanuela che con le loro lunghe telefonate ed email hanno 
condiviso ogni momento di questa mia esperienza in Svizzera. Grazie anche a 
Giorgio un amico insostituibile sempre pronto a farmi dimenticare le frustrazioni 
lavorative con un bicchiere di vino o una bachata. 
 
Un particolare grazie va a mia sorella Katia, confidente per tutto, che mi ha sempre 
supportata sia nei momenti di grande entusiasmo che in quelli di maggior incertezza.  
 
  Acknowledgments 
 151
Un grazie di cuore va ai miei genitori, costante punto di riferimento, che mi hanno 
sempre aiutata, confortata incoraggiata e spronata ad andare avanti per la mia 
strada.
   
 152
 
 
